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ABSTRACT 
Exercise testing is used for a variety of purposes, in particular for the evaluation 
of patients with or at high risk of having coronary artery disease. The occurrence of 
chest pain or electrocardiographic (ECG) changes indicative of restricted coronary 
blood supply (ischaemia) during exercise are diagnostic for the presence of disease and 
prognostic of poor coronary outcomes. In a clinical setting the analysis of exercise test 
data is the responsibility of an experienced physician, based on test outcomes and 
knowledge of the particular patient. 
In clinical trials of anti-anginal therapies, the use of exercise tests in the 
evaluation of treatment efficacy is required by agencies responsible for authorising the 
use of new medicinal products. Considerable attention has been paid to the development 
of standardised exercise protocols that elicit reproducible ischaemic responses, and to 
alternative methods of analysing exercise test outcomes in order to improve the 
diagnostic or prognostic value of the test. However, comparatively little research has 
addressed the problem of analysing exercise test data produced for the assessment of 
treatment efficacy in clinical trials. 
Exercise tests have played a prominent role in the evaluation of therapies 
currently used for the management of patients with angina, such as nitrates, ß-blockers, 
and calcium antagonists. Such evaluations have shown dramatic improvements in 
exercise tolerance, most commonly measured by the time spent exercising until the 
occurrence of anginal pain or ECG signs of ischaemia, and often amongst patients with 
severe disease. However, the statistical methods used have generally been based on 
Normal theory, such as the t-test, or non-parametric equivalents, such as the Wilcoxon 
rank sum test. Such methods make no allowance for the fact that ischaemic endpoints 
may not occur in all patients, particularly when patients are under active treatment or in 
patients with less severe symptoms. In the current situation, where there are several 
therapeutic options of proven clinical effectiveness, new treatments must be evaluated 
in opposition, or in addition to existing therapies. Thus it is of particular importance that 
the statistician responsible for an analysis of exercise test data should use appropriate 
and efficient techniques, since the benefits of new treatments may be small. 
Since exercise times may be censored, in that the event of interest need not occur, 
it has been recognised that methods for the analysis of survival data are the most 
appropriate for analyses of exercise test data. Using data from the TIBET Study, a large 
ri 
clinical trial of two anti-anginal therapies administered singly or in combination, this 
thesis examines in detail the appropriateness of the Cox proportional hazards model, the 
most popular method for survival regression in the medical literature, to this type of 
data. It then considers alternatives to this model, and addresses the implications of some 
common features of exercise test data, in particular the presence of interval censoring 
and the possibility of multiple exercise tests being conducted on the same patient, using 
data from the TIBET Study and through simulation studies. Finally, using real data 
examples, two methods that appear to have received little or no attention with respect to 
exercise test data are explored, namely competing risks and repeated measures analyses. 
It is shown that the Cox model, and potentially other parametric survival 
regression models perform well with these data, even in the presence of moderate 
interval censoring. When multiple exercise times are analysed from the same group of 
patients, however, there is the potential for considerable bias and loss of power if this is 
not taken into account in the analysis. There is also much potential in the use of more 
complex statistical models, considering the volume of data routinely collected as part of 
each exercise test, and these may prove to be useful avenues for further research. 
The research contained in this Thesis was carried out by the author during the period 1993-2003, whilst a 
research student (1993-1997) at: 
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University of Glasgow Department of Statistics 
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CHAPTER 1 Introduction 
1.1 Exercise Testing 
The diagnosis and treatment of patients with cardiac conditions begins with their 
medical history and a physical examination. An important step in determining the 
aetiology of chest pain, the extent of disease, the response to therapy and the capacity to 
do work or other activities is to then perform an exercise test. At relatively little cost in 
terms of both health care resources and patient discomfort, clinically useful information 
is obtained that can drive the decision-making process, leading to the appropriate 
implementation of more expensive, invasive and/or dangerous procedures'. 
1.1.1 Preparation and Safety Precautions 
The patient's history and physical exam, including resting electrocardiogram and 
lung function tests, will identify many of the numerous contraindications to performing 
an exercise teste, including serious cardiac conditions (such as acute myocardial 
infarction, serious dysrhythmias or unstable angina), acute or serious non-cardiac 
disorders and severe physical disability. Other conditions that might contraindicate an 
exercise test include less serious disorders (cardiac or non-cardiac), drug effects and 
psychiatric disease. 
Patients should not have smoked tobacco, drunk caffeine or had a meal for at least 
two hours prior to a test. They should wear clothes and shoes appropriate for exercise 
and be allowed time to familiarise themselves with the apparatus. They must give 
written informed consent to participate and be aware that they can terminate the test at 
any time they choose. 
Under such conditions, the safety of exercise testing has been established3A 
though facilities for emergency cardiopulmonary resuscitation should be available, and 
trained staff should be close at hand in the event of an emergency. 
1 
1.1.2 Types of Exercise 
Exercise can be classified into two types, isometric and dynamic, though most 
activities consist of a mixture of the two. Isometric exercise involves constant muscular 
contraction, whereas dynamic exercise is that which results in movement, usually by the 
rhythmical contraction of large muscle groups. For the assessment of cardiac patients, a 
dynamic exercise test is preferred since it results in a greater increase in the total oxygen 
requirement of the whole body. 
As the total body oxygen requirement is increased, cardiac output must increase to 
ensure that sufficient blood is delivered to the working muscles, where oxygen is used 
in the energy releasing process, and to the lungs, where oxygen is extracted from the 
inhaled air, in exchange for the carbon dioxide produced in the muscles. As the result of 
an exercise load, the metabolic rate can increase by up to 20 times, and cardiac output 
by up to 6 times relative to the resting rate. The maximal extent of these increases will 
depend on the age, sex and fitness of the patient, the type of exercise performed, and the 
presence and extent of heart disease. 
During an exercise test, the total workload can be controlled, as can the cardiac 
output needed to meet the increased oxygen requirements. If necessary, total workload 
(and hence cardiac output) can be increased to the point where the subject is unable to 
continue. By studying the patient's haemodynamic and electrocardiographic responses 
to exercise, particularly near their maximal exercise capacity, the physician may be able 
to determine the cause or extent of heart disease, evaluate suitability for a surgical 
procedure or other course of action, or assess the progress of current therapies. 
In modem clinical practice, exercise tests are often performed using either a 
treadmill or bicycle. Bicycle ergometry is cheaper and requires less space, but many 
patients will suffer muscle fatigue before reaching their cardiorespiratory exercise limit. 
Treadmills are larger and more costly, but offer greater flexibility in terms of controlling 
workload. They may also elicit greater effort from patients who are more used to 
walking than cycling, thereby producing a greater maximal work rate. 
1.1.3 Exercise Protocol 
Any exercise test should be carried out according to a pre-specified protocol. An 
early example is the Master step test5 in which subjects made a certain number of trips 
on standard sized steps, the number being determined by their age, sex and weight. This 
was a single stage test in the sense that an individual exercised against a fixed load 
2 
throughout the test. More recently, with the use of treadmill and bicycle ergometers, it 
has become possible to alter the workload during a test without interruption, whilst 
keeping the patient in a relatively fixed position. This enables measurements to be made 
throughout the test under increasing levels of stress, giving a more detailed picture of 
the response to exercise. 
A large number of exercise protocols are currently in use, some of which are 
based on protocols devised more than 30 years ago6'7'8. For some time, the most 
commonly used protocol was that devised by Bruce6, though the relatively large and 
unequal increments in workload were found to give biased estimates of exercise 
capacity9, and protocols with small or even continuous increments have subsequently 
been recommended'o, ii, iz, t3 
1.1.4 Responses to Exercise 
Cardiac output is defined as the product of stroke volume (the quantity of blood 
pumped at each beat) and heart rate. When exercise begins, stroke volume increases 
almost immediately14, with the magnitude of this increase dependent upon fitness, age 
and body size'5. As exercise continues, changes in stroke volume are small, and the 
16 
necessary increases in cardiac output are predominantly met by increases in heart rate 
As workload increases, cardiac output must increase in order for the muscles to 
perform to the greater work rate. Consequently, myocardial oxygen consumption will 
increase, as the heart must also perform to a higher work rate. Myocardial oxygen 
consumption is dependent upon intramyocardial wall tension (the product of left 
ventricular pressure and end diastolic volume), contractility and heart rate'. An accurate 
measurement of myocardial oxygen consumption requires catheters to be placed in the 
coronary arteries and coronary venous sinus to measure oxygen content. In most clinical 
settings this is impractical, but the "double product" of heart rate and systolic blood 
pressure (SBP) is a good surrogate measure17. During progressively increasing exercise, 
SBP (as well as heart rate) will normally increase', as will diastolic blood pressure 
(DBP), though the increase is less marked. 
1.1.5 Measurements 
For cardiac patients, the main objective of exercise testing is to assess the 
response to increased demand of myocardial oxygen supply, which is measured by the 
double product of heart rate and SBP. Automatic devices for recording blood pressures 
3 
during exercise initially suffered from technical difficulties caused by the patient's 
motion, but have since improved performance' 8'19 SBP, as measured by cuff and 
auscultation, is a reliable method where an automated device is not available. DBP 
provides little additional information to the test, and is generally not recorded. If data on 
SBP are not available, the heart rate alone can be used as a proxy for myocardial oxygen 
consumption, since it correlates almost as well as the double product20. 
The principal device used to monitor the patient during exercise testing is the 
electrocardiogram (ECG). This measures the variations in electrical potential across the 
heart, with a recognisable pattern occurring during each heartbeat. The length of each 
cycle of this pattern, or an average over several beats, is used to calculate the heart rate 
of the patient at any stage before, during or after the test. 
The level of exercise performed can be measured by several methods. The total 
workload, or the time spent exercising under a standard protocol, measures the amount 
of work that a subject is doing, whereas the double product or heart rate estimate the 
amount of work that the heart is doing. What is often of interest is the level of exercise 
that a subject can achieve before the blood supply to the heart fails to match its oxygen 
requirements (ischaemia). When this occurs, a patient will often experience pain to the 
chest (angina) and/or abnormal ECG changes (see Section 1.3.1). Though the 
occurrence of anginal pain will be of most interest to the patient, it is a subjective 
endpoint and may be influenced by motivation. ECG changes offer a more objective 
measure of ischaemia. However, anginal pain and abnormal ECG changes give 
alternative but dependent indications of coronary artery disease and increased risk21, ý2. 
With the necessary equipment, it is possible to measure the gases expired by a 
subject during exercise. This enables calculation of total body oxygen uptake and thus 
accurate measurement of workload. It is also useful in assessment of respiratory and 
physical response to exercise, such as anaerobic threshold. Other physical responses to 
exercise can be measured by taking small blood samples during exercise. However, in 
cardiac patients, it is the response to exercise of the heart, rather than the whole body, 
which is of greatest interest, and these measurements do not add much to a test. 
Other methods of detecting myocardial ischaemia are based on the premise that 
when an area of heart muscle becomes ischaemic, the muscle ceases to move. Such wall 
motion abnormalities can be detected by nuclear imaging techniques, in which a 
radioactive substance is injected into the subject, making the heart visible to detectors 
once the heart becomes filled with blood containing the radionuclides. An alternative 
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technique is to use an echocardiogram, whereby ultrasound is used to view the heart'. 
These methods allow measurement of wall motion as well as estimation of the volumes 
of the chambers of the heart. The images can be digitised and recorded for later 
analysis. Methodological advances have enabled measurements to be made during 
exercise, when ischaemia is most likely to occur, rather than after the subject has 
stopped moving, thus increasing the sensitivity of these tests for detecting ischaemic 
events. However, the equipment required does increase the costs involved in conducting 
a test, and may be prohibitive for routine tests on a single patient as well as in the 
clinical trial setting, where large numbers of patients may be tested on several occasions 
at a number of different sites. 
1.2 Angina 
Angina pectoris (AP) is a collection of symptoms characterised by discomfort in 
the chest area associated with a disturbance to the function of the heart 23. It usually 
involves pain to the chest, but the pain can radiate to the arms (more often the left), the 
neck or the back. Sufferers often describe the pain as a sense of tightness, of pressure or 
an aching or burning feeling across the chest; the name angina comes from the Greek 
work meaning to choke. It is common, with symptoms becoming more severe with age. 
In the 1998 Scottish Health Surve/4, the prevalence of angina in the Scottish 
population was estimated as 3.5% in men and 3.1% in women, based on the Rose 
Angina Questionnaire 25 definition of angina, Grade I or Grade H. In the oldest age 
group surveyed (65-74 years) these prevalences were estimated as 8.9% and 5.9% 
respectively. 
Angina can be categorised as stable or unstable. As the term implies, stable angina 
will have been present for a number of weeks with no recent increase in frequency or 
severity of attacks. It is brought on by effort or other predictable stressors, and is 
relieved by rest or sublingual nitrates (see Section 1.2.2). Unstable angina is of recent 
onset, of increasing frequency or severity, or occurs at rest for no obvious reason. 
Exercise tests should not be performed on a subject suffering from unstable angina 
(Section 1.1.1). 
1.2.1 Causes 
Angina is ischaemic cardiac pain. It occurs when the coronary blood supply 
cannot meet an increased myocardial demand for oxygen, such as during exercise. It is 
usually a reflection of coronary artery disease (CAD), the second leading cause of death 
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after cancer in both men and women26 accounting for 22.9% of all male deaths and 
18.8% of female deaths in Scotland in 2001. CAD is mostly caused by occlusion of the 
coronary arteries, which reduces the rate at which blood can be supplied to the heart 
muscle. Any factor which causes an increase in heart rate and thus in the need of the 
heart muscle for oxygen is likely to precipitate angina. Common causes are exercise, 
strong emotion (anger or fear), a recent meal, cold temperature, vivid dreams or sex. 
Combinations of factors increase the risks. 
Arterial narrowing is not the only cause of angina. The extent of symptoms does 
not predict the extent of CAD well; up to 30% of those who have coronary 
arteriography for the evaluation of chest pain are found to have normal coronary 
arteries27 and many of those with CAD are asymptomatic28. Several possible 
mechanisms have been postulated for alternative causes of anginal symptoms, such as 
29 31 coronary vasospasm, platelet aggregation" and small vessel disease 
1.2.2 Management and Treatment 
The first phase of management of angina patients involves lifestyle changes, 
including stopping smoking, improving diet, stress management and possibly some 
exercise, depending on the patient. Further management of angina is obtained through 
drug therapy, or in severe cases, surgical intervention. The treatment of stable angina 
has two aims, namely to prevent coronary endpoints such as myocardial infarction (MI) 
or death, and secondly to reduce the symptoms of angina. 
1.2.3 Drug Therapies to Prevent MI and Death 
The primary concern in the management of patients with stable angina is to 
extend life. Aspirin is antithrombotic and should be used routinely32, and Angiotensin 
Converting Enzyme (ACE) Inhibitors are also useful for patients with or at high risk of 
developing CAD33. Statins and antihypertensive agents that are used to control risk 
factor levels can also prevent severe coronary endpoints and should be prescribed to 
34 patients at highest risk 
1.2.4 Drug Therapies to Prevent Anginal Symptoms 
The four main classes of medical treatment for the relief of anginal symptoms are 
nitrates, beta-blockers, calcium antagonists and potassium channel openers32. Though 
primarily used to prevent ischaemic symptoms, in some cases they also prevent 
coronary endpoints such as MI and death. 
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Nitrates cause vasodilatation, resulting in improved myocardial perfusion and 
reduced oxygen requirements of the heart. Sublingual nitroglycerin tablets or sprays act 
within 1-2 minutes and last for half an hour, and are used in the short term to give relief 
from symptoms or prophylactically, before an activity which is likely to be 
precipitative. Slow release nitrates, such as isosorbide dinitrate, transdermal 
nitroglycerin patches and ointments can also be used to prevent the recurrence of 
angina, but tolerance can become a problem unless sufficient nitrate-free periods are 
provided. Side effects include headache, syncope, tachycardia and halitosis. 
Beta-blockers reduce heart rate, blood pressure and contractility, thereby reducing 
myocardial oxygen demand. They are effective in most patients, leading to fewer 
ischaemic events and less need to use sublingual nitrates. They also improve prognosis 
in terms of survival and the occurrence of stroke and chronic heart failure in patients 
with a recent infarction35. Adversely, they can cause fatigue, insomnia, nightmares and 
impotence. 
Calcium antagonists reduce coronary vascular resistance and arterial pressure, 
reducing cardiac demand and increasing coronary blood flow. They are therefore of 
benefit in the treatment of both supply and demand ischaemia. Side effects are due 
mainly to vasodilatation and include headaches and water retention. They can 
potentially increase the risk of adverse cardiac events36 and are used in combination 
with beta-blockers if the initial treatment is ineffective, or as an alternative when the 
side effects of initial treatment are unacceptable. 
Nicorandil is a potassium channel opener with nitrate-like properties, which 
dilates coronary blood vessels, increasing blood flow and reducing cardiac preload and 
afterload37. Nicorandil is the only antianginal agent to have been shown to reduce 
coronary endpoints in patients with stable angina3S. Evidence regarding side effects is 
scarce, though there have been some reports of oral39 and anal40 ulceration as well as 
other gastrointestinal events and headache38. 
1.2.5 Surgical Intervention 
For patients who are at high risk of death or whose symptoms do not improve 
after some weeks of medical treatment, surgical intervention will be considered4t 
Depending on the particular circumstances, treatment will be either percutaneous 
coronary intervention (PCI) or coronary artery bypass grafting (CABG). PCI originally 
involved the inflation of a balloon within an occluded artery to reduce the level of 
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stenosis, but more recent techniques have involved the use of rotating blades or lasers to 
remove lesions, and the insertion of intracoronary stents to prevent restenosis. CABG 
involves bypassing the damaged section of a coronary artery with a section of another 
blood vessel. 
Both methods increase the blood flow to the myocardium, reducing anginal 
symptoms and the need for drug therapy, and improving prognosis in terms of 
subsequent MI or death. However, the chances are high that a severe coronary event 
will occur or further treatment will be required, even if lifestyle changes are made. In 
general, CABGs involve longer hospitalisations and recovery periods, but patients show 
greater improvements in symptoms, whilst PCIs are relatively inexpensive, low risk and 
repeatable. Mortality and re-infarction rates are similar, except for diabetic patients, for 
whom CABG offers a better prognosis42. 
1.3 Exercise Testing and Angina 
Exercise testing of angina patients is used for a number of reasons. It is used as a 
diagnostic tool, to detect both the presence and severity of disease; for evaluation of 
prognosis; to monitor the progress of patients after drug or surgical therapy; and in 
clinical trials for the comparison of different drug treatments. 
1.3.1 Ischaemia 
When subjected to increasing levels of exercise, an individual's heart rate and 
systolic blood pressure will increase, as will the need of the heart muscle for oxygen, 
and therefore blood. The main factor in controlling supply is the resistance of the 
vessels that deliver the blood. These are the coronary arteries, which are basically fixed 
in width and cannot vary their resistance, and arterioles, which can dilate in the presence 
of increased need and supply greater amounts of blood. The ability of these vessels to 
dilate is limited; for people with normal coronary arteries this limit is not reached and 
fatigue or breathlessness is the limiting factor in exercise. For people with obstructed 
coronary arteries, which have reduced capacity to carry the blood, the arterioles are 
slightly dilated at rest and under exercise they reach the limit of their ability to increase 
diameter. The coronary blood supply is then unable to meet the raised requirements of 
the heart, resulting in myocardial ischaemia. 
When ischaemia occurs, it may result in chest pain, though the inability of a 
subject to exercise may prevent the individual reaching the necessary level of cardiac 
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work to produce this response. This exercise capacity will depend on both physical 
fitness and on motivation, which reduces the usefulness of exercise induced chest pain 
as an outcome. An alternative measure of ischaemia can be defined through ECG 
changes, usually by inspection of the ST-segment of the ECG curve. 
During ischaemia, the ST-segment can become elevated, normalise or become 
depressed. ST elevation at rest is normal, but during exercise could have one of several 
causes including variant angina43, and is more common in those with a prior myocardial 
infarction. Normalisation of the ST-segment can be thought of as ST elevation in a 
subject whose ST-segment was depressed at baseline. The most common manifestation 
of exercise induced myocardial ischaemia is ST-segment depression. 
1.3.2 Diagnosis of CAD 
Both the occurrence of chest pain and ST-segment depression during exercise can 
be used as diagnostic indicators for CAD, though the occurrence of either is generally 
taken as a positive test. A depressed but up-sloping ST-segment is normal; horizontal or 
down-sloping ST-segment depression indicates ischaemia. Greater levels of ST-segment 
depression, as well as a more down-sloping ST-segment are related to a greater 
likelihood of, and greater severity of disease. The level of ST-segment depression used 
as a sign of disease will influence the sensitivity and specificity of the diagnostic test. A 
threshold often used to indicate significant ischaemia is zlmm of ST-segment 
depression. 
1.3.3 Evaluation of Prognosis 
In those with severe CAD, the use of exercise testing to predict outcome is 
valuable to identify patients for whom surgery will improve prognosis. It is those 
patients with the poorest prognosis that are most likely to benefit from surgery. 
Indicators of high risk or improved prognosis with surgery include short exercise time, 
significant ST-segment depression at low exercise levels that persists late into the 
recovery period or large amounts of ST-segment depression44 . 
1.3.4 Post Myocardial Infarction Testing 
Patients may be at greater risk of death or major dysrhythmia during an exercise 
test after a myocardial infarction (MI). Risks can be reduced, however, by using a 
submaximal test for these patients. Benefits of post MI exercise testing include 
optimising the date of discharge, assessment of drug therapy and evaluation of 
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prognosis. By involvement of the patient's spouse, through watching the test or even 
performing one themself, the confidence of both patient and spouse can be 
increasedas, as 
1.3.5 Patient Follow-Up 
After starting a course of drug therapy or after surgical treatment, the exercise test 
can be used to monitor a patient. There is a tendency for an individual to have improved 
exercise tolerance in terms of total exercise times as more tests are performed, due to 
improved efficiency or lower levels of anxiety caused by the test47. However, endpoints 
of anginal pain and >_lmm ST-segment depression will occur at approximately the same 
double product or heart rate. Thus, changes in the condition of a patient can be seen in 
changes in the heart rate or double product at ischaemic endpoints during exercise. 
1.3.6 Treatment Evaluation 
The comparison of different anti-anginal drug treatments in clinical trials is a 
major application of exercise testing. The European Agency for the Evaluation of 
Medicinal Products cite exercise testing as the principal method for assessment of 
efficacy of anti-anginal products in stable angina pectoris48. 
The aim of this thesis is to review methods of analysis of the various data that are 
produced during exercise tests, with the objective of highlighting differences between 
treatments. Most trials are performed under a parallel groups design49, where subjects 
are randomised to different treatments, and after a period of stabilisation, are given an 
exercise test. 
Since angina is a comparatively stable condition in which treatments are used to 
control symptoms rather than to cure, it is also sensible to use crossover designs in their 
evaluation50. Here subjects are given all of the treatments under consideration, in a 
randomised order, allowing a period between the start of each treatment and the exercise 
test for the effects of the previous treatment to wear off. Such designs should allow 
more accurate comparisons of treatment effects, since the effects of all treatments are 
observed in each individual. 
1.4 Exercise Test Data 
A number of variables are analysed in trials involving exercise tests. Dichotomous 
variables include the occurrence or not of anginal pain or significant ST-segment 
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depression. Exercise times include total exercise time and the time until the onset of 
anginal symptoms or until significant ST depression. Other variables are heart rate or 
double product at the end of exercise, at the onset of anginal pain or at the occurrence of 
significant ST-segment depression. 
The exercise times or haemodynamic variables at the occurrence of ischaemia are 
censored, since there is no guarantee that the ischaemic events will occur. The 
participants in a study may be chosen according to the criterion that at least one of these 
ischaemic events occurred during an exercise test when no treatment was administered; 
it may be that when treatment is given to the same subject, an exercise test will not be 
able to induce these events. Hence in large trials involving patients whose angina is not 
severe there maybe considerable censoring of these variables. 
Initially, comparisons of treatments that used exercise testing looked at exercise 
times, and used methods such as t-tests or non-parametric equivalents to compare 
treatment groups. The same techniques were used for haemodynamic variables such as 
heart rate and double product. Censoring of these variables was not a major problem 
since the patients studied were mostly those with severe CAD, with most suffering 
ischaemic events during exercise, even when under treatment. Also, treatments were 
often compared to placebo, and large treatment effect differences were observed, so that 
the small bias involved in ignoring the censoring of the response did not affect the 
conclusions of the trials. 
More recently, it has been recognised that these response variables are censored 
and that to ignore this fact will lead to biased estimates of treatment effect differences. 
This may be important with larger trials, involving healthier subjects for whom 
treatment effects may not be so drastic. Also, trials that compare new with standard 
treatments are becoming more commons' as the benefits of therapy become accepted, so 
the expected treatment differences are less. Biased estimating procedures may have less 
power to detect treatment differences. Methods are needed that take account of the 
censoring to give as much power as possible to find differences between treatments. 
For dealing with time to event data, the obvious methods to use for any analysis 
are those of survival analysis. Simulations52 have shown that survival methods are more 
appropriate than other methods in the presence of censoring. For the heart rate or double 
product at these events, it should be noted that these variables are also, in a sense, 
censored, since the events do not always occur. 
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Given that the onset of anginal pain is a subjective response variable, it is 
desirable to conduct an analysis of the exercise times until significant ST-segment 
depression occurs. However, though the ECG is monitored throughout the test, it will 
only be recorded at certain times, usually at regular intervals, for example, every 
minute. Most ST-segment depression data will thus be interval censored; that is, most 
events that occur will be detected as having done so at one of these predetermined 
recording times. In fact, (assuming that ST-segment depression varies monotonically 
between recording points) we only know that the event occurred during an interval. 
Analytic methods that take account of this form of censoring could be applied, but the 
amount to be gained by this in terms of reduced bias or increased power is unclear. 
Also, since we know that within any particular individual, the haemodynamic 
endpoints are highly reproducible, it would seem that within subject variability with 
these outcomes is much less than between subjects. Models that allow for such 
heterogeneity in survival data, known as frailty models, can be used to fit a random 
effect to the hazard of each individual. These methods may be particularly useful for 
situations where there are repeated exercise tests, either with baseline tests, or tests on 
different treatments, as in a trial with a crossover design. 
1.5 Summary 
Exercise tests can be used for a wide range of patients, but are particularly useful 
in cardiology. They have many applications for angina sufferers, and are a vital part of 
the process of evaluating new drug therapies. Drug development depends on accurate 
analysis of exercise test data, some of which is subject to heavy interval censoring and 
large between subject variability. This thesis will look at the relative merits of various 
analytical methods, by looking at their application to real and simulated data. 
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CHAPTER 2 Clinical Trials of Anti-Anginal 
Therapies 
This thesis will outline the various methods that have been used or could be used 
to analyse data from exercise tests. These methods will be applied to data from exercise 
tests carried out during the Total Ischaemic Burden European Trial (TIBET). This 
Chapter describes the TIBET study and other major studies of angina therapies, with 
particular emphasis on their use of exercise testing. 
2.1 Total Ischaemic Burden European Trial (TIBET) 
TIBET was a double-blind, parallel-group clinical trial of three anti-anginal 
therapies, Atenolol (a ß-blocker), Nifedipine (a calcium antagonist) and their 
combination. The main outcomes were cardiovascular morbidity and mortality. 
Secondary outcomes were exercise test results and 48-hour Holter monitoring. 
The study was innovative in that it examined the long-term effects of medical 
therapy on morbidity and mortality in patients with chronic stable angina. It was a large 
study, with over 200 patients assigned to each of the three treatments. Each patient 
underwent four exercise tests, some of which could be used to compare the effects of 
treatments. Patients were tested by either a bicycle or treadmill exercise test, and were 
evenly divided between the two types of exercise. 
2.1.1 Design 
Men and women, aged 40-79 with chronic stable angina were selected for 
inclusion in the trial (Figure 2.1). Each underwent a two-week active run-in period, 
when the combination therapy was given to ascertain if the patient was able to tolerate 
the treatments under study. After a further two weeks of placebo washout, patients 
underwent their first exercise test of the study, which was also the final inclusion test. 
Those who did not demonstrate exercise-induced ischaemia defined as _lmm 
ST- 
segment depression occurring before 10 METS (metabolic equivalents of oxygen 
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Figure 2.1 Desien of the Total Ischaemic Burden European Trial (TIBET 
consumption) were excluded. A more complete description of inclusion and exclusion 
criteria has been given elsewhere 53 
Those who were selected to take part in the study were then randomised to one of 
the three treatments; Atenolol (50mg b. i. d. ), Nifedipine (20mg b. i. d. ) or their 
combination. Since each treatment had been previously demonstrated to be beneficial, 
there was no placebo control group. After two weeks of treatment, patients underwent 
an examination and a second exercise test; those for whom there was clinical indication 
for increased therapy were given placebo if they were on Atenolol, or a further dose of 
20mg Nifedipine if they were on one of the other treatments. A third exercise test took 
place four weeks later. Patients were followed up with regular visits for an average of 2 
years, and were given a final exercise test upon withdrawal from randomised treatment. 
2.1.2 Endpoints 
Primary endpoints related to morbidity and mortality. Hard endpoints were 
defined as cardiac mortality, MI and unstable angina. Soft endpoints were defined as 
CABG, PCTA and treatment failure. Secondary endpoints related to exercise test data 
and 48 hours of continuous ECG (Holter) monitoring. Endpoints from exercise tests 
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were time to and exercise capacity at onset of ? lmm ST-segment depression, onset of 
anginal pain and termination of exercise. Holter endpoints were number, total duration 
and circadian distribution of significant ischaemic episodes (defined as _lmm 
ST- 
segment depression). 
2.1.3 Exercise Tests 
Approximately half of randomised subjects were given treadmill exercise tests 
and half used a bicycle. All treadmill tests were conducted according to a standard 
Bruce protocol6. That is, each patient began exercising on a treadmill moving at 1.7mph 
on a gradient of 10%. Every 3 minutes, both the speed and the gradient of the treadmill 
were increased: the speed to 2.5,3.4,4.2,5.0,5.5 and 6.0mph; the gradient increased by 
2% at the end of each stage, up to a maximum of 22% at the start of stage 7 (18 
minutes). Bicycle tests used a protocol that started at a workrate of 30W and increased 
by 30W every 3 minutes. 
ECG was recorded before exercise commenced, then at the end of every minute of 
exercise and immediately on stopping; it was also recorded at 1,3 and 5 minutes after 
exercise, while the patient was seated and resting. From the ECG recording, the level of 
ST-segment depression as well as heart rate could be determined. Systolic blood 
pressure was measured immediately prior to exercise, after every stage (3 minutes) 
during the exercise test and at the end of exercise. 
2.1.4 Baseline Characteristics 
Table 2.1 shows some baseline characteristics for the TIBET Study population. 
There were 682 participants randomised to one of the study treatments, though after 
subsequent examination of exercise test ECG data, the dataset was reduced to 608 for 
some analyses. The results given in this thesis are based on the full dataset. 
2.1.5 Published Results 
The results of the TIBET Study relating to primary54 and secondary55 endpoints 
were published simultaneously in 1996. There were no significant differences between 
treatment groups in terms of the time to primary endpoint though the trend was towards 
fewer events with the combination therapy (Atenolol, 47 events; Nifedipine, 46 events; 
Combination, 31 events; logrank test p=0.14). There were, however, significantly more 
withdrawals from study medication for those using Nifedipine (Atenolol, 60 
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Atenolol Nifedipine Combination 
N Total 226 232 224 
Treadmill 
N 119 119 116 
(%) (52.7%) (51.3%) (51.8%) 
Males N 193 191 197 (%) (86.9%) (82.3%) (88.3%) 
Age (years) Mean 59.3 59.3 59.1 (SD) (7.6) (7.5) (7.9) 
Weight (kg) Mean 78.2 75.4 78.7 (SD) (11.0) (10.0) (11.2) 
Previous MI N 77 71 77 
Previous Heart 
Failure N 2 4 1 
Hypertension N 52 54 47 
Diabetes N 10 7 18 
Previous Angiogram N 67 62 64 
Previous PTCA N 4 5 5 
Previous CABG N 14 12 9 
Table 2.1 Baseline characteristics of TIBET Study population 
withdrawals; Nifedipine, 93 withdrawals; Combination 64 withdrawals; logrank test 
p=0.001). 
Though it was reported that survival analysis techniques had been used to analyse 
exercise times55, these results were reduced to a single paragraph stating that no 
significant differences were found. The data were mainly reported in terms of 
improvement compared to the baseline exercise test of total exercise time, time to pain 
(or total exercise time, if pain did not occur), time to 1mm ST Segment depression (or 
total exercise time) and maximum ST segment depression, with data from treadmill and 
exercise tests reported separately. Also given, for both types of exercise combined, were 
changes from baseline heart rate, systolic and diastolic blood pressure, both sitting and 
standing. These data are summarised in Table 2.2. 
Atenolol and Combination were associated with reductions in resting heart rate, 
whilst Nifedipine was found to cause a slight increase. All treatments caused reductions 
in blood pressure, though these were greater for combination therapy. All treatments 
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Atenolol Nifedipine Combination 
N 177 175 162 
Sitting HR (bpm) 15.4 (0.8) -2.9 (0.8) 13.5 (0.8) 
Sitting SBP (mmHg) 12.9 (1.2) 12.5 (1.3) 20.6 (1.3) 
Sitting DBP (mmHg) 7.3 (0.6) 6.7 (0.8) 11.0 (0.8) 
Standing HR (bpm) 17.2 (0.8) -3.7 (0.9) 15.6 (0.9) 
Standing SBP (mmHg) 12.8 (1.2) 13.6 (1.2) 20.4 (1.2) 
Standing DBP (wig) 7.5 (0.7) 6.5 (0.7) 11.4 (0.8) 
N 91 87 80 
Total exercise time (s) 91.4 (10.0) 90.5 (11.1) 98.0 (11.7) 
Treadmill Time to pain (s) 128.0 (11.3) 126.7 (15.0) 144.3 (13.7) 
Time to 1mm ST depression (s) 136.4 (12.4) 131.4 (13.9) 147.3 (11.3) 
Maximum ST depression (mm) 0.43 (0.08) 0.49 (0.09) 0.50 (0.11) 
N 86 88 82 
Total exercise time (s) 63.2 (11.0) 63.6 (13.3) 78.5 (17.3) 
Bicycle Time to pain (s) 106.8 (15.4) 109.4 (15.3) 138.8 (17.9) 
Time to lmm ST depression (s) 147.4 (14.4) 146.5 (15.6) 162.7 (17.6) 
Maximum ST depression (mm) 0.59 (0.08) 0.74 (0.08) 0.76 (0.10) 
Table 2.2 Reductions baseline sitting and standing heart rate (HR), systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) at rest, and increases from baseline 
exercise times (total exercise time, time to pain (or total exercise time), time to 1mm ST 
segment depression (or total exercise time)) and maximum ST segment depression, 
reported as mean (SE) 
were associated with increased exercise times and reduced ST-segment depression 
during exercise, and though none of these improvements were significantly different 
between treatment groups, there was a tendency for those on combination therapy to 
perform better than either single treatment. 
2.2 Previous Studies 
Clinical studies of the treatment of stable angina concentrate on endpoints such as 
myocardial infarction (MI) and death (coronary or all cause) to measure the quantity of 
life, and anginal symptoms and the occurrence of ischaemia to measure the quality of 
life. Exercise tests are used in the assessment of the latter of these objectives. 
2.2.1 Drug Therapies to Prevent MI and Death 
Many treatments used in patients with stable angina are targeted at the prevention 
of MI and death, which is the primary concern in the management of these patients. 
However, they do not directly influence the myocardial response to exercise and so will 
be dealt with briefly here. 
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Aspirin has antithrombotic effects and is recommended as a routine therapy for 
patients with stable angina32, since the risk of adverse cardiovascular events has been 
shown in randomised trials to be reduced by about a third in this way56. Angiotensin 
Converting Enzyme (ACE) Inhibitors are now advocated for patients with or at high 
risk of developing coronary artery disease (CAD), particularly diabetics33; a 20% 
reduction in the incidence of MI was observed in the HOPE Study57 which included 
5162 (55.5%) sufferers of stable angina. None of these studies reported results of 
exercise tests, since the reduction of anginal symptoms was not of concern. 
It has been observed that fibrinolytic function is associated with subsequent 
cardiovascular mortality in patients with stable angina58, and despite evidence of 
reduced coronary events after treatment with the anticoagulant warfarin in patients 
without stable angina59, there is as yet no firm evidence of reduced mortality amongst 
symptomatic patients. However, low-molecular-weight heparin has been shown to 
reduce fibrinogen levels and increase exercise time to 1mm ST-segment depression6o 
This study involved 29 patients and analysed exercise times to 1mm ST-segment 
depression, peak exercise and moderate anginal symptoms, as well as the maximal 
double product achieved and the double product at 1mm ST-segment depression. 
Analyses were performed using t-tests and ANOVA methods, though no mention was 
made of whether all participants achieved the stated endpoints during the on-treatment 
exercise test. If it occurred, censoring may have been minor, since all participants were 
required to achieve ischaemic endpoints on two baseline exercise tests 
Therapies that aim to reduce risk factors for coronary events have also been 
shown to reduce subsequent coronary event rates. Lipid lowering with statins has been 
associated with a reduction in mortality and coronary events of approximately one 
third61,62 in large randomised controlled trials that included sufferers of stable angina. 
Similarly, those with stable angina and hypertension benefit from antihypertensive 
treatment63. These trials have again focused on reductions in morbidity and mortality, 
without measuring exercise tolerance. 
2.2.2 Drug Therapies to Prevent Anginal Symptoms 
The main classes of pharmacotherapy for ischaemia and angina, namely 
blockers64, calcium antagonists65, nitrates66 and potassium channel openers67'68, have all 
been shown to improve exercise tolerance. The statistical methods used in these studies 
have been based on normal theory methods, such as t-tests and ANOVA. A variety of 
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endpoints were used, including time to angina (onset or exercise-limiting), time to 
_lmm ST-segment 
depression, total exercise time and double product at maximal 
exercise. One of these studies used individualised exercise protocols for each subjectTM, 
another used log-transformed exercise times65 and a third analysed changes in exercise 
times compared to a baseline exercise test66 
In general, patients with stable angina should be administered sublingual 
nitroglycerin spray or tablets and be educated in their use for the immediate relief of 
symptoms and to prevent pain when this can be anticipated32. For the long-term 
prevention of symptoms, the initial treatment choice would be ß-blockers32, though in 
patients who are intolerant, each of the other classes of treatment may be used as 
monotherapy, though oral nitrates should be used in a way that avoids nitrate tolerance. 
Undesirable side effects may be reduced by combination therapy, and there is 
evidence of beneficial effects of adding isosorbide mononitrate69 or a long-acting 
dihydropiridine7° (calcium antagonist) to a ß-blocker. Studies have compared times to 
_lmm 
ST-segment depression, levels of ST-segment depression at comparable 
workload or maximal workload, and maximal ST-segment depression. The method of 
analysis has been the t-test. Other therapeutic combinations are not recommended, nor is 
treatment with more that two agents; patients for whom treatment fails to control 
symptoms may be candidates for surgical intervention. 
2.2.3 Surgical Intervention 
Surgical interventions for patients with CAD, whether by CABG or PCI, aim to 
increase life expectancy and relieve symptoms. The survival of patients treated with 
CABG is greater than that of patients treated pharmacologically71 at first, particularly 
for those with the most severe disease, who were at the greatest risk of death without 
surgery. Approximately 80% of CABG patients are free from angina 5 years after 
surgery72; CABG offers a greater level of symptom relief than initial medical treatment 
at 5 years and, to a lesser extent at 10 years, though more than 40% of patients initially 
treated medically will have undergone CABG within that time71. 
In patients with mild symptoms, who are at relatively low risk of coronary death, 
PCI offers a greater reduction in symptoms than medical treatment, but at a slightly 
higher rate of future coronary events73. Both CABG and PCI provide better symptom 
74 relief than medical treatment in patients with more severe, single vessel disease, 
demonstrated using the exercise test endpoint of the occurrence or not of an ischaemic 
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event. All three methods have similar rates of mortality and MI74, though CABG offers 
the lowest risk of future coronary events including surgical interventions. In patients 
with multivessel disease, CABG and PCI result in similar rates of survival from 
mortality, MI or stroke, and despite higher rates of additional surgical interventions 
following PCI, the cost per patient is lower75. Only in patients at the highest risk of 
death does CABG offer lower mortality rates, for example in diabetics76 and/or those 
with severe multivessel disease". 
2.2.4 Literature Review 
To assess the statistical methods used to analyse time to event data from exercise 
tests in situations similar to those seen in the TIBET Study, a brief literature search was 
performed. Using the PubMed search system78, a search was carried out using the 
expressions "exercise test", "clinical trial" and "angina". Searches were limited to 
English language articles and studies of human subjects. To determine whether there 
have been any changes in the statistical methods used with these data, the same search 
was performed for articles published during 1983,1993 and 2003. 
A total of 105 articles were identified (31 from 1983,52 from 1993 and 22 from 
2003). Six were excluded as they were review articles, editorials or meta analyses. On 
closer inspection, 30 were found not to include any analyses of exercise times. The 
remaining 69 articles were inspected to determine whether survival methods were used 
to analyse exercise times, or methods that ignore the censored nature of the data, such as 
those based on Normal theory (t-tests, ANOVA, regression), or similar non-parametric 
methods. 
Table 2.3 summarises the findings of this literature search. Amongst these articles, 
the overwhelming majority were found to use methods of analysis suitable for 
uncensored continuous data, predominantly those based on a Normal distribution. Only 
two papers79'80 presented results of survival analysis of exercise times. Equally few used 
neither method81'82, reporting comparisons of exercise times in terms of the numbers of 
participants showing improvement in exercise time under treatment. Though the sample 
is limited to only three years' publications, they seem to indicate a considerable 
preference towards the more widely used statistical techniques. 
A number of factors might be influencing this apparent lack of use of survival 
analysis methods with censored time to event data from exercise tests. In medical 
research, many small-scale studies are carried out by individual or small groups of 
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Method of Analysis 
Year Total 
Both Survival Uncensored Neither 
2003 00 10 0 10 
1993 11 31 0 33 
1983 00 24 2 26 
Total 11 65 2 69 
Table 2.3 Numbers of articles published in 2003,1993 or 1983, analysing exercise 
times using survival analysis and/or methods for uncensored continuous data (based 
on the Normal distribution or non-parametric equivalent) methods, by year of 
publication 
clinicians. In such cases, the statistical analyses may be conducted by those without the 
breadth of statistical training to recognise the need for survival analysis. Furthermore, 
based on previous studies, it would appear that survival techniques are not the standard 
method of analysis for such data, and an individual confident in the use of t-test or 
ANOVA methods would be able to report the . findings of their study. 
In larger trials, in which more experienced statisticians are employed to perform 
the analyses, the use of survival methods may be under reported. If methods for both 
censored and uncensored data are used, it may be the case that the results, whether 
showing statistically significant differences or not, result in similar conclusions being 
reached. Since, in general, the readership of such articles will be, or be perceived to be 
(by the authors of the articles or the editors of the journals) less able to comprehend 
analyses presented using survival techniques, such analyses may be omitted from 
articles. It may even be the case that studies analysed using survival analysis methods 
are less likely to be accepted for publication, particularly when the results are negative. 
Finally, in many studies, multiple exercise tests are employed, and the results are 
presented in terms of the change in exercise time following intervention. Methods for 
the analysis of repeated survival data are relatively new, particularly with respect to 
their application using standard statistical software packages. As a result, their use may 
be limited to those with an interest in current research into statistical methodology, 
particularly academic statisticians. Statisticians working in medical research may be less 
aware of developments in methodology. They will be working to more stringent 
timescales, with the emphasis on producing coherent results on time, with less scope to 
experiment with alternative methods. Furthermore, they will have to report their results 
to clinical colleagues in formats that are clearly understood, a constraint that often 
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precludes the use of more novel approaches, even when these are superior in terms of 
efficiency or validity. 
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CHAPTER 3 Estimation of Treatment Effect 
Differences I: Cox Proportional Hazards Models 
Clinical trials of angina therapies are required to include exercise testing to 
demonstrate differences in treatment efficacy48. In order that test results are comparable 
between subjects, they should be performed to a standard protocol, or performed to the 
same protocol on several occasions to demonstrate changes in individual exercise 
performance. There are numerous response variables that can be recorded, but primary 
analyses will often be carried out using the time spent exercising until the occurrence of 
chest pain and/or significant ST-segment depression, or the total exercise duration. 
There may be a single exercise test per subject, or a series of tests to measure 
responses to exercise before and during active treatment. In a randomised trial, subjects 
will be allocated to receive one of the candidate treatments (in a parallel groups design) 
or different treatments during different periods of the study (in a crossover design) at 
random. Since allocations are random, differences in average exercise response between 
treatment groups can be attributed to differences in treatment effects, subject to the 
limits of uncertainty due to chance differences between the groups. 
It will often be the case that other patient information will be available. In a 
clinical trial setting, it may be of interest to test whether intervention effects are 
homogeneous across subgroups of the study population. In clinical epidemiology, it 
may be necessary to adjust for the potentially confounding effects of factors other than 
the exposure of interest. 
This would generally be achieved through regression models, whereby treatment 
and covariate effects are estimated simultaneously. It is possible to incorporate 
covariates that change over time, but this thesis shall only consider models in which 
covariates are fixed, such as age, sex and weight. Variables that change during exercise, 
such as heart rate or blood pressure, are undoubtedly connected with the risk of 
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suffering an ischaemic event, but are also affected by workload, and so to include them 
in models of the time to an ischaemic event could be misleading. 
3.1 Survival Analysis 
Survival data consist of survival times, failure indicators and covariate data. That 
is, (t;, S;, z; ) for i=1,2, ..., n, where S; =0 if the it' subject is censored at t; and S; =1 if 
the subject suffers an event at t;. 
3.2 Proportional Hazards Regression Models 
Proportional hazards regression models relate the hazard function for an 
individual to a common baseline hazard function through multiplication by a positive 
function of that individual's covariates. That is, if X(tlz) is the hazard function for an 
individual with covariates z, and ? o(t) is the baseline hazard function, then 
X(tlz)=Xo(t)w(z, ß). The vector ß is a set of parameters, at least some of which it may be 
of interest to estimate. 
A common form for the function w(z, (3) is exp(z(3), so that an element of ß, f3j say, 
has the interpretation of being the log hazard ratio associated with a unit increase in the 
corresponding covariate, zj, with all other covariates held constant. In particular, if a 
binary covariate is represented by a {0,1) indicator variable, then the corresponding 
parameter is the log hazard ratio between the subgroups. The effects of categorical 
variables of more than two levels can be estimated by the construction of dummy 
indicator variables, in exactly the same way as for other linear models. 
3.3 Cox Proportional Hazards Regression Model 
Different proportional hazards regression models make different assumptions 
about the baseline hazard function, ? o(t). There are a number of fully parametric 
formulations for Xo(t), some of which are demonstrated in Section 4.1; however, the 
Cox proportional hazards model83, which makes no assumptions about Xo(t), is the most 
commonly used84. It is termed semi-parametric in the sense that, while the baseline 
hazard is unspecified and is estimated non-parametrically, the covariate effects are 
modelled parametrically. 
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3.4 Parameter Estimation 
The likelihood of a set of survival data can be written as 
L(O, jI{t;, S;, z; :i =1,2,..., n})= FIS(t; I9, ß, z; )k(t; I6, ß, z; y' 
i-I 
n 
Iexp(-A(t, 10, p, z1))x(t, lo, p, z1 
i-I 
_ 
fT 
exp(_ Ao(t1je)w(z1 P)){ x0(t1Jo)W(Z>>ß)r' 
i-I 
where 0 is the set of parameters for the baseline hazard function. Under the Cox 
proportional hazards model, this is 
L(O, (3I{t;, 8j, z; : i=1,2,..., n})=fJexp(Ao(t; jO)exp(z1p)){? 0(tiJO)exp(z; p)}s` 
i=l 
so that the log likelihood can be written as 
1(0, pl{t;, 8;, z; : i=1,2,..., n})=Z{-Ao(t110)exp(zip)+8; (log, %O(t; lo)+z; ß)}. 
i=l 
3.4.1 Partial Likelihood 
When fitting the Cox proportional hazards model, the log likelihood cannot be 
maximised directly, since the functional form of the baseline hazard function is 
unknown, and an alternative method must be adopted. The partial likelihood function is 
defined as 
Lp lpJz)= 
f eXp(z(i)ß) 
t1 11=1 
exp(z(i)ß) 
jER(t(i)) 
(Eq. 3.1) 
where the t(j), i=1,2, ..., k, are the ordered failure times and R(t(I)) denotes the risk set 
at time t(j), or those subjects whose survival times are at least as large as t(j). The term 
exp(z(; )ß) is equivalent to 
x(t(')Iz(')) 
and can be interpreted as the conditional 2: exp(zo)ß) 
4(j)Iz(j) 
jeR(t(; )) jeR(t(i)) 
probability that subject (i) fails at time t(i) given that one of those under observation at 
t(i) fails at that time. Maximum partial likelihood estimates have similar properties to 
normal maximum likelihood estimates83, and asymptotic variances of the parameter 
estimates are derived from the second derivative of the log partial likelihood function. 
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The partial likelihood function as defined by (Eq. 3.1) is valid only when all 
failure times are distinct. In practice, failure times are not unique, since times are often 
rounded to convenient values. For example, total exercise time, or the time to 
occurrence of anginal pain, might be recorded to the nearest 10 seconds. What is more, 
the time to occurrence of significant ST-segment depression can only be one of those 
times when an ECG trace was recorded, which might be every minute. 
In situations where failure times are tied, the partial likelihood is defined as 
Lt(pIZ1_ý exp(s(i)ß) 
ZE exP z(j)ß 
ReR(t(; ), d(; ))jcR 
(Eq. 3.2) 
where d(j) is the number of events occurring at time t(i), s(i) is the sum of covariate 
vectors of individuals observed to fail at time t(j) and R(t(1), d(1)) denotes the set of all sets 
of size d(j) drawn from R(t(1)). An individual term in this product can be interpreted as a 
conditional probability, that it was those subjects who were observed to fail at that time 
who did so, given that d(I) individuals fail at time t(j). 
With large datasets or large numbers of ties, the number of calculations required 
to evaluate (Eq. 3.2) can make its maximisation slow, and approximations may be used 
to speed up the calculations. When there are few ties at each failure time, the partial 
likelihood is well approximated (Breslow83) by 
Lb (ý, Iz) _ fT 
exp(s(1)ß) 
i=1 
exp(zo)ß) 
je i)/ 
(Eq. 3.3) 
However, when the number of ties at any failure time is large, (Eq. 3.3) can produce 
biased estimates, and a better approximation (Efron85) is given by 
Lý (ß1z)= fJ exp(s(; )ß)d exp(z(. i)ß)- 
(r-1) 
exPýzo)ßý X9.3.4) 
1-1 
d H i-ý )E iýý (1) QED(t(i)) 
Example 3.1 TIBET Study, Cox Proportional Hazards Models for Time to Anginal Pain 
Table 3.1 shows the treatment effect estimates obtained by fitting proportional 
hazards regression models to the time until anginal pain under exercise (with 95% 
confidence intervals and p-values) from the TIBET study. For each model, the estimates 
were obtained using the Efron approximation to the partial likelihood; almost exactly 
the same values were achieved using the Breslow approximation, in terms of effect 
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Unadjusted Model 
Haz. Ratio 95% CI p 
Adjusted Model 
Haz. Ratio 95% CI p 
Nifedipine-Atenolol 
Nifedipine-Combination 
1.36 (0.96,1.91) 0.081 
1.06 (0.74,1.52) 0.75 
1.32 
1.06 
(0.94,1.87) 
(0.74,1.52) 
0.11 
0.76 
Age (/10 years) 
Gender (Female-Male) 
Weight (/10 kg) 
1.19 
1.19 
0.96 
(0.97,1.45) 
(0.75,1.91) 
(0.83,1.12) 
0.093 
0.46 
0.60 
-2 log likelihood 1943.2 1939.1 
Table 3.1 Treatment and covariate effect estimates from Cox proportional hazards 
models for the time to anginal pain 
estimates (and CIs) and the values of the log likelihoods of the fitted models. Each 
model allows different baseline hazard functions for the different types of exercise, and 
effect estimates are shown from models that do not adjust for other covariates as well as 
models adjusting for gender, age (as a linear effect) and body weight (linear effect). The 
changes in -2 log likelihood after inclusion of covariate effects (not shown) are small, 
thus suggesting that none of these variables improves the fit of the model. 
3.5 Goodness-of-Fit 
When fitting any regression model, a number of assumptions are made, and the 
extent to which the data deviate from these assumptions should be checked. Serious 
lack of fit invalidates any inferences drawn and would indicate that the model needs 
modification, if not complete respecification. However, study reports often do not refer 
to any assessment of goodness-of-fit. 
Under a proportional hazards regression model, it is particularly important to 
check the appropriateness of the linear predictor, zß, and the validity of the proportional 
hazards assumption. Whilst the Cox model in particular and proportional hazards 
models in general are readily available as part of many statistical packages, methods for 
checking the goodness-of-fit are more limited. However, some have been implemented 
within standard software, and by manipulation of model outputs it is possible to carry 
out a number of checks of model assumptions. 
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3.5.1 Linear Predictor 
An implicit assumption under the proportional hazards regression model in its 
usual form, ? (tIz)=%o(t)exp(z(3), is that equal increments in a continuous covariate, zj, 
are associated with equal proportional increases in hazard. 
This assumption can easily be checked by a simple graphical technique. The 
covariate is divided into categories, for example into quartiles or quintiles, and the 
model is refitted including the categorical variable in place of the continuous variable. 
When the effect estimates for the levels of the new variable are plotted against the 
median value of the continuous variable within each category, any severe departures 
from the assumption of linearity will become apparent. 
Alternatively, the assumption may be checked statistically. Including a quadratic 
term in the covariate may be used to detect simple departures from linearity, though in 
the same way as with linear regression models, parameter estimates are more stable and 
more interpretable if covariates are centered by subtraction of a suitable value, such as 
the mean or median. A more flexible method of determining non-linearity of covariate 
effects is through the use of cubic splines86, in which a smooth function of the covariate 
is estimated to represent the association between the covariate and the hazard. A 
likelihood ratio test can then be used to test whether there is any statistically significant 
departure from non-linearity for that covariate. These methods have been incorporated 
into standard software87. 
3.5.2 Proportional Hazards Assumption 
The model assumption that receives the greatest attention in proportional hazards 
models is that of proportional hazards, and many methods have been proposed for 
checking this assumption. Some of these are applicable under any proportional hazards 
model, whilst some are exclusive to the Cox proportional hazards model. 
Many of the global goodness-of-fit tests for the Cox proportional hazards model 
are related to each other. The methods presented here are some of the more frequently 
recommended, ranging from the simplest graphical checks to more formal significance 
tests. 
3.5.2.1 Log Cumulative Hazards Plots 
This method is applicable to any proportional hazards model for survival data. If 
the proportional hazards assumption holds, subjects in the separate treatment groups 
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will have hazard functions that are proportional to the same baseline hazard function. If 
there are J treatment groups, 
x; (t)= r; Xo(t) 
where j=1,2, ..., J, and the yj are constants, so that 
t 
logAj(t)=log JXj(u)du 
0 
t 
=1og y, 
fl(u) du 
(Eq. 3.5) 
0 
=logy, +logA0(t). 
and the curves of Af(t) against t are parallel. A check of proportional hazards is given by 
a plot of log(Ä3 (t)) against t for each treatment group; severely non-parallel curves 
indicate non-proportional hazards. 
Af(t) is estimated by first generating Kaplan Meier estimates of the survivor 
functions, §j (t), for each treatment group. A (t) is then evaluated as - log S. j 
(t). It can 
be useful to smooth the log cumulative hazard curves as an aid to assessing parallelism. 
However, this assessment can be difficult even after smoothing, and by plotting the 
differences between pairs of curves, log Ajjt) - log 
Ä 
j2 
(t), against time, a clearer 
impression is given since these curves should be constant if the proportional hazards 
assumption holds, as 
log 
,& 
(t) 
- log 
A2 (t) = log 
Y' 
. Yz 
These methods can be employed with many statistical packages that generate 
Kaplan Meier curves, but there are difficulties in assessing parallelism of curves, or 
constancy of differences between curves. It is not obvious how much non-parallelism 
will occur due to random variations in survival or in covariates that affect survival 
between groups. 
Example 3.2 Logged Cumulative Hazards Plots for Cox PH Model of TIBET Time to 
Anginal Pain 
Figure 3.1 shows log cumulative hazards plots for the time until the onset of 
anginal pain for patients exercising on a bicycle ergometer. Plot (a) is the estimated log 
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Figure 3.1 Log cumulative hazards plots for time to anginal pain during bicycle 
exercise: (a) raw estimates; (b) smoothed estimates. 
cumulative hazard, log A(t), plotted against t for each treatment. If the hazards in the 
three groups are proportional, these curves would be parallel, due to (Eq. 3.5); this is not 
easy to assess, since the curves are step functions. In (b), a smooth version of plot (a) is 
shown, where a normal kernel smoother with a bandwidth of 60 seconds" has been 
used. The question of parallelism is still difficult to judge, however, since the lines are 
curved and are close together relative to the range of the y-axis. 
Figure 3.2 shows differences in log cumulative hazards against t for each pairwise 
treatment comparison. The steps in plot (a) confuse the issue, and a smooth of this plot 
is given in (b). If the hazards are proportional, the lines should be horizontal, and this 
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Figure 3.2 Log cumulative hazards contrast plots for time to anginal pain during 
bicycle exercise: (a) raw estimates; (b) smoothed estimates. 
plot is perhaps the most informative; the same graph is shown in Figure 3.3 for the time 
until anginal pain for those who exercised on a treadmill. 
The main difficulty in interpreting these plots is in deciding the extent of any 
departures from horizontal lines. In general, a plot would to be interpreted as showing 
non-proportionality if there was a clear and consistent trend over the time axis. For the 
bicycle data, Figure 3.2(b) gives some cause for concern but is not equivocal, and 
further investigation will be required; the treadmill data shown in Figure 3.3 do not 
indicate non-proportional hazards, with the lines departing from horizontal during the 
initial part of the time axis only. 
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Figure 3.3 Smoothed log cumulative hazard contrast plots for time to anginal pain 
during treadmill exercise 
3.5.2.2 Time Dependent Covariates 
Implicit in the proportional hazards assumption is that hazard ratios between 
groups are constant over time. A test of the proportional hazards assumption is achieved 
by adding time dependent covariates to the model and testing if this significantly 
improves the fit. 
To illustrate, consider a trial with two treatments, A and B, represented by an 
indicator variable z that takes the values 0 and 1 according to whether treatment A or B 
is administered. By fitting the model 
7X(tlz)= xo (t)expU jz+ ß2 z(log(t)- Y)} 
(where y= mean log failure time), the hazard ratio between treatment groups B and A 
under this model will be exp(ß, -ß2y)ta' . Since exp(ßl-02y)>O, this ratio will increase 
over time if ß2>O or decrease if ß2<O. A similar test of the proportional hazards 
assumption can be achieved by including any covariate of the form zf(t), where f(t) is a 
monotonic function of time. 
This method has the advantage that it involves a formal significance test for a 
monotonic trend in hazard ratio, though its power to detect non-proportional hazards 
will be dependent upon the choice of functional form of the time dependent covariate. 
In particular, it will be less effective if the hazard ratio between groups does not follow 
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Exercise 
Type 
Bicycle 
Treadmill 
-2 log likelihood 
Without time dependent With time dependent 
covariates covariates 
933.88 
1455.03 
933.13 
1454.56 
Difference p- 
(-X'2 ) value 
0.75 0.69 
0.47 0.79 
Table 3.2 Results of adding time dependent covariates to Cox models for the time to 
anginal pain 
a monotonic trend; in such instances a further time-dependent covariate, including a 
quadratic function of time, might be considered. 
Example 3.3 Time Dependent Covariates in Cox PH Model for TIBET Time to Anginal 
Pain 
The TIBET study involved the comparison of three treatment regimes. The 
proportional hazards model for the time until the onset of anginal pain, allowing for the 
effects of treatments can be written as 
x(tlz)=xo(t)exp{ß, z, +ß2z2}, (Eq. 3.6) 
where zi and z2 are indicator variables for whether the patient is receiving the first or 
second treatments. The effects of the third treatment are absorbed into the baseline 
hazard, 2 o(t), and the parameters ßl and ß2 estimate effects of the first and second 
treatments relative to that of the third. Assuming that zl identifies treatment with 
atenolol and z2 nifedipine, fi(t) will be the hazard function of an individual on the 
combination therapy. 
Adding time dependent covariates involves fitting the model 
?, (tlz)=? (t)exp{ßizl +ßiz1(log(t)-7)+ß3z2 +ß. Z2(leg(t)- y)} (E9.3.7) 
where y is the mean log failure time. Evidence that either ß2 or ßä are non-zero would 
indicate that there are time trends in the hazard ratios between atenolol and combination 
or between nifedipene and combination respectively. The change in -2(log likelihood) 
between the models represented by (Eq. 3.6) and (Eq. 3.7) will follow a x2 distribution 
if the hypothesis of proportional hazards is true. 
Table 3.2 shows the improvement in fit as measured by the change in -2(log 
likelihood) caused by including time dependent covariates into the Cox models. There is 
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no sign that any of the more complex models gives a better fit, so there is no evidence to 
suggest that the proportional hazards assumption is incorrect. 
3.5.2.3 Distinct Time Epochs 
This method can be used to give a global test of the proportional hazards 
assumption, as well as providing a graphical representation of changing hazard ratios 
over time. Briefly, the time axis is divided into distinct intervals, or epochs, and the 
model is fitted to the data in each epoch. As a global test of the proportional hazards 
assumption, the individual models are compared to the model applied to the full dataset. 
Graphically, the regression coefficients for each model parameter can be plotted against 
time, to look for patterns in hazard ratios over time. The times that divide the epochs 
would normally be chosen to keep roughly equal numbers of events in each dataset, 
though in some situations, particularly for the purposes of presentation, natural dividers 
might be more convenient, such as every year in a long-term follow-up study. 
Splitting the time axis into two epochs, the cut-point might be the median failure 
time, T0.5, so that approximately half of the observed failures fall into each epoch. Let 
the full dataset be denoted by {Ti, Si: i=1,2, ..., n}. 
The set of data corresponding to the first epoch will contain all subjects, with 
survival times right-censored at T0.5. That is, if Ti S To, 5, then the survival time is Ti and 
the failure indicator is Si. If, on the other hand, Ti > T0.5, then the survival time is To. 5 
and the failure indicator is 0. The set of data corresponding to the second epoch will 
consist of the full data set left-truncated at To, 5. That is, it will only contain observations 
for those subjects where Ti > T0.5; the failure indicators will be unchanged. 
In large studies where many failures are observed, data sets can be created based 
on more than two epochs. Fork epochs the cut-points will be {to, t1) ..., tk}, where tß_1 < 
tj, to =0 and tk = oo. Left truncating at tj_1 and right censoring at tt creates the data set for 
thejth epoch. 
A significance test of the proportional hazards assumption is achieved by 
comparing the log likelihood of the full model to those of the model applied to the k 
epochs. The statistic for the global test will be 
-2x log lik(full model) -- 2Z log lik(j`h epoch model) 
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Exercise Type Number of Epochs - 21: log lik Difference df p-value 
1 933.88 --- 
Bicycle 2 933.86 0.01 2 0.995 
4 924.40 9.48 6 0.15 
1 1455.03 --- 
Treadmill 2 1454.71 0.32 2 0.85 
4 1451.44 3.59 6 0.73 
Table 3.3 Results of fitting Cox models when the time axis is divided into distinct 
epochs 
which, under the null hypothesis of proportional hazards, will follow a x2 distribution 
with q(k-1) degrees of freedom, where q is the number of regression parameters 
estimated in each model. 
This method has the advantage that non-monotonic changes in hazard ratio can be 
detected. Any departures from the proportional hazards assumption can be evaluated by 
plotting the regression parameters for each covariate against time. The time value 
against which to plot effect estimates is arbitrary, though the median or mean failure 
time of those failing during each epoch would seem the most sensible options. 
Example 3.4 Distinct Time Epochs in Cox PH Model for TIBET Time to Anginal Pain 
Table 3.3 shows the values of -2(log likelihood) for the model fitted to all the data 
(1 epoch), as well as the sum of -2(log likelihood) for models fitted over partitioned 
time axes (2 or 4 epochs) and the change in -2(log likelihood) compared to the full 
model. The degrees of freedom (d. f) for the x2 distribution of this difference under the 
hypothesis of proportional hazards and the corresponding p value are also shown. These 
figures give no evidence against the proportional hazards assumption. 
3.5.2.4 Score Process 
The methods presented thus far can be used for any proportional hazards 
regression model. The following two methods are specifically designed for use with the 
Cox model. They are most readily described by adopting the notation of the Anderson- 
Gill generalisation of this model89, which will be described briefly here. 
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Each subject is associated with a counting process, Ni(t), which increases by 1 at 
each event time. The standard survival situation, where each subject may experience at 
most one event (for example, death), N; (0) =0 for all i; if subject i experiences the event 
at time t; then Ni(t) =0 for all t<t; and Ni(t) =1 for t >_ t;. N; (t) therefore "counts" the 
number of events experienced by subject i up to and including time t. Also associated 
with each subject is the risk indicator function, Y; (t), which indicates if subject i is at 
risk and under observation immediately prior to time t; thus if subject i has a survival 
time of t;, at which point they either suffer an event or are censored, then Y; (t) =1 for all 
t <_ t;, and Y; (t) =0 for all t>t;. The proportional hazards regression model is then 
written as a, (tlz) = Xo(t)Y; (t)exp(zß). 
Within the framework of the Anderson-Gill generalisation of the Cox proportional 
hazards model, the partial likelihood is written as 
dN; (s) 
Lp@lz)=flff 
Y; (s)exp(zjß) 
i=i sZo Y , j_, 
Yj(s) exp(z , f; 
) 
Notice that dN; (s) =1 only at the instant that subject i fails, if at all; otherwise 
dN; (s) = 0. Consequently, contributions are made to the likelihood only at those instants 
where subjects are observed to fail, and the product over s>_0 need only be calculated at 
the unique failure times. The derivatives of the log partial likelihood with respect to ß 
are 
n 00 a(ý 
1ogLp = 
${ z; j -zj 
(fi, s)} dN; (s) ap 
j i=1 0 
where 
n 
lY; (s)z; 
jexp(z; ß) 
Z; 
(ß, s) =' In 
l Y; (s) exp(z; ß) 
The interpretation of zi (j ,t (k)) 
is as a weighted mean of the jth covariate amongst 
those still at risk just before time t(k), with weights equal to the hazard for each 
individual. 
The j`h score process, Si(t), is defined as 
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n CO 
Sj(t)_ J{z; j -zj(ß, s)}dN; 
(s), 
ý_ý 0 
where 0 is the maximum partial likelihood estimate of 0 from the Cox proportional 
hazards model. The standardised score process, S, ' 
(t), is defined as 
s; (t)=v(j)sj(t), 
where VOj) is the estimated variance of the jt' parameter estimate. Sj(0) = S#o) = 0, 
and it can be shown9° that S j*(t) converges asymptotically to a tied down Brownian 
motion process, Wo(t). This result can be used to derive a test of the fit of the j`h 
covariate in the model; a possible statistic for such a test could be the maximum 
deviation of the standardised score process, sup 
l Si (t)l . Critical values 
for this statistic 
ost<o 
can be found by referring to the distribution of supl Wa 
(t)l 
, which 
has been tabulated 
ost<i 
elsewhere91, but it is not known how well the statistic fits this distribution with 
moderate sample sizes, heavy censoring or a large number of tied failure times. 
The increments of the unstandardised score process, f{z; j - zjß, s)}dN; 
(s), are 
0 
the Schoenfeld residuals92 of a fitted Cox proportional hazards regression model and 
readily accessible with many statistical computer packages. As an alternative to 
comparing sup 
IS 
j* 
(t)l to the distribution of supl Wo (t)) ,a randomised permutation test 
of the observed statistic could be used as a test of the proportional hazards assumption 
for the jt' covariate. This requires the calculation of the test statistic using a large 
number of random reorderings of the Schoenfeld residuals; the distribution of values 
obtained is taken as the null distribution to which the observed value is compared to 
obtain a p-value. Since deviations from the proportional hazards assumption are evident 
from large values of the statistic, the p-value will be one-sided. Whichever method is 
used, the test statistic should be sensitive to departures from the proportional hazards 
assumption where the effect of a covariate is increasing or decreasing over time, but not 
to situations where effects vary in a more complex manner. 
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Figure 3.4 Standardised score processes for time to anginal pain during (a) bicycle and 
(b) treadmill exercise 
Example 3.5 Score Process for Cox PH Model of TIBET Time to Anginal Pain 
Figure 3.4 shows the standardised score processes for each treatment contrast, 
relative to Atenolol therapy, for the data from both exercise types. The critical value91 of 
sup IS; (t)I at the 5% significance level is 1.4802, and it is clear that none of the 
Ost<a, 
processes shown approach this value. This is confirmed by the results given in Table 
3.4, which gives the maximum observed deviation of the processes, the 5% critical 
values based on 100,000 random permutations of the Schoenfeld residuals, and an 
approximate p-value for the observed data based on the randomised permutation test. 
Again there is no evidence against the proportional hazards assumption. 
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Exercise 
Type Treatment Contrast 
Observed 
maximum 
Threshold p 
value 
Nifedipine-Atenolol 0.85 1.33 0.42 
Bicycle 
Combination-Atenolol 0.86 1.43 0.51 
Nifedipine-Atenolol 0.54 1.54 0.97 
Treadmill 
Combination-Atenolol 0.67 1.61 0.89 
Table 3.4 Observed maximum absolute values of score processes, with approximate 
thresholds and p-values from randomised permutation tests (sample size =100,000) 
3.5.2.5 Time Varying Coefficients 
The following method for checking the proportional hazards assumption of the 
Cox model is based on considering a more general model and then testing if the new 
model would offer a significant improvement in fit. It provides a global test of the 
proportional hazards assumption, and for each covariate it gives a statistical test of the 
assumption as well as a graphical representation of how its effect exhibits non- 
proportionality. 
Under the assumption of proportional hazards, the effect of a covariate is constant 
over time. The time varying coefficients (TVC) mode192°93 generalises the standard 
proportional hazards model by allowing the coefficients for each covariate to be a 
function of time. Using the Andersen-Gill notation, the TVC model can be written as 
X(tlz 1)=10 
(t)Y1 (t)exp(z 
i ß(t)), 
so that the Cox model is expressed as the special case, ß(t) = P. To test the proportional 
hazards assumption, j3(t) is written as ß+ G(t)O, where G(t) is a diagonal pxp matrix (p 
being the number of covariates in the model), with elements Ge(t) = ge(t) that vary about 
0. G(t) is chosen in advance according to the type of non-proportional hazards that it is 
desired to detect. Under this formulation, a test of the proportional hazards assumption 
is a test of the hypothesis 0=0. 
Let there be d observed events, occurring at times tk, where k=1,2, ... d, and 0 <_ 
tl 5 t2 S ... < td 5 co. Under the proportional 
hazards model, the conditional weighted 
mean of the covariates amongst those still at risk at time s is 
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n 
j]Y; (s)z; exp(z; ß) 
E Y; (s) exp(z; ß) 
i-I 
and the conditional weighted variance-covariance matrix of the covariates is given by 
n 
Y; (s) z; z; exp(z; I3) 
VZS) i=' 
n 'z(ßßS)z(ßßS)/. 
Yº (s) exp(z; (3) 
i=l 
If is the maximum partial likelihood estimate of ß under the proportional 
hazards model, the observed Schoenfeld residuals92 under this model are defined to be 
rkýß)=z(k) - zlß, tk/ 
IkItk)--'0'tk)I 
=Tk(ß(tk))+{Z(Attkl, tk)-Z(, tk)} 
where z(ß(s), s) is the conditional weighted mean of the covariates amongst those still at 
risk at time s under the TVC model. If the TVC model is correct, then the true 
Schoenfeld residuals under this model, rk(ß(tk)), have zero mean. By expanding 
z(ß(t k 
), t k) as a Taylor series about ß(t k) =6 and ignoring 2 "a and higher order terms, 
_ 
(ß(tk)-F'} 
Zýltk)ýtk)-Zýýtk)ý 
aýZv'tk) 
ßß 
= VZ02tk)(r(tk)-P) 
so that 
E(VA, tk)rk(A))=E(Y(tk)-M) 
= 
(tk)-ß 
=G(tk)e. 
That is, V Z' (i, tjrk O) has an expectation of zero under the proportional hazards 
assumption, but an expectation of G(tk)O under the TVC model. 
If there are proportional hazards, a plot of Vz' iptk 
)rk (ßj) 
against gg(tk) should 
show no linear association. If the specified TVC model is more appropriate it will have 
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slope O. 6 can be estimated by ordinary least squares, but since the observed residuals 
rk 
(i) 
are correlated, it is more correct to use a weighted least squares estimate93, namely 
e=D iI: C'`tk)rko/ 
k 
where 
º 
D=EG(tk)VZ('tk)G(t3[G(tk )VZ( ß>tk)][2: VZý>tk) 
Z 
k 
('tk) 
kkk 
and a global test of the proportional hazards assumption is given by the statistic 
[G(tk 
)rk 
(i) 
D' EG(tk)rký) 
k 
which is asymptotically xP distributed. In practice, VZ t k) can be substituted by the 
average value 
Yd' where I 
(=j: 
VI. ('tk)) is minus the second derivative of the log 
k 
partial likelihood from the Cox model. 
The advantage of this method is its versatility, since it provides a formal test of 
deviations from the proportional hazards assumption, and a graphical representation of 
how the effect of each covariate changes over time. Different choices of G(t) lead to 
different alternative hypotheses to proportional hazards, and many global tests that have 
been proposed can be seen as special cases of this approach93. 
Example 3.6 Time Varying Coefficients in Cox PH Model for TIBET Time to Anginal 
Pain 
Figure 3.5 shows plots of VZ' 
(i 
, tk 
)rk ()ý (j versus t, where j subscripts the 
two treatment variables in the Cox model for the time to anginal pain during bicycle 
exercise. Each plot shows a smooth of the data with confidence bands at ±2 standard 
errors. This shows the functional form of ß; (t), so that a horizontal line is consistent with 
the assumption of proportional hazards, whereas a trend in the graph would imply an 
increasing or decreasing treatment effect. These and similar figures for exercise using a 
treadmill give no indication of non-proportional hazards. 
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Figure 3.5 Time varying coefficients plots for (a) Nifedipine-Atenolol and (b) 
Combination-Atenolol treatment contrasts under Cox model for time to anginal pain 
during bicycle exercise. 
Table 3.5 gives the results of the formal tests of proportional hazards. For each 
outcome, the test results for each treatment variable and for a global test of both 
variables are listed. None of these tests indicate non-proportional hazards. 
N 
'ý. 
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Exercise Type Contrast x2 df p-value 
Nifedipine-Atenolol 0.46 1 0.50 
Bicycle Combination-Atenolol 0.02 1 0.90 
Global 0.77 2 0.68 
Nifedipine-Atenolol 0.003 1 0.95 
Treadmill Combination-Atenolol 0.05 1 0.83 
Global 0.08 2 0.96 
Table 3.5 Results of time varying coefficients test for non-proportional hazards in Cox 
models for treatment effects 
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CHAPTER 4 Estimation of Treatment Effect 
Differences II: Other Methods 
This Chapter will outline a number of alternative methods that have been or could 
be used to analyse exercise test data from clinical trials. Some alternative methods of 
analysing censored survival data will be considered, followed by some standard 
regression methods, such as analysis of variance, that have been used with such data, 
despite their inherently censored nature. Throughout, methods will be illustrated using 
data from the TIBET Study. 
4.1 Parametric Distributions of Survival Time 
The Cox proportional hazards model described in Section 3.3 makes no 
assumptions regarding the functional form of the baseline hazard function, ? o(t). The 
partial likelihood method of estimating the regression coefficients effectively treats the 
baseline hazard as a nuisance. The popularity of this model lies in its flexibility; by 
allowing ko(t) to take any shape, there is no need to assess the fit of the data in terms of 
assumptions about the baseline hazard function. 
There are, however, a number of candidate functions for the distribution of 
survival data for which there is an extensive literature94'9s Some of these are outlined in 
Table 4.1, which shows their hazard functions, X(t) and the survivor functions, S(t). 
The simplest is the exponential distribution, in which the hazard is constant. It is 
often of limited applicability, since it has only one parameter and is therefore sensitive 
to moderate lack of fit, particularly in the tail. It is, however, the most important 
distribution in survival analysis, since many of the other distributions shown in Table 
4.1 contain the exponential distribution as a special case. 
The Weibull distribution is equivalent to the exponential when the shape 
parameter, y is 1. When y<1, the hazard at t=0 is infinite, and decreases with time; when 
y>1, the hazard at t=0 is zero, and increases with time. The linear exponential and 
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Name X(t) S(t) 
Exponential exp(- Xt) 
Weibull xy(, %tY-' expl (,, t) 
J 
Linear exponential + Tt exp[- 
(Xt +Z yt Z )] 
Gompertz exp(, %+yt) exp - 
eX 
y 
{exp(Yt) 
-1} 
(kt)y-, exp(- xt) 
Gamma kx y-' ex , %x x rý 
f(x)T' exp(-, %x)dx jý p(' ýY) t 
t 
YýýY 
Log logistic 
1 v} 
1+ (tx )Y 
1t 
1+ 
Table 4.1 Some common distributions of survival times 
Gompertz distributions both revert to the exponential when y=0, and otherwise have 
monotonically increasing (if y>O) or decreasing (y<O) hazard functions. Regardless of y, 
the hazard at t=0 is X with the linear exponential distribution, or exp(? ) with the 
Gompertz distribution. The gamma distribution contains the exponential as a special 
case when y=1. For y<1 then hazard decreases monotonically from infinity and when 
y>1 it increases monotonically from zero; in either case the hazard approaches 2, as time 
progresses. 
The log logistic distribution does not include the exponential as a special case. 
Indeed, when y>1, the hazard function is not monotonic, having a single maximum 
value, though when y<1, the hazard is monotonic decreasing. 
Example 4.1 Parametric Model Selection with TIBET Time to Anginal Pain 
When considering which survival distribution would be most suitable as a model 
for a particular set of data, graphical techniques based on the cumulative hazard 
function, A(t), can be used. The Kaplan-Meier estimate of the survivor function, 
S(t), is 
used to estimate the cumulative hazard function, since A(t) = -log§(t). For example, 
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Figure 4.1 Cumulative hazard plots for the time to anginal pain, by exercise type 
using the time to anginal pain data from the TIBET Study, Figure 4.1 shows Ä(t) 
plotted against t for those exercising on a treadmill and on a bicycle separately. The 
simplest survival distribution, the exponential distribution, with a constant hazard would 
have a cumulative hazard function that is linear in t. Similarly, if the data followed a 
linear exponential distribution, the cumulative hazard function would be quadratic in t. 
These distributions are clearly not supported by these data, though the fact that the two 
curves are of a similar shape would suggest at this stage that the time to anginal pain 
could follow similar distributions under the two types of exercise. 
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Figure 4.2 Cumulative hazard plots for the time to anginal pain with y-axis log- 
transformed, by exercise type 
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Figure 4.3 Cumulative hazard plots for the time to anginal pain with x- and y-axes log- 
transformed, by exercise type 
By showing k(t) on a log scale, a linear relationship would suggest a Gompertz 
distribution, since 
log(A(t)) oc 1og(exp f ,%+ yt} -1) 
sz: ý x +yt 
which is also clearly not the case, as shown by Figure 4.2. However, if logA(t) were 
linear in log(t), this would suggest a Weibull distribution, since 
log(A(t)) = y[log(? )+ log(t)]. 
Figure 4.3 shows this to be a possibility with these data. There appears to be a 
predominantly linear relationship over most of the time axis, though there is some 
evidence of non-linearity for large exercise times. The variance of the estimator of A(t) 
is greatest towards the right of this graph, so this apparent non-linearity may be within 
the limits of chance. However, the patterns are similar for both types of exercise, which 
might be taken to indicate a true deviation from the Weibull distribution. For the 
purposes for further examples, it shall be assumed that these data are Weibull 
distributed, though the goodness-of-fit of any models should be examined for large 
values oft in particular. 
5ý 
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4.2 Parameter Estimation 
Whilst many standard statistical packages will fit parametric survival models for 
some of the distributions shown in Table 4.1, particularly the Weibull distribution (and 
therefore the exponential distribution), it is often not possible to compare the fits of all 
of the distributions shown. However, by the application of maximum likelihood, it is, in 
general, possible to fit any specified distribution to any set of survival data. If {t1,61: 
i=1,2,..., n} are an observed set of survival times and failure indicators, and'%(tjO), A(tIO) 
and S(tIO) are the proposed hazard, cumulative hazard and survivor functions, dependent 
upon parameters 0, then the likelihood can be written as 
fIs(t1Io)x(t 
L(OI{t;, S, :i =1,2,..., n}) =; 
1 0)81 
and the log likelihood as 
{ A(t; IA)+S; log%(t; l6)} l(9I{t; , S; : 
i=1,2...... n})=F 
so that as long as the hazard and cumulative hazard functions can be expressed 
algebraically, standard maximum likelihood methods can be used to estimate 0. 
Inferences can be drawn about and confidence intervals constructed for parameter 
estimates either by using likelihood ratio tests or by using the second derivative of 
minus the log likelihood to estimate the variance-covariance matrix for the estimates. 
Example 4.2 Weibull Parameter Estimation for TIBET Time to Anginal Pain 
Table 4.2 shows the maximum likelihood estimates obtained for the Weibull 
distribution parameters X and y, using all data as well as data from subgroups defined by 
exercise type and treatment group. To evaluate whether the times to anginal pain follow 
different distributions under the two types of exercise, the log likelihood of the model 
fitted to all data is compared to those obtained from the data separated by exercise type. 
Twice the difference in log likelihood is compared to a x2 distribution with 2 degrees of 
freedom (since an additional 2 parameters are estimated), yielding a highly significant 
(p<0.0001) result and providing very strong evidence that the distributions are not the 
same under treadmill and bicycle exercise. 
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Estimates 
Data 
Scale Shape 2xLog Test 2x Log p xy Lik Lik 
All A 0.064 2.03 -2061.3 
Treadmill T 0.090 2.28 -1132.5 
Bicycle B 0.053 2.60 -822.2 
T=B 106.7 <0.0001 
Treadmill TA 0.088 2.37 -363.6 (Atenolol) 
Treadmill TN 0.090 2.21 -403.5 T =T =T 0.6 0.97 (Nifedipine) A N- C 
Treadmill TC 0.092 2.27 -364.7 (Combination) 
Bicycle BA 0.052 2.67 -266.7 (Atenolol) 
Bicycle BN 0.056 2.50 -294.0 BA=BN= Bc 1.5 0.82 (Nifedipine) 
Bicycle Bc 0.053 2.72 -260.0 (Combination) 
Table 4.2 Weibull parameter (2 y) estimates and values of 2xlog likelihood for models 
applied to all data, by exercise types and by treatment groups, with likelihood ratio 
statistics andp-values 
Similarly, within each exercise type, the Weibull distribution is fitted to the three 
treatment groups separately, and the likelihoods compared to test whether the survival 
distributions are different. No evidence of differences can be seen for either treadmill 
(p=0.97) or bicycle (p=0.82) exercise. 
To determine in what way the survival distributions differ between exercise types, 
the likelihood ratio method can be used to derive joint 95% confidence intervals for the 
parameter estimates 5, and y. These are shown in Figure 4.4, and whilst there appears 
to be little evidence that the shape (y) of the survival distributions differ between 
exercise types, the scale (X) of the distribution is larger under treadmill than bicycle 
exercise. This corresponds with a shorter mean time to anginal pain, since the mean of a 
F`i+ YY 
Weibull distributed variable is 1l. 
It is also of note that neither confidence 
interval is close to the value y=1, supporting the earlier observation that the time to 
anginal pain is not exponetially distributed. 
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Figure 4.4 Joint 95% confidence intervals derived by the likelihood ratio method for 
estimates of the scale (, %) and shape (y) parameters of Weibull survival distributions for 
the time to anginal pain from trial subjects exercising with treadmill or bicycle. 
4.3 Regression Models for Survival Data 
In order to estimate differences in treatment effects in clinical trials of antianginal 
therapies, possibly taking account of individual patient characteristics such as age, sex 
and weight, it is most efficient to develop regression models. The effects of explanatory 
variables, or covariates, are quantified by unknown parameters within the framework of 
a comprehensive model. Differences between groups are modelled by inclusion of 0/1 
dummy variables and interaction effects can be examined by the inclusion of additional 
variables formed by combinations of covariates in the same way as with multiple linear 
regression models. This Section outlines some of the possible regression models that 
could be used. 
4.3.1 Proportional Hazards Models 
As described in Section 3.2, the proportional hazards regression model can be 
expressed as %(tjO, P, z)=%o(t, O)y(z, P). The hazard for an individual is the product of a 
baseline hazard function, Xo(t, O), and a function yr(z, (3) of their covariates, constrained 
so that w(O, ß)=1. The parameters 0 encapsulate the underlying survival distribution of 
an individual with covariate vector 0, and the parameters ß quantify the effects of the 
covariates z. The most common function used to represent covariate effects is 
y, (z, (3)=exp(zß). Covariates are commonly organised so that the vector 0 has some real 
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interpretation, for example an individual in the placebo or standard treatment arm of a 
parallel groups clinical trial, or continuous covariates have the mean or median value 
subtracted so that 0 corresponds to a central value. 
Example 4.3 Weibull Proportional Hazards Regression for TIBET Time to Anginal Pain 
Example 4.2 found that a Weibull distribution could adequately describe the 
baseline distribution of the time to anginal pain during both treadmill and bicycle 
exercise. A proportional hazards model could be used to estimate the effects of 
treatment on survival time, with or without adjustment for the effects of other 
covariates. Table 4.3 shows the maximum likelihood estimates obtained by fitting four 
models: the null model, with separate Weibull distributions for the times to anginal pain 
during treadmill and bicycle exercise; a model with two dummy variables to represent 
treatment differences; a model with covariates to represent gender differences and 
effects of age and body weight; and a model including both treatment and covariate 
effects. 
For each model parameter, 95% confidence intervals have been constructed by the 
method of profile likelihood. If the model parameters, 0, are written as a single 
parameter, 0, and the vector of other parameters, 0e, then the function 1(0, Via) is the 
profile likelihood for 0, where 1() is the log likelihood function and is the maximum 
likelihood estimate of O o. A 95% confidence interval for 0 is defined as 
}(j"2ll(0,0)-1(0, A)J5v. 1,0.95}, 
where 1(6, $O)=1(O) is the global maximum log likelihood, and xi o. 95 is the 95th 
percentile point of a x2 distribution with 1 degree of freedom. 
Models with treatment or covariate effects included are compared to models with 
those effects omitted by means of likelihood ratio tests; to ensure comparability all 
models have been fitted using only those subjects for whom there is complete data on 
all covariates. Treatment and covariate effect estimates are interpretable as log hazard 
ratios. 
There is little evidence that treatments affect exercise times (p=0.18 without 
covariate adjustment, p=0.28 with adjustment), though the confidence interval for the 
Nifedipine-Atenolol treatment contrast only just includes zero (-0.01 to 0.27 without 
covariate adjustment, -0.03 to 0.24 with adjustment). Jointly, the three covariates 
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Model 
Age, Sex & Treatments, 
Null Treatments Weight 
Age, Sex & 
Weight 
Weibull parameters 
x 
0.085 0.079 0.086 0.081 
(0.076,0.093) (0.068,0.090) (0.077,0.094) (0.069,0.092) 
Treadmill 
Bicycle 
2.31 2.30 
T (1.94,2.72) (1.93,2.70) 
0.054 0.051 
(0.048,0.059) (0.044,0.057) 
2.35 
(1.97,2.35) 
0.052 
(0.045,0.059) 
7 
2.62 
(2.20,3.07) 
2.63 
(2.21,3.09) 
2.36 
(1.98,2.78) 
0.055 
(0.049,0.060) 
2.74 
(2.30,3.21) 
2.74 
(2.30,3.22) 
Treatment effects 
Nifedipine-Atenolol - 
0.31 
- 
0.28 
(-0.03,0.66) (-0.07,0.62) 
Combination-Atenolol - 
0.11 0.10 
(-0.25,0.48) (-0.26,0.47) 
Covariate effects 
Gender 
(Female-Male) 
0.31 
(-0.18,0.77) 
0.29 
(-0.20,0.74) 
Age 0.22 0.22 
(/10 years, centred at 60 years) (0.02,0.42) (0.02,0.42) 
Weight -0.05 -0.04 
(/10 kg, centred at 75 kg) (-0.20,0.09) (-0.19,0.11) 
Tests 
2xlog likelihood -1483.3 -1479.9 -1475.3 -1472.8 
p (treatment effects) - 0.18 - 0.28 
p (covariate effects) --0.019 0.029 
Table 4.3 Maximum likelihood estimates, with 95% confidence intervals calculated 
by profile likelihood, of Weibull parameters and treatment and covariate effects, with 
likelihood ratio test results, from proportional hazards models with baseline hazard 
stratified by exercise type 
improve the fit of the model (p=0.019 without adjustment for treatment effects), though 
age is the only covariate to have an effect estimate significantly different to zero 
(estimated hazard ratio 1.24,95% CI 1.02-1.52), so that older patients have increased 
hazard and therefore shorter average exercise times. 
Interaction effects can be included in the model between exercise types and each 
treatment or covariate effect, in the same way as with standard linear regression models. 
Building on the model adjusting for treatment and covariate effects, there is evidence of 
an interaction between exercise type and weight (p=0.0072); the estimated hazard ratios 
associated with a 10 kg increase in weight are, under treadmill exercise, 1.17 (0.95, 
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1.44) and under bicycle exercise, 0.79 (0.64,0.98). The other terms in the model are 
effectively unchanged compared with the fourth model shown in Table 4.3. Thus, with 
bicycle exercise, in which the apparatus supports the body, the greater strength 
associated with increased body weight allows longer exercise times and so is associated 
with lower hazard with respect to the occurrence of anginal pain. With treadmill 
exercise, in which body weight must be carried, greater weight will result in higher 
workload and is therefore associated with increased hazard, though this association does 
not reach statistical significance in these data. 
4.3.2 Accelerated Failure Time Models 
The accelerated failure time model can be represented as S(tjO, (3, z)=So(tw(z, ß), 0), 
so that X(t! 0, ß, z)=Xo(tyr(z, ß), 0)yr(z, (3). As with the proportional hazards model, w(0, (3) is 
constrained to be 1. If T is the random variable having survivor function S(tlO, ß, z), then 
the model can be viewed in terms of the relationship T=To/yr(z, ß), where To has 
survivor function So(t, O). Written in this way, w(z, ß) represents the rate at which an 
individual "uses up" time, hence the name of the model. 
If go is the expected value of log(To), 
log(T) =µo (A) -1og{yr(z, ß)} +s 
where s has zero mean and is independent of z. A natural formulation of p(z, ß) is again 
w(z, ß)=exp(zß), so that 
log(T)=µo(6)-zß+E 
and %(tlO, ß, z)=), o(t. exp(zp), O)exp(zp). 
Example 4.4 Weibull Accelerated Failure Time Regression for TIBET Time to Anginal 
Pain 
In the same way as a Weibull baseline hazard was extended in the previous 
example with a proportional hazards model, the same baseline hazard can be used in an 
accelerated life model. Table 4.4 shows the maximum likelihood estimates obtained 
from four models using the same covariates as Example 4.3; a null model with separate 
Weibull baseline hazard functions for those using treadmill or bicycle exercise (this is 
identical to the null model used in Example 4.3), a model adjusting for treatment 
effects, a model adjusting for covariate effects and a model adjusting for both treatments 
and covariates. 
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Model 
Age, Sex & Treatments, Null Treatments Weight Age, Sex & Weight 
Weibull varameters 
0.085 0.080 0.086 0.081 
% (0.076,0.093) (0.069,0.090) (0.076,0.094) (0.071,0.092) 
Treadmill 
2.31 2.31 2.29 2.30 
'1' (1.94,2.72) (1.94,2.71) (1.92,2.71) (1.92,2.71) 
0.054 0.051 0.055 0.053 
(0.048,0.059) (0.044,0.057) (0.050.0.060) (0.046.0.059) 
Bicycle 
2.62 2.63 2.84 2.82 
Y (2.20,3.07) (2.21,3.08) (2.37,3.35) (2.36,3.33) 
Treatment effects 
Nifedipine-Atenolol _ 
0.12 
_ 
0.10 
(-0.01,0.27) (-0.03,0.24) 
Combination-Atenolol - 
0.04 
- (-0.10,0.19) 
0.04 
(-0.10,0.18) 
Covariate effects 
Gender 0.13 0.12 
_ (Female-Male) - (-0.06,0.31) (-0.07,0.30) 
Age 0.09 0.09 
(/10 years, centred at 60 years) (0.01,0.16) (0.01,0.17) 
Weight -0.029 -0.023 
(/10 kg, centred at 75 kg) (-0.087,0.029) (-0.082,0.036) 
Tests 
2xlog likelihood -1483.3 -1480.0 -1474.0 -1471.8 
p (treatment effects) - 0.19 - 0.32 
p (covahate effects) --0.010 0.017 
Table 4.4 Maximum likelihood estimates, with 95% confidence intervals calculated 
by profile likelihood, of Weibull parameters and treatment and covariate effects, with 
likelihood ratio test results, from accelerated failure time models for the time to 
anginal pain with baseline hazard stratified by exercise type 
The conclusions reached by this model are very similar to those reached using a 
proportional hazards model. Overall, there is no evidence of treatment effects, though 
the Nifedipine-Atenolol treatment effect contrast approaches significance. Inclusion of 
other covariates does improve the fit of the model, primarily through the effect of age. 
As with the proportional hazards model, there is evidence of an interaction between 
exercise type and body weight (p=0.010). The effect estimates for a 10 kg increase in 
weight, adding an interaction between exercise type and weight to the last model shown 
in Table 4.4 are for treadmill exercise, 0.06 (-0.02,0.16) and for bicycle exercise, -0.08 
54 
(-0.15,0.01). Neither effect is significantly different to null, despite the strong evidence 
that the two effects differ from each other. 
4.3.3 Other Regression Models 
There are some less common alternatives that can be used to model survival data. 
Their lack of popularity amongst the medical literature could be due to a number of 
factors. There is a vast literature on the use of proportional hazards and accelerated 
failure time models, which are implemented within a number of statistical software 
packages, with a small selection of baseline hazard functions, at least. The most widely 
used regression method, that of the Cox proportional hazards model, is highly flexible 
with respect to the baseline hazard function, can be easily applied with standard 
software, and effect estimates are simple to report and are widely understood in terms of 
hazard ratios. The alternative methods shown here are more difficult to implement and 
would be less readily accepted unless a considerable benefit over more commonly used 
methods could be demonstrated. 
Under an additive hazards model, hazard functions are parallel between groups, 
rather than proportional. This can be expressed as 
X(tle, ß, z)=a, a(t, O)+W(z, ß), with y, (z, R)? O. 
The transferred origin model incorporates covariate effects through a translation in time, 
so that 
a, (tle, ß, z)=Xo(t+W(z, P), O) 
and, if Xo(x) is defined to be zero for negative x, then if w(z, ß)<O, -y(z, ß) can be 
thought of as a hazard free interval, during which time an individual with covariates z is 
immune from failure. Otherwise, if yr(z, ß)>O, the individual can be considered to be at a 
more advanced stage relative to one with a covariate vector of 0. 
In principle, different types could be combined within the same model, so that, for 
example, a model could consist of proportional hazards and a transferred origin parts, 
X(tle, ß, r, z)=o(t+w(Z, ß), O)4(z, Y) 
where some components of ß and y could be zero, corresponding to whether a particular 
element of z acts only through the proportional hazards or transferred origin parts of the 
model. 
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4.4 Non-parametric Survival Methods 
The log rank test96 is used to compare survival distributions between subgroups of 
a population and can be reduced to a comparison of the observed and expected numbers 
of events using a x2 test94. If rj is the size of the risk set at the jth failure time, with rik 
being the size of the risk set amongst the kt' subgroup (k=1,2,..., K), and dd the number 
of events occurring at the jt' failure time, then the expected number of events in the kth 
subgroup is 
rk Ek =Ed. dý 
r; 
The test statistic is defined as 
X2 = 
Dk 
- 
Ek z 
k 
Ek 
where Dk is the number of events observed in the 0 subgroup. If the survival 
distributions of the K subgroups are the same, then X2-xk_1, so that large values of X2 
provide evidence of differences between the K survival distributions. 
Example 4.5 Log Rank Test for Treatment Effects on Time to Anginal Pain, TIBET 
Study 
Table 5.2 shows the results of log rank tests applied to the time to anginal pain 
data from the TIBET Study. The test is applied to all data, to data from treadmill and 
bicycle tests separately, and to all data, stratified by exercise type. There is no evidence 
from any of these tests of any differences in survival between treatment groups. 
4.5 Standard Regression Methods 
The methods considered thus far are designed for use with censored data. These 
methods are preferable for use with exercise test data, because endpoints such as the 
occurrence of anginal pain, or significant ST-segment depression need not necessarily 
occur before the patient has to stop exercising for some other reason, such as fatigue or 
breathlessness. 
However, the subjects recruited into a clinical trial of antianginal therapies may be 
selected on the basis of having poor exercise tolerance, and even under an improved 
treatment regime, would most likely experience an ischaemic event during exercise. As 
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Treatment All Treadmill Bicycle 
Stratified by 
Exercise Type 
Subjects 218 114 104 218 
Atenolol Obs 85 53 32 85 
Events 
Exp 90.4 56.3 34.1 90.3 
Subjects 219 111 108 219 
Nifedipine Obs 96 60 36 96 
Events 
Exp 88.3 58.2 30.9 89.2 
Subjects 211 107 104 211 
Combination Obs 85 54 31 85 
Events 
Exp 87.3 52.5 34 86.5 
x2 (2 df) 1.1 0.3 1.2 0.9 
p 0.59 0.86 0.54 0.64 
Table 4.5 Log rank test results for time to anginal pain for all subjects, separately by 
exercise type and stratified by exercise type; numbers of subjects, numbers of events 
(Obs), expected numbers of events (Exp), with associated x2 statistics and p-values 
a result, the proportion of exercise tests producing censored observations might be 
small, as would any loss of efficiency from applying standard regression techniques 
instead of survival analysis methods. Also, it is likely that withdrawals due to non- 
ischaemic events would occur after a long period of exercise, so that times to ischaemic 
and non-ischaemic events would be positively correlated. Furthermore, the outcome of 
total exercise time is never censored, unless one considers exercising to the end of the 
exercise protocol, or withdrawal due to particular causes, such as leg pain or cramp, to 
determine an unobserved total exercise time. If biases or loss of efficiency due to 
ignoring censoring are of concern, then analyses can be repeated with censored 
observations included or excluded, to compare the results and assess the impact of 
censoring. 
Nevertheless, the use of standard methods that do not take account of censoring 
where it occurs, is conceptually incorrect and is theoretically and empirically biased52. 
For the analysis of clinical studies involving human subjects, the most efficient methods 
should be used97, so the analysis of censored data using these methods could not be 
advocated. 
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Effect Estimate (s) Censored Observations (95% Cl) All Data Excluded 
p-value 
490.5 388.9 
Intercept (459.3,521.8) (343.8,434.0) 
<0.0001 <0.0001 
Exercise 198.2 185.2 
( Bicycle - Treadmill ) 
(168.4,228.0) (142.5,227.9) 
<0.0001 <0.0001 
Treatment -0.5 3.6 
(Nifedipine - Atenolol) 
(-34.9,33.9) (-45.7,52.9) 
0.98 0.89 
Treatment -7.7 10.1 
( Combination - Atenolol) 
(42.1,26.7) (41.9,62.0) 
0.66 0.70 
Gender -116.9 -101.0 
( Female - Male) 
(-159.7, -74.1) (-170.7, -31.4) 
<0.0001 0.0050 
Age -55.6 -39.6 
(/10 years) 
(-74.6, -36.7) (-64.9, -14.4) 
<0.0001 0.0024 
Weight -20.9 -10.4 
(/10 kg : Treadmill) 
(-42.5,0.7) (-39.4,18.6) 
0.058 0.48 
Weight 58.9 41.5 
( /10 kg : Bicycle) 
(41.6,76.2) (14.7,68.4) 
<0.0001 0.0028 
Table 4.6 Linear regression model effects estimates with 95% confidence intervals and 
p-values, for models of time to anginal pain or end of exercise, using all data or 
restricted to subjects experiencing anginal pain 
4.5.2 Exercise Times 
When analysing exercise times using classical statistical techniques, the natural 
methods to use would be based on Normal theory, such as t-tests, ANOVA or, more 
generally, multiple linear regression. These methods are robust to mild departures from 
the assumption of Normality, though the data may require transformation to ensure that 
model residuals are Normally distributed. Otherwise, non-parametric methods, such as 
the Wilcoxon Mann-Whitney test could be used. 
Example 4.6 Multiple Linear Regression Analysis of Time to Pain, TIBET Study 
Table 4.6 shows the effect estimates obtained by fitting a linear regression model 
to the time to anginal pain data from the TIBET Study, with those subjects who did not 
experience pain during the test having their total exercise time substituted. Also shown 
are the estimates from the same model applied only to those subjects that experienced 
pain. The model shown includes effects of exercise type, treatment, gender, age and, for 
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Figure 4.5 Normal probability plot of residuals from linear regression model of time to 
anginal pain or end of exercise, as shown in Table 4.6 
each exercise type separately, weight. This was consistently the best model found 
amongst those that included treatment effects, regardless of whether or not censored 
individuals were included in the analysis. 
There is no evidence that exercise times are any different under the three 
treatments. Exercise times are more than 3 minutes longer on a bicycle than on a 
treadmill, and older patients have shorter exercise times. The weight effects are different 
under the two exercise types, with heavier patients exercising for longer with a bicycle, 
and, if there is any real effect, for a shorter period on a treadmill. 
Whereas gender was not found to have any effect on exercise times when using 
survival models, it has a large effect in this analysis. Using all data, women are seen to 
exercise for nearly two minutes less than men, an effect that persists when those who do 
not experience anginal pain are excluded. 
Perhaps surprisingly, it was not necessary to transform exercise times to obtain an 
adequate model fit in terms of the assumption of Normally distributed errors. Figure 4.5 
shows the Normal probability plot of the residuals from the first model shown in Table 
4.6. The graph is similar when the model is restricted to those who experienced anginal 
pain during exercise. 
4.5.3 Endpoints 
The analysis could be focused on the occurrence of ischaemic endpoints, such as 
anginal pain or significant ST-segment depression. The proportions of individuals 
59 
Treatment Group 
Atenolol Nifedipine Combination x2 p-value 
All 87/221 96/219 88/214 0 9 0 63 (39.4%) (43.8%) (41.1%) . . 
Anginal Pain Treadmill 
54/116 60/111 56/109 1.3 0.52 (46.6%) (54.1%) (51.4%) 
Bicycle 33/105 36/108 32/105 0.2 0 90 (31.4%) (33.3%) (30.5%) . 
All 157/226 135/232 126/224 7 9 0 0078 (69.5%) (58.2%) (56.2%) . . 
1mm ST-Segment Depression Treadmill 
90/119 74/119 71/116 6.9 0 032 (75.6%) (62.2%) (61.2 /o) . 
Bicycle 67/107 61/113 55/108 3.2 0 20 (62.6%) (54.0%) (50.9%) . 
Table 4.7 Numbers and percentages o f subjects experiencing anginal pain and ST- 
segment depression during exercise, for all subj ects and by exercise type 
suffering an event in different treatment groups could then be compared using X2-tests 
or, to take account of covariate information, logistic regression. 
Example 4.7 TIBET Ischaemic Endpoints 
Table 4.7 shows the numbers of individuals suffering the ischaemic endpoints of 
anginal pain and lmm ST-segment depression during exercise, with x2 tests for 
association. There is no evidence of any treatment differences in the proportions 
suffering anginal pain, though there is evidence that more of those using Atenolol suffer 
lmm ST-depression during exercise (p=0.0078). The data as shown also suggest this 
difference to be apparent during treadmill rather than during bicycle exercise, though a 
formal test of this difference, using logistic regression, is required. 
Table 4.8 shows the results of applying logistic regression models to the 
occurrence of anginal pain and 1mm ST-segement depression during exercise. All 
models include exercise type and treatment, though models are shown with and without 
adjustment for gender, age and body weight. Though the Nifedipine-Atenolol treatment 
contrast appears to suggest some effect upon the occurrence of anginal pain, as a whole 
there is no evidence of any treatment effect (joint treatment effect; p=0.12 without 
covariates, p=0.088 with covariates). However, there is evidence that treatments affect 
the occurrence of 1mm ST-segment depression during exercise, with (p=0.023) or 
without (p=0.020) adjustment for covariates. Under the adjusted model, both Nifedipine 
(odds ratio [OR]=0.64 [95% CI: 0.41,0.99], p=0.045) and combination therapy 
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Endpoint 
Odds Ratio 
(95% Cl) Angina 
l Pain Imm ST-Segment Depression 
p-value Without With Without With 
Covariates Covariates Covariates Covariates 
Exercise Type 
0.56 0.57 0.78 0.73 
( Bicycle / Treadmill ) 
(0.39,0.80) (0.39,0.82) (0.55,1.10) (0.51,1.05) 
0.0017 0.0028 0.16 0.090 
Treatment 1.55 1.60 0.63 0.64 
(Nifedipine / Atenolol) 
(1.00,2.39) (1.03,2.50) (0.41,0.96) (0.41,0.99) 
0.052 0.038 0.031 0.045 
1.10 1.09 0.56 0.56 Treatment 
( Combination / Atenolol) 
72) (0 7 (0.70 71) (0.37 6) (0.36 86) 
0.69 0.70 0 0087 0.0089 
Gender 0.67 1.06 
( Female / Male) 
(0.38,1.20) (0.62,1.83) 
0.18 0.83 
Age 
0.96 1.49 
(/10 years) 
(0.75,1.22) (1.18,1.89) 
0.73 0.0010 
Weight 1.04 1.14 
(/10 kg) (0.86,1.24) (0.96,1.36) 0.71 0.15 
Table 4.8 Logistic regression model effect estimates (as odds ratios), with 95% CIs and 
p-values, for models of occurrence of anginal pain or lmm ST-segment depression 
during exercise 
(OR=0.56 [0.36,0.861, p=0.0089) reduce the likelihood of suffering lmm ST-segment 
depression during exercise. 
For the endpoint of anginal pain, there is no evidence that any of the covariates 
considered influences the occurrence of the endpoint. There is evidence that advanced 
age increases the occurrence of lmm ST-segment depression during exercise (OR=1.49 
/10 years [1.18,1.89], p=0.0010). With regard to the type of exercise performed, those 
using a bicycle appear less likely to suffer anginal pain (adjusted model, OR=0.57 [0.39, 
0.82], p=0.0028), and though the trend is in the same direction, does not reach statistical 
significance for the effect estimate for the occurrence of 1mm ST-segment depression 
(adjusted model, OR=0.73 [0.51,1.05], p=0.090). 
Since no account has been taken of the time spent exercising in this analysis, the 
results are difficult to interpret. For example, older patients are no more likely to 
experience anginal pain than younger patients according to this analysis, though 
previous analyses suggest that older patients experience pain after a shorter period of 
exercise. Consequently, an analysis based on the occurrence of ischaemic events after a 
fixed period of exercise could be used to avoid this source of confounding. 
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CHAPTER 5 Interval Censoring 
5.1 Introduction 
Myocardial ischaemia during an exercise test can be determined by the occurrence 
of anginal pain by the subject or through the use of an electrocardiogram (ECG). Figure 
5.1 shows a normal ECG trace, and the trace of a patient who is suffering from 
ischaemia. The ST-segment is the horizontal section of the trace to immediately to the 
right of the "spike"; when ischaemia occurs, the ST-segment of the ECG trace tends to 
move downwards, as in Figure 5.1(b). By monitoring the ECG of a patient during 
exercise, it is possible to detect the incidence of myocardial ischaemia in the absence of 
anginal pain. The ECG can also inform of adverse events such as severe ischaemia or 
dysrhythmia that indicate that the test should cease for the safety of the patient. 
The occurrence of >_lmm ST-segment depression is often used to indicate 
myocardial ischaemia, though the cut-off value is to some degree arbitrary. Larger 
values will be more specific, but less sensitive for detecting ischaemia. Other values that 
have been chosen vary from 0.5 to 2mm. In terms of patient safety, reasons to stop an 
exercise test would include rapidly increasing ST-segment depression or a severe level 
such as _5mm. 
Electronic monitoring of the ECG allows for automatic detection of 
dangerous levels of ST-segment depression and direct recording of results for later 
analysis. 
In principle, it is possible to measure ST-segment depression at every heartbeat of 
the patient during a test. However, this would result in large amounts of data being 
collected on each patient, and for studies with hundreds of participants, with more than 
one exercise test, each lasting for several minutes, the quntity of data generated would 
be extremely large. Consequently, levels of ST-segment depression are usually 
measured at regular intervals, often every minute, with each reading being an average 
taken over several heartbeats. The capacity of an individual to endure an increased 
workload to the heart is measured by the time for which he/she can exercise against a 
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(a) 
Figure 5.1 Examples of ECG traces from (a) a normal subject and (b) a subject with 
ST-segment depression 
standard exercise protocol before myocardial ischaemia occurs. This can be measured 
by the time until the first occurrence of >_lmm ST-segment depression. 
5.1.2 Interval Censoring 
The time until ? lmm ST-segment depression is "interval censored"; that is, given 
the time until the first observed occurrence of Zlmm ST-segment depression, it is 
known only that the first actual occurrence of the event took place during the interval 
since the previous recording of ST-segment depression. (In fact, it is possible that the 
ST-segment could have become depressed by more than 1mm during a previous interval 
but returned to a level of depression below lmm before the end of that interval, when 
the next reading was taken. For the sake of simplicity, however, this possibility will be 
ignored, since it would be assumed that ischaemia would worsen during exercise. ) 
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This chapter will outline some methods of analysing interval censored survival 
data, with examples of the methods being applied to data from the TIBET study on the 
time until _lmm 
ST-segment depression. 
5.2 Standard Methods 
The time until the first observed occurrence of >_lmm ST-segment depression is 
often analysed as though it is not interval censored. That is, the time for which a patient 
exercises until _lmm 
ST-segment is observed is assumed to be a continuous random 
variable, even though it is not. Also, it is not uncommon for the fact that exercise times 
are survival times (which may be censored) to be ignored. Exercise times are often 
analysed by standard statistical techniques, such as t-tests or linear regression. An 
allowance for observations that are censored, where _lmm ST-segment depression was 
not seen to occur, might be to re-analyse the data with these subjects omitted, and 
compare the results to those obtained using all observations (Example 4.6). 
Since the publication of simulation studies comparing these simple approaches to 
survival methods for the analysis of exercise times52, the latter have been used more 
often. Generally, groups of exercise times are compared with log rank tests and 
covariate information is adjusted for by use of Cox proportional hazards or other 
survival regression methods. 
Example 5.1 TIBET Study, Time to >_lmm ST-Segment Depression 
Table 5.1 shows the results of linear regression modelling of the times until z1mm 
ST-segment depression from the TIBET Study. Models were fitted to data from 
treadmill and bicycle exercise tests combined, with the type of exercise treated as a 
covariate. Interaction terms between exercise type and all other terms in the model were 
fitted, and included in the final model if this resulted in an improved model fit. Models 
were fitted using all data, in which those subjects that did not experience zlmm ST- 
segment depression during the exercise test had their total exercise time substituted, and 
to a reduced dataset, in which these subjects, whose times to zlmm ST-segment 
depression were strictly censored, were excluded. 
The only significant interaction with exercise type was in the effect of body 
weight; every 10 kg increase in weight was associated with a 48.5 sec (95% CI, 32.1- 
65.0 sec) greater exercise time if exercising using a bicycle ergometer (according to the 
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Effect Estimate (secs) Censored Observations (95% CI) All Data Excluded 
p-value 
438.0 407.5 
Intercept (408.5,467.5) (373.7,441.3) 
<0.0001 <0.0001 
Exercise 
199.4 191.3 
( Bicycle - Treadmill) 
(171.3,227.5) (157.0,225.5) 
<0.0001 <0.0001 
Treatment 
5.8 
(-26.5,38.2) 
0.3 
(-38.8 39.4) (Nifedipine - Atenolol) 0.73 , 0.99 
Treatment 
0.7 -5.8 
( Combination - Atenolol) 
(-31.7,33.2) (-45.0,33.5) 
0.96 0.77 
Gender -106.1 -102.6 
(Female - Male) 
(-146.4, -65.7) (-152.9, -52.3) 
<0.0001 0.0001 
Age -68.4 -49.9 
(/10 years) 
(86.2, -50.6) (-71.8, -28.1) 
<0.0001 <0.0001 
Weight -10.2 -5.1 
(/10 kg : Treadmill) 
(-30.5,10.1) (-29.1,19.0) 
0.33 0.68 
Weight 48.6 46.1 
(/10 kg : Bicycle) 
(32.1,65.1) (26.0,66.1) 
<0.0001 <0.0001 
Table 5.1 Linear regression model effects estimates with 95 % confidence intervals and 
p-values, for models of time to _lmm ST-segment depression or end of exercise, using 
all data or restricted to subjects exp eriencing _lmm ST-seg ment depression 
model using all data), whilst for those exercising using a treadmill, body weight showed 
no association with the time to _lmm 
ST-segment depression. 
Increased age and female gender were both associated with reduced exercise time, 
but there was no evidence that any treatment affected the time to zlmm ST-segment 
depression (or end of exercise). 
Excluding those individuals that did not reach >lmm ST-segment depression 
introduces more uncertainty about the effect estimates, as the sample size was reduced 
by 33% amongst those using treadmill exercise and 41% in those using a bicycle. 
However, the estimates were not substantively affected, and so the conclusions of the 
model using all subjects could be adopted with the knowledge that the results are not 
overly influenced by those that do not reach the specified endpoint of zlmm ST- 
segment depression. 
Figure 5.2 shows the Normal probability plot of the residuals from the model 
using all data, suggesting an adequate model fit in respect of the residual distribution. 
This figure is similar for the model using uncensored observations only. 
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Figure 5.2 Normal probability plot of residuals from linear regression model of time to 
>lrnm ST-segment depression or end exercise 
Since the time to _lmm 
ST segment depression is often censored, it is preferable 
to use survival techniques52. Table 5.2 gives the results of applying log rank tests to 
these data. There was no evidence of differences between treatment groups (p=0.14), 
when all data were combined. However, previous analyses would suggest fundamental 
differences between bicycle and treadmill exercise, and when the test was stratified by 
exercise type there was some evidence of differences between treatments (p=0.095). 
Splitting the data by mode of exercise, it appeared that under treadmill exercise, those 
on Atenolol were more likely to experience >_lmm ST-segment depression than would 
be expected. Those using bicycle exercise, however, showed no differences in survival 
from >_lmm ST-segment depression. 
To estimate treatment and covariate effects simultaneously requires the use of 
regression models for survival data; the most commonly applied method is the Cox 
proportional hazards model83. Table 5.3 shows the effect estimates obtained from a Cox 
model for the time to _lmm 
ST-segment depression, fitted with separate baseline 
hazard functions for each exercise type. The model shown includes terms for treatment, 
gender and age, with gender and age having different effects under each exercise type, 
since these interactions were found to improve the fit of the model. Body weight was 
not found to have a significant effect in this model. 
Those on either Nifedipine or Combination therapy had lower hazard for suffering 
>lmm ST-segment depression than those on Atenolol only, suggesting a protective 
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Treatment All Treadmill Bicycle Stratified by Exercise Type 
Subjects 218 115 103 218 
Atennlnl Obs 157 90 67 157 
Nifedipine 
Combination 
Events 
Exp 140.1 74.4 64.2 138.6 
Subjects 217 111 106 217 
Obs 135 74 61 135 
a: vcuw 
Subjects 
Events 
Exp 137.6 81.9 56.9 138.9 
211 110 101 211 
Obs 126 71 55 126 
Exp 140.2 78.7 61.8 140.5 
x2 (2 df) 4.0 5.6 1.3 4.7 
p 0.14 0.061 0.52 0.095 
Table 5.2 Log rank test results for time to >lmm ST depression for all subjects, 
separately by exercise type and stratified by exercise type; numbers of subjects, 
numbers of event occurrences (Obs), expected numbers of event occurrences (Exp), 
with associated x2 statistics and p-values 
Exercise Hazard Ratio PH Test 
Type Estimate 95% CI p p 
Treatment Effects 
Nifedipine - Atenolol 0.81 (0.64,1.02) 0.076 
0.1 
0.79 
Combination - Atenolol 0.76 (0.60,0.97) 0.027 
0.5 
0.48 
Covariate Effects 
Treadmill 1.26 (0.84,1.89) 0.26 0.5 Gender 0.49 
(Female - Male) Bicycle 2.92 (1.89,4.51) <0.0001 
0.5 
0.47 
Age Treadmill 1.36 (1.15,1.62) 0.0005 
6 
0.11 
(/10 years) Bicycle 1.91 (1.53,2.38) <0.0001 0.3 0.56 
Table 5.3 Effect estimates, 95% CIs and p-values from Cox proportional hazards model 
for time to >lmm ST-segment depression, with baseline hazard function stratified by 
exercise type, with x2 statistics and p-values for goodness-of-fit with respect to 
proportional hazards assumption, as determined by the time varying coefficients method 
(section 3.5.2.5) 
effect of Nifedipine compared to Atenolol. Under treadmill exercise, gender did not 
affect the hazard for suffering an ischaemic event, whereas on a bicycle, the hazard for 
women was nearly three times that for men. Similarly, the effect of age was greater with 
bicycle compared to treadmill exercise, though under both forms, older patients were 
more likely to suffer the event. 
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Goodness-of fit with respect to the proportional hazards assumption was tested by 
the time varying coefficients method93 (section 3.5.2.2). None of the variables in the 
model showed any sign of non-proportionality. 
5.3 Logistic Model 
Thompson98 suggested a logistic regression model for grouped survival data, 
modelling the conditional probability of surviving to the end of an interval given that a 
subject survived to the end of the previous interval without experiencing an event. In 
other words, if tja is the probability that the it' subject survives to the end of the j`h 
interval, conditional upon their survival through the first j-1 intervals, then the model 
assumes that 
log 
7c '' =z ;i+ yi 1-7tij 
(Eq. 5.1) 
where z; j is a vector of (possibly interval dependent) covariates, ßa vector of associated 
parameters and yj is a parameter to model the j'' interval effect. 
This model can be fitted directly using logistic regression methods as supplied by 
standard statistical packages, though this would require that censoring times are interval 
censored in the same way as failure times. That is, when an individual is withdrawn 
from observation without experiencing an event, this happens at the end of an interval. 
With exercise test data the censoring times are not so well behaved, since a subject may 
withdraw from a test at any time due to fatigue or pain, whether anginal or not. The 
exact time that a subject withdraws from a test will be recorded, and at withdrawal, the 
ECG and with it the level of ST-segment depression will be measured. 
Consequently, data on each individual will fall into one of three categories. For 
those who first experience ? lmm ST-segment depression at the end of an interval (the 
jth interval, say), their contribution to the data will be that no event occurred during the 
first j-1 intervals, but it did occur at some time during the jth. Those who do not 
experience an event at all, and withdraw from exercise during the jth interval, will 
contribute that no event occurred during the first j-1 intervals or the start if the jth 
interval. That is not to say that the event would not have occurred had the patient been 
able to continue exercising to the end of that interval. Most subjects will fall into one of 
these two types. Some, however, will withdraw from exercise during an interval (the jth, 
say) and when their ECG is recorded will be suffering ; ->lmm ST-segment depression. 
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Such an individual would contribute the information that no event occurred during the 
first j-1 intervals, but there was an event at some time during the start of the jth interval. 
A decision must therefore be made about how to treat partially observed intervals. 
Either some of the information about these intervals must be ignored, or an attempt 
must be made to model these data. 
5.3.2 Ignoring Partially Observed Intervals 
To ignore some of the information will involve either treating these partial 
intervals as if they were complete (ignoring the fact that only part of the interval was 
observed), or ignoring them completely, and only using the information gathered on 
wholly observed intervals. 
Example 5.2 Logistic regression model for interval censored times to >_lmm ST-segment 
depression, ignoring partial observation of final intervals 
To fit the logistic model for interval censored survival data, interval effects are 
included as categorical variables with as many levels as there are intervals. In the case 
of those exercising with a treadmill, the longest exercise time without zlmm ST- 
segment depression was into the 13th minute, and with a bicycle ergometer, the longest 
test lasted into the 21St minute. When fitting any logistic regression model with a large 
number of categorical variables, care must be taken that there are no levels of the 
predictor variables for which there are either no successes or no failures. In other words, 
the yj in (Eq. 5.1) are estimable for levels of predictor variables at which there occur 
both ischaemic events and survivals. 
As with previous models, the data strongly suggested that the relationships 
between time and the probability of surviving an interval were different for the two 
types of exercise, so that the model included an interaction between exercise type and 
interval of exercise. As a result, no data could be used from the 13th minute of treadmill 
exercise, and the 2°d, 17th, 19th, 20th and 21st minutes of bicycle exercise. 
Figure 5.3 shows the interval effect estimates and Table 5.4 shows the treatment 
and covariate effect estimates from the final models fitted to these data. Table 5.4 shows 
the results from the same model applied by either treating partially observed intervals as 
complete, or by ignoring these intervals completely. Out of 641 subjects without 
missing data that were included in these analyses, there were 110 partially observed 
intervals, each being the last interval of observation for a single patient. Of these 110 
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Figure 5.3 Interval effect estimates (for a male patient aged 60 years, treated with 
Atenolol alone), with pointwise 95% CIs from logistic model for interval censored data 
applied to the TIBET time to >_lmm ST-segment depression data, treating partially 
observed intervals as complete 
patients, 22 (20.0%) suffered the event of >lmm ST-segment depression during their 
final interval, accounting for 5.3% of the 413 events that occurred. 
The probability of survival through each interval for patients exercising on a 
treadmill clearly decreases more rapidly than for those on a bicycle, for whom there is 
very little probability of experiencing _lmm 
ST-segment depression for the first 6 
minutes. 
Overall, there are statistically significant differences between treatment groups 
(p=0.048), with Nifedipine appearing to reduce the occurrence of ischaemic events 
relative to Atenolol. Gender did not appear to influence the probability of experiencing 
>lmm ST-segment depression whilst exercising with a treadmill, though with a bicycle, 
women were more than 3 times as likely to have an event (p-value for heterogeneity, 
0.0029). Similarly, there were significant differences in the effect of age between 
exercise types (p=0.021), with older patients less likely to survive an interval without an 
event, particularly when using a bicycle. 
There was little difference in effect estimates between the two models, though CIs 
are wider when partially observed intervals are ignored; this greater uncertainty is 
inevitable given the loss of data. The loss of precision is small, however, since only 5% 
of events are lost. 
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5 10 15 
Treating partial intervals 
Odds Ratios as complete 
Excluding partial intervals 
Estimate 95% CI p Estimate 95% CI p 
Treatment Effects 
Nifedipine - Atenolol 1.26 (0.96,1.64) 0.093 1.24 (0.94,1.63) 0.13 
Combination - Atenolol 1.39 (1.06,1.82) 0.016 1.44 (1.09,1.90) 0.011 
Covariate Effects 
Gender Treadmill 0.89 (0.57,1.41) 0.63 0.76 (0.47,1.23) 0.26 
(Female - Male) Bicycle 0.32 (0.19,0.52) <0.0001 0.31 (0.19,0.52) <0.0001 
Age Treadmill 0.72 (0.59,0.88) 0.0011 0.71 (0.58,0.87) 0.0011 
(/10 years) Bicycle 0.50 (0.39,0.64) <0.0001 0.49 (0.38,0.63) <0.0001 
Table 5.4 Treatment and covariate effect estimates (as odds ratios) with 95% CIs and p- 
values from logistic model for interval censored data applied to the TIBET time to 
_lmm 
ST-segment depression data, either treating as complete or excluding partially 
observed intervals 
5.3.3 Modelling Partially Observed Intervals 
In Example 5.2 it was noted that about 1 in 6 patients were not observed to suffer 
_lmm 
ST-segment depression up to and including their last scheduled ECG recording 
prior to stopping exercise, so that their final measurement came at withdrawal, allowing 
a shorter time for the event to occur. These patients accounted for only 5% of all 
occurrences of the event, suggesting that the occurrence of zlmm ST-segment 
depression is less likely in these partial intervals. 
This could be tested within the logistic model, by including a term to indicate that 
an interval is only partly observed and/or by the addition of a variable, qij, denoting the 
proportion of the jth interval for which the i"' subject was unable to exercise (so that qjj is 
zero in most instances and between 0 and 1 for partially observed intervals). If the effect 
of qij is positive, this would imply that the chance of suffering an event is greatest in 
fully observed intervals. 
Alternatively, if an assumption is made about the distribution of failures within 
intervals, the whole of the data can be modelled. For subject i during interval j, denote 
the covariate vector by zy the event indicator by d1, and the proportion of the interval 
for which the subject was able to exercise by pu=1- qij. p; u will take the value 1 for 
each interval except possibly the last for that subject, when it will take a value in the 
interval (0,1]. 
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When p; j =1 and a subject is able to exercise throughout interval j, the expectation 
of 1-d; j = s; j is 7rj. However, when p; j < 1, and the subject can exercise for only part of 
the interval, then assuming that the hazard for the event is constant during that interval, 
we can write the expected value of the survival indicator (s13) as 
pÜ 
µo = E(s; j _ 71 ;i. 
For a standard logistic regression model, j2 = n; j, and the link function is given by 
g(ij)= logit(µij)_ 
"ii irij 
1-µij 1-nij 
in this case, however, to preserve the original form of the logistic model, the link 
function can be written as 
r-- _ 
N'9Vp9 
gtFý°ý 
1-µ.. Ypy 1-ý; ý 
(Eq. 5.2) 
Given the link function, it is now a relatively simple matter to fit this as a 
generalised linear model, using iteratively reweighted least squares". Treatment effect 
differences and the effects of other covariates can be estimated in the same way as with 
other linear regression models. 
Example 5.3 Logistic regression model for time to >_lmm ST-segment depression with 
adjustment for partially observed intervals 
Table 5.5 shows the treatment and covariate effects from the logistic model 
applied to the time to zlmm ST-segment depression, adjusting for the proportion of 
each interval for which each patient is under observation. Also shown are the estimates 
from the same model applied without including information about partially observed 
intervals, in which all intervals of observation are assumed to be complete. The 
estimates from the two models are very similar, suggesting that explicitly modelling the 
partially observed intervals is unnecessary. 
This is confirmed by extending the models shown in Table 5.4 to include terms 
for the proportion of each interval for which each subject was under observation and/or 
the fact of whether each interval was fully or partially observed. None of these 
modifications offered any improvement to the fit of the model (data not shown), 
indicating that suffering ? lmm ST-segment depression was not associated with 
withdrawal from the test during an interval. 
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Ignoring Partial 
Intervals 
Modelling Partial 
Intervals 
Odds Ratio Odds Ratio (95% CI) p 
Treatment Effects 
Nifedipine - Atenolol 1.26 1.26 (0.96,1.65) 0.099 
Combination-Atenolol 1.39 1.36 (1.03,1.79) 0.030 
Covariate Effects 
Gender Treadmill 0.89 0.82 (0.51,1.31) 0.40 
(Female - Male) Bicycle 0.32 0.31 (0.19,0.52) <0.0001 
Age Treadmill 0.72 0.71 (0.58,0.87) 0.0009 
(/10 years) Bicycle 0.50 0.50 (0.39,0.64) <0.0001 
Table 5.5 Treatment and covariate effect estimates from logistic model incorporating 
information regarding partially observed intervals, with estimates from model ignoring 
partially observed interval shown for comparison 
5.3.4 Goodness of Fit 
An effective method for testing goodness-of-fit for logistic regression models is to 
rank observations in terms of their associated risk as predicted by the model, and to 
compare the observed and predicted numbers of events that occur in groups defined by 
this measure, for example in quintiles or deciles of predicted risk'00 
Example 5.4 Goodness-of-fit of logistic regression model for time to >lmm ST-segment 
depression 
The different applications of the logistic model for the time to zlmm ST-segment 
depression shown in Example 5.2 and Example 5.3 appear to fit the model equally well, 
so the standard model treating partial intervals as complete, might be considered the 
best choice, on the grounds that it is simpler than attempting to model the partially 
observed intervals, and it does not waste data by excluding these intervals. 
This example explores the goodness-of-fit of these models formally, by 
comparing the observed and expected numbers of occurrences of zlmm ST-segment 
depression in subgroups defined by quintiles of predicted risk. Predicted risk was 
defined as the average predicted risk under the three models considered. 
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Numbers of Events 
(>_lmm ST-Segment Depression) 
Observed: Expected: Expected: Observed: Expected: 
Total Modell Model 3 Completed Model 2 
Quintile of Predicted Risk 
Intervals 
Ist 4 3.3 3.3 4 3.3 
2nd 15 20.3 20.2 14 19.9 
3`d 59 54.3 54.0 59 52.9 
4`s 117 112.0 108.9 111 105.2 
5`h 218 223.1 225.8 203 209.7 
Goodness-of-fit: 
All Data xZ 
2.3 3.7 
- 
4.9 
p 0.68 0.44 0.30 
Treadmill 
X2 0.9 2.7 
_ 
2.7 
p 0.93 0.60 0.61 
Bicycle X2 
2.2 2.6 
_ 
3.1 
P 0.70 0.63 0.54 
Table 5.6 Observed and expected numbers of occurrences of _>lmm ST-segment depression according to Model 1 (logistic model, treating partially observed intervals as 
complete), Model 2 (logistic model, excluding partial intervals) and Model 3 (logistic 
model adjusting for partial intervals), with corresponding x2 goodness-of-fit statistics 
and p-values as a global test, and applied to treadmill and bicycle data separately 
Writing O; and E; for the observed and expected numbers of events in quintile i, 
the statistic used was V E1 which, 
if the models fits, will have ax2 distribution 
on 4 df. Furthermore, since there is a clear distinction between those using treadmill and 
bicycle exercise, the fit is assessed in quintiles of predicted risk stratified by exercise 
type. For the treadmill data, the statistic was compared to a x2 distribution on 3 df, since 
none of those using a treadmill were in the lowest quintile of predicted risk. 
Table 5.6 shows the results of this assessment. None of the models demonstrate 
any lack of fit, and the earlier view that the simple logistic model, treating partial 
intervals as complete, would be the most useful in practice. 
5.4 Proportional Hazards Model 
The proportional hazards model has, since the development of the semi- 
parametric Cox model, been the most widely used method of analysing survival data84. 
It has the property of robustness to non-proportional hazardslol, making it a reliable tool 
for many situations. A proportional hazards model applied to interval censored data 
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might show similar properties to the continuous data model. The Cox model can be 
adapted to interval censored data, under the umbrella of generalized linear models'°2 
Under the proportional hazards model, the hazard for subject i at time t is 
X(tIz)=ko(t)exp(Zjß) 
where z; is a vector of covariates for the ith individual. Interest lies in the conditional 
probability of failure during any particular interval, 
en = (t -l - 
Ti "ý ti I Ti ::,, ti-1 ) 
S(t; ) 
=1- 
S(t; _1) 
where Si(. ) is the survivor function for the it' subject. Now, 
t 
S(t) = exp - 
fl(u) du 
0 
=exp exp(z; ß) f A, o(u)du 
0 
so that 
cj 
Sri =exp -exp(z1p) 
j, %o(u)du 
IYý 
and 
log(- log(1- 0ý )) = log(- log(1- 0g ))+ ziß 
where Oj is the conditional probability of failure during interval j given survival to the 
end of the previous interval for a subject with covariates 0. 
The model can be fitted using the methodology of Generalized Linear Models, 
with the link function 
g(, ) = log(- log(1- µ)). 
Again, as for the logistic model (Eq. 5.2), information about the proportion, pik, for 
which subject i was observed to exercise during interval j, can be incorporated into the 
link function. Using an assumption of piecewise constant hazards, the link function 
becomes 
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Ignoring Partial Intervals 
Hazard Ratio 
(95% Cl) p 
Treatment Effects 
Modelling Partial Intervals 
Hazard Ratio 
(95% CI) p 
Nifedipine - Atenolol (0.96 
018.21) 0.20 (0.96 
01.21) 0.22 
Combination -Atenolol (1.01,11.27) 0'041 (1.00,11.26) 0.059 
Covariate Effects 
Treadmill 
0 *94 0.55 0.91 0 37 
Gender (0.77, ) (0.74,1.12) . 
(Female - Male) 0'69 0 69 Bicycle (0.56,0.85) 0.0004 . (0.56,0.85) 0.0005 
Treadmill 
0,87 0.0015 0.86 0016 0 
Age (0.79 0.95) (0.79 ,0 95) . 
(/10 years) 0.79 0 79 Bicycle 0 72,0 87 () <0.0001 . (0.72,0.87) <0.0001 
Goodness-of-Fit x2 
3.1 3.2 
P 0.54 0.53 
Table 5.7 Model effect estimates, with 95% confidence intervals and p-values, from 
proportional hazards regression models for interval censored data, either ignoring 
partial intervals (treating as if they were complete) or assuming a constant hazard 
rate within intervals and adjusting for partial intervals, with x2 goodness-of-fit 
statistics 
g(µ) = log - log(1- µy 
)1J 
. 
The model can now be fitted by iteratively reweighted least squares, and treatment 
and covariate effects estimated. 
Example 5.5 Proportional hazards model for interval censored times to zlmm ST- 
segment depression 
Table 5.7 shows the effect estimates from proportional hazards models for interval 
censored data applied to the time to _lmm 
ST-segment depression data from the TIBET 
Study. Two models are shown, the first treating intervals that were only partially 
observed as if they were complete intervals, and the second modelling data from the 
intervals using an assumption of constant hazards within an interval. The two models 
give almost identical effect estimates. Also shown are goodness-of-fit statistics 
calculated in the same way as in Example 5.4, comparing the observed and expected 
numbers of events in quintiles of predicted risk (calculated in this instance as the 
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average predicted risk over the two models). Neither model shows any lack of fit, and 
so the first model would appear to be the best choice in practice, since any benefit to be 
gained by modelling partially observed intervals in this way would seem to be 
negligible. 
5.5 Imputation 
An alternative method for analysing interval censored data is to consider the time 
that the event occurred as missing data. The actual survival time can be imputed, or 
estimated, given that failure occurred at some point during a particular interval, and 
standard survival methodology then applied to the imputed survival times. There are a 
number of methods by which survival times could be imputed; some of these are 
outlined below. 
5.5.1 Right Imputation 
One possibility for imputing the time that an event occurred, given that it occurred 
at some point during an interval (tj. l, ti], is to use the right hand end of the interval, tt. 
This is identical to ignoring the interval censoring, and using standard techniques on the 
observed failure times, as if they were fully observed. The results of applying this 
approach have been given in Example 5.1. 
5.5.2 Single Imputation 
If it is assumed that more accurate results are obtained if a more accurate guess at 
the true failure time is made, then it would seem probable that using any value within 
the interval during which failure occurred would be better than simply using the 
maximum possible value. For example, the mid-point of the interval in which the event 
occurred is a natural candidate. 
With exercise test data, however, it is possible to make a more considered 
estimate. As well as the fact that _lmm 
ST-segment depression has occurred during an 
interval, the level of ST-segment depression will be recorded at the start and the end of 
the interval in question. If, for example, the ST-segment was depressed by 0.9mm 
immediately prior to the interval, but by 1.5mm at the end of the interval, then it might 
be deduced that the event of _lmm 
ST-segment depression occurred near to the start of 
that interval. Another natural assumption would be that changes in ST-segment 
depression occur linearly during the interval, so that the time at which it crosses the 
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threshold of 1mm can be interpolated; in the case outlined above, if the interval is one 
minute long, _lmm 
ST-segment depression would be imputed to have occurred 10 
seconds into the interval. 
5.5.3 Multiple imputation 
The fact that the time at which _>lmm ST-segment depression occurred is 
unobserved would imply that any imputed time is liable to a degree of uncertainty. By 
imputing a single value for each time to zlmm ST-segment depression and analysing as 
if this were the true data, model effect estimates may be obtained with standard errors 
that are too small. Because they are based on imputed failure times but estimated as if 
the failure times were observed, they will not reflect the degree of uncertainty with 
which they are estimated. 
To incorporate this uncertainty into the model, the method of multiple 
imputation103 can be used. Rather than create a single dataset, with imputed values for 
every individual for whom the failure time was interval censored, several datasets are 
created, with imputed values in each that are to some degree random. For example, 
when creating a dataset with randomly imputed failure times, individual times could be 
based on sampled values from a uniform distribution. Alternatively, linear interpolation 
could be used to obtain an expected value for the time that zlmm ST-segment 
depression occurred, and multiple imputations could then be made based on a Beta 
distribution with a mean value equal to the proportion of the interval after which linear 
interpolation would suggest the event to have occurred. 
Once multiple imputed datasets have been created, each is analysed using the 
preferred statistical method. For each of the J analyses, a set of model effects estimates, 
(3ý , and their variance-covariance matrices, 
V3, are produced. The mean of the effect 
estimates, 
ß=Jýä;, 
is used as the final estimate of the model parameters. The variance of is then 
considered to be 
V=vw+1+J VB 
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Method of Single Imputation 
Midpoint 
Haz. Ratio PH Test 
(95% CI) x2 
Pp 
Treatment Effects 
Linear Interpolation 
Haz. Ratio PH Test 
(95% CI) x, 2 
Pp 
0.81 0.1 0.73 0 2 Nifedipine - Atenolol (0.64,1.02) (0.57,0.94) . 
0.072 0.78 0.016 0.70 
0.77 
0'5 0.67 0 8 Combination - Atenolol (0.60,0.97) 0.49 (0.52,0.86) . 36 0 3 0.029 0.0022 . . 
Covariate Effects 
1.19 1.13 0.5 Treadmill (0.79,1.78) 
0.50 (0.73,1.75) 0.40.6 5 
(; ender 0.40 0.58 
( Female - Male) 2.91 2 88 
Bicycle (1.88,4.49) 0.6 
0.44 
. (1.82,4.58) 00 
57 <0.0001 <0.0001 . 
1.35 2.5 1.31 5 2 Treadmill (1.14,1.61) 0.12 (1.09,1.58) . 0 11 
Age 0.0007 0.0043 . 
(/10 years) 1.92 2 11 
Bicycle (1.54,2.39) 0.3 
0.61 
. (1.65,2.71) 0.0 
0 94 <0.0001 <0.0001 . 
Table 5.8 Effect estimates, with 95% CIs and p-values, from Cox proportional hazards 
models for time to Imm ST-segment depression, with time of event imputed as either 
the midpoint of final interval of exercise, or by linear interpolation from ST data before 
and after final interval of exercise. Also shown are tests of proportional hazards 
assumption for each effect, by the time varying coefficients method (section 0) 
where the within- and between imputation variances are estimated by 
1 
VW = -I: V, , and 
j 
)T( 
.. '). VB- 
l 
Example 5.6 Imputation methods for time to lmm ST-segment depression 
Table 5.8 shows the results of fitting Cox proportional hazards models for the 
time to 1mm ST-segment depression, where the time to event is singly imputed for 
those who experience the event during exercise. The two methods of imputation used 
were midpoint and linear interpolation. The estimates obtained after midpoint 
imputation are almost identical to those obtained from the model applied to the 
observed times of occurrence of >lmm ST-segment depression; using the observed 
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Hazard Ratio 
Estimate 
Treatment Effects 
95% CI 
Nifedipine - Atenolol 0.80 (0.64,1.02) 0.072 
Combination - Atenolol 0.76 (0.60,0.96) 0.024 
Covariate Effects 
Gender Treadmill 1.19 (0.79,1.79) 0.40 
( Female - Male) Bicycle 2.92 (1.89,4.51) <0.0001 
Age Treadmill 1.35 (1.14,1.61) 0.0006 
(/10 years) Bicycle 1.92 (1.54,2.40) <0.0001 
Table 5.9 Treatment and covariate effect estimates, with 95% CIs and p-values from 
Cox proportional hazards models applied to time to _lmm 
ST-segment depression 
using multiple imputation 
times can be thought of as right imputation, since the time at the right-hand end of the 
interval in which the event is first known to have occurred is used. The estimates after 
linear interpolation are also similar, though treatment effects and the effect of weight for 
those exercising using a bicycle are larger, with the log hazard ratios moving away from 
zero by approximately one standard error. Furthermore, standard errors of effect 
estimates using midpoint imputation are very similar to the original model, but those 
from the linear interpolation model are all larger; in general by a factor of 6 to 9% (as 
log hazard ratios), though the standard error of the weight effect estimate on a bicycle is 
13% larger when using linear interpolation. 
Table 5.9 shows the treatment and effect estimates obtained by application of 
multiple imputation. Ten datasets were imputed, assuming a uniform distribution of 
failure times within intervals, and Cox proportional hazards models applied to each. The 
mean effect estimates are shown, with 95% CIs and p-values derived using the estimate 
of the total variance of the parameter estimates. The estimates obtained by this method, 
and their confidence intervals are very similar to those obtained by right or midpoint 
imputation, and the additional variation due to multiple imputation is slight. This would 
suggest that single imputation methods are adequate in this instance. 
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CHAPTER 6 Simulation Study I: Analysis of 
Interval Censored Survival Data 
This chapter presents the results of a simulation study to investigate the relative 
performance of different models for analysing interval censored survival data. The main 
aim is to investigate the extent to which the analysis of times until significant ST- 
segment depression might be influenced by the choice of model used. As well as 
looking at different models for the analysis, the size of the treatment effect and the level 
of interval censoring (analogous to the time between successive recordings of ST- 
segment depression) will be varied, in order to find those models that perform best 
under a range of situations. 
6.1 Generation of simulated data 
Data were simulated in a parallel groups design, with two groups (to be referred to 
as groups A and B) and 100 subjects in each group. Simulations were generated in five 
batches, each with a different "treatment" effect, represented by a constant hazard ratio 
between groups B and A. The hazard ratios were 1 (corresponding to no treatment 
effect), 0.80,0.67,0.57 and 0.50. In each batch there were 1000 simulated studies. Each 
study was subjected to different levels of interval censoring, to simulate the effect of the 
frequency with which the ECG is recorded during an exercise test. 
Failure times were generated from a Weibull distribution with a shape parameter 
of 2. Group A was scaled to have a mean failure time of 400, by a scale parameter of 
Yo = 
I'(l + Y3' 
where a=2 was the shape parameter. Group B had a scaling factor 
of Yoh' , with 
h the hazard ratio between groups B and A. Censoring times were 
generated from an exponential distribution with a mean of 800 in both groups, 
independently of the failure times. 
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If a simulated subject had a failure time less than or equal to their censoring time, 
it was considered to have experienced the event of interest. If the censoring time was 
after the end of the interval in which the event occurred, then the "observed" failure 
time was at the end of that interval. If, however, the censoring time came after the 
failure time, but before the end of that interval, the "observed" failure time was taken to 
be the censoring time, to reflect the possibility that a subject who withdraws from an 
exercise test could be observed to have experienced significant ST-segment depression 
since the previous recording of the ECG. Otherwise, when censoring occurred before 
failure, the subject was censored without an event at the generated censoring time. 
Given that simulated failure and censoring times could be arbitrarily large, any large 
survival times were censored at the end of the first interval after 1000. This is to mimic 
the situation where an exercise protocol will be of finite length, so that any subject who 
exercises for more than a predetermined time will discontinue the test. 
Several interval widths were considered; 25,50,75,100,125,150,175,200,300, 
400 and 500. These correspond to 2,3,4,5,6,7,8,10,14,20 and 40 intervals (or 
recordings of the ECG). This range encompasses the usual range of maximum exercise 
times (about 10 to 20 minutes, with ECG recordings every minute) as well as exploring 
the effects of having narrower or broader intervals. 
6.2 Models 
Six different models were investigated. Two methods based on the t-test were 
used, either using all survival times regardless of whether or not the time was a failure 
or a censoring, or using only those survival times that were not censored. In either case, 
the response variable was the simulated time of the first observation of zlmm ST- 
segment depression. Two Cox proportional hazards models were implemented, one 
using the exact partial likelihood, and one using the Efron approximation to the partial 
likelihood. Since the data are interval censored, there will be many tied survival times, 
and the Efron approximation performs better than the Breslow approximation in the 
presence of a large number of ties. Two models designed for interval censored survival 
data were employed: the logistic model of the probability of survival to the end of an 
interval given survival to the start of that interval, and the proportional hazards model 
for interval censored survival data. With both of these methods, effect estimates were 
multiplied by -1 (since they estimate probabilities or hazards of survival to the end of 
an interval, rather than of failure) to make them comparable to the other methods. No 
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Figure 6.1 Median effect estimate against interval width, with 5th and 95th percentiles, 
from simulated trials with no treatment effect, comparing the grouped proportional 
hazards (PH) model, logistic model, Cox PH model using the Efron approximation to 
the partial likelihood and Cox PH model with exact partial likelihood 
allowance was made for whether the failure times fell within or at the end of an interval, 
so that the only information that is used about survival times is the intervals into which 
they fall. 
6.3 Results 
6.3.1 Bias 
The grouped data proportional hazards (PH) model and the two Cox PH models 
are estimating the same quantity in the log hazard ratio between the two groups, and the 
logistic model, in estimating the log odds ratio between the groups should produce 
estimates that approach the log hazard ratio as the interval size tends to zero98. Figure 
6.1 shows the median estimated log hazard ratio plotted against the interval width from 
the 1000 simulated trials where the hazard ratio was 1, as well as points showing the 
cut-offs for the lower and upper 5%. The data being analysed by each model is 
equivalent in the two groups, so each model should on average find no differences 
between groups, regardless of how well each model fits the data. 
Of more interest are the ranges of estimates produced by the different models. The 
logistic model is estimating a different quantity to that of the PH models, which 
approximates the log hazard ratio more closely as the interval widths become smaller98; 
the converse of this observation is that as interval widths become larger, the log odds 
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Figure 6.2 Median effect estimates against interval width, with 5t' and 95th percentiles, 
from simulated trials with no treatment effect, comparing t-test of time to failure or 
censoring and t-test of time to failure excluding censored observations 
ratio approximates the log hazard ratio less well, and as a result the range of estimates 
from the logistic model increases as the intervals become wider. The range of estimates 
produced by the grouped PH and exact Cox PH models remain approximately constant 
across all interval widths, though the effect estimates produced by the Cox PH model 
using the Efron approximation to the partial likelihood show slightly less variability as 
the intervals become wider. 
As interval widths approach zero, the four models will become equivalent. The 
median limiting value appears to be slightly less than zero, indicating a minor bias over 
the 1000 simulations. 
Figure 6.2 shows the same plot for the t-test methods. These models are 
estimating the mean difference in survival time between the groups, which will be zero 
in this case. The model using all data shows less variability than the analyses excluding 
censored observations, except possibly for the most extreme levels of interval 
censoring. 
Figure 6.3 shows the median bias, with 5h and 950` percentiles, found under each 
model with a simulated treatment effect of 0.67. As the interval width approaches zero, 
the survival methods, including the logistic model, give estimates that are unbiased for 
the log hazard ratio. The logistic model becomes progressively more biased away from 
zero as the data are interval censored into fewer, wider intervals, except when there as 
few as two or three intervals, when the estimated log odds ratio between groups 
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Figure 6.3 Median deviations of effect estimates from target values, with 5th and 95th 
percentiles found in simulated studies with a hazard ratio between groups of 0.67, 
using (a) survival analysis methods and (b) t-test methods 
approaches the log hazard ratio once more. The three PH models remain relatively 
unbiased down to as little as five or six intervals, after which they become biased 
towards zero, with the Cox PH model using the exact partial likelihood being least 
biased, and the Cox model with the Efron approximation being most biased. 
Both t-test methods are negatively biased, underestimating the true difference in 
mean survival times between groups. The model using all data shows greater 
underestimation, since it includes observations in both groups that were censored; 
censoring times were assumed to have the same distribution in each group, so their 
inclusion will shrink estimates of the true difference towards zero. The extent of the bias 
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Figure 6.4 Median deviation of effect estimates from target values with 5`h and 95"' 
percentiles found in simulated studies with hazard ratio between groups of 0.5, using (a) 
survival analysis methods and (b) t-test methods 
under both approaches does not vary much as interval widths increase, becoming 
slightly larger in the most extreme cases. 
Figure 6.4 shows the same result from simulations with a hazard ratio of 0.50 
between groups. Similar patterns are seen, with the Cox PH model using the exact 
partial likelihood again showing the least bias of the PH models, though none are 
severely biased except when there are few intervals. The t-test methods are very biased, 
particularly when censored observations are included, though when these are excluded, 
there is a greater variability in treatment effect differences over the 1000 simulations. 
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Figure 6.5 Median deviation of effect estimates from true log hazard ratio, with 5t' and 
95th percentiles found in simulated studies using the logistic model, under a range of 
between-group hazard ratios 
To allow more direct comparisons between the levels of bias found with different 
simulated treatment effects, deviations of effect estimates from their target values can 
be expressed relative to the true log hazard ratio or mean survival time differences. 
Figure 6.5 shows the relative deviation of the logistic model estimates, for which the 
bias of the log odds ratios estimated for the true log hazard ratio appeared to become 
more severe with increasing simulated treatment effect in Figure 6.4(a). However, the 
shapes of the graphs of median relative deviations against interval width are very 
similar under the differing treatment effects. Between-simulation variability in terms of 
relative deviation is smaller for larger treatment effects, since absolute levels of 
variation do not depend greatly on treatment effects. 
6.3.2 Error Rates and Power 
The Type I error rate of a statistical test is defined as the probability that the null 
hypothesis will be "rejected" when it is in fact true. This error rate will depend upon the 
level of statistical significance used to define evidence against the null hypothesis; the 
traditional value of 5% might be used. If a test performs well, then the Type I error rate 
will be the same as the significance level, though a conservative test would have an 
error rate below the level of significance. It would be expected that the Type I error rate 
would be no more than the level of significance used to perform the test; otherwise an 
investigator would falsely consider there to be differences between groups more often 
than would be liked. 
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Model 
No. of Interval nom. o x .. x 
Intervals Width 0 k k 0Ä 
° Ü'- Üv ýU ö ; 
40 25 6.5% 6.8% 6.2% 6.4% 6.3% 6.5% 
20 50 6.5% 7.0% 6.6% 6.8% 6.7% 6.4% 
14 75 6.2% 6.7% 5.9% 6.0% 6.2% 6.2% 
10 100 6.8% 6.9% 6.4% 6.8% 6.5% 5.9% 
8 125 6.4% 6.8% 5.7% 5.9% 6.6% 5.4% 
7 150 5.6% 6.3% 5.7% 6.4% 6.5% 5.9% 
6 175 7.0% 7.0% 6.0% 6.5% 7.4% 5.8% 
5 200 6.3% 5.8% 5.5% 6.1% 6.5% 5.6% 
4 300 5.9% 6.0% 3.8% 4.9% 6.3% 4.6% 
3 400 4.9% 5.7% 3.8% 5.5% 5.3% 5.2% 
2 500 5.6% 5.4% 3.6% 5.4% 6.1% 5.2% 
Table 6.1 Estimated Type I error rates for each model, estimated from 1000 simulated 
studies, under different levels of interval censoring 
Table 6.1 shows the estimated Type I error rates of each model in this simulation 
study, at every level of interval censoring considered. 
For a single binomial significance 
test using a sample of 1000, values of 3.4% or below, or 
6.4% or above would indicate 
evidence that the true proportion is not equal to 
5%. Since the same simulated datasets 
are being analysed by different models under differing 
levels of interval censoring, 
these estimates will be inter-related. However, the cut-off of 6.4% 
is a useful guide to 
whether the tests are being too liberal. Each of the methods 
demonstrates some degree 
of poor performance, though the t-test after excluding censored observations appears to 
be the least likely to suffer a Type I error. As previously observed, this method provides 
estimates that are severely biased and the Cox PH models would appear to offer the 
best 
alternative in terms of Type I error rates, though the 
Efron approximation to the partial 
likelihood may be slightly conservative when the data are extremely 
interval censored. 
Whereas the Type I error rate is the probability of falsely rejecting a null 
hypothesis, the Type II error rate is the probability of failing to reject the null 
hypothesis when it is in fact false. This will depend on the significance 
level being used 
in the statistical test as well as the true effect size and the sample size. 
In this case, the 
Type II error rate will be dependent upon the true treatment effect, 
though the influence 
of sample size cannot be examined as this was not varied 
in this study. 
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Model 
x 
Hazard Interval 04 1= x^ x^ M U) 
° 2 
Ratio Width ö, 
V) 
än wA .1 ý' °' 
o 
0 
,. 
0w 
U 
oW 
Uv Q "-ý 
C7 
50 23.9% 23.9% 23.5% 23.8% 14.5% 16.8% 
0.80 100 24.6% 23.8% 23.0% 23.9% 13.1% 16.6% 
200 22.6% 23.0% 21.4% 22.3% 11.2% 15.6% 
50 57.7% 58.0% 57.2% 57.3% 27.7% 41.0% 
0.67 100 57.3% 57.0% 56.1% 56.6% 25.3% 40.3% 
200 55.0% 54.4% 52.4% 54.3% 21.9% 39.6% 
50 84.5% 84.0% 83.5% 83.7% 48.1% 63.3% 
0.57 100 84.2% 83.5% 82.9% 83.2% 43.0% 61.8% 
200 82.8% 82.2% 81.4% 82.1% 34.5% 59.7% 
50 96.0% 95.8% 95.2% 95.2% 65.5% 82.7% 
0.50 100 94.9% 94.7% 95.0% 95.2% 59.7% 81.7% 
200 93.7% 93.1% 93.1% 93.8% 49.2% 78.8% 
Table 6.2 Power (%) of statistical models to detect treatment effects, simulated as 
constant hazard ratios of 0.80,0.67,0.57 and 0.50, for selected levels of interval 
censoring (interval widths of 50,100 and 200 units) 
Type II error rates are often described in terms of the power of a statistical test, 
defined as 1-ß, where ß is the Type II error rate. Power is lowest, or Type II error rates 
are highest, when effects are small or the sample size is small. Power increases with 
larger effects and larger samples; this is intuitively obvious, since the chances of 
detecting a difference will clearly be greatest when the effect is large or there are large 
amounts of data. 
Table 6.2 shows the estimated power of the six models studied, for each treatment 
effect other than the no effect scenario (hazard ratio = 1), for three levels of interval 
censoring, chosen as interval widths of 50,100 and 200, which correspond to 20,10 or 
5 intervals respectively. Power is greater when the treatment effect is larger, and though 
usually greater when the degree of interval censoring is lower, the dependence on 
censoring is small. 
The t-test methods clearly have much lower power than the survival analysis 
methods, and for every combination of treatment effect and interval width, excluding 
the censored observations leads to a more powerful test. Amongst the survival methods, 
power levels are very similar, with none having consistently better performance. 
89 
Model 
b 
No. of Interval 
b 
ä ä 
Intervals Width 0 ,ý 
0 w x0 
N 
;A w0 
0 
,0 00w u 
Q 
C7 e 
40 25 2 1 4 3 6 5 
20 50 1 2 4 3 6 5 
14 75 1 2 4 3 6 5 
10 100 1 3 4 2 6 5 
8 125 1 /2 3 4 1'/z 6 5 
7 150 1 3 4 2 6 5 
6 175 1'/2 1'/2 4 3 6 5 
5 200 1 2 4 3 6 5 
4 300 3 2 4 1 6 5 
3 400 3 2 4 1 6 5 
2 500 3'/z 2 3'A 1 6 5 
Table 6.3 Ranking of the six methods in terms of average power over the range of 
effect sizes simulated within each level of interval censoring (1=most powerful, 6=least 
powerful) 
To investigate more closely the method with the best power under a range of 
situations, the six models were ranked within each treatment effect x interval width 
combination with the most powerful method being given the rank 1 and the least 
powerful the rank 6. The ranks for each method x interval width combination were then 
averaged over the four treatment effect sizes, and finally, for clarity the six methods 
were ranked within each interval width. 
These ranks are shown in Table 6.3. The least powerful methods, in order of 
increasing power are the t-test applied to all data, the t-test with censored observations 
excluded and the Cox PH model using the Efron approximation to the partial likelihood. 
Of the remaining three methods, the exact Cox PH model appears to be least powerful 
when there are a large number of intervals, but most powerful when there are few 
intervals. 
The better performance of the exact Cox model when there are a few large 
intervals is likely to be due to the way failure times were simulated to have been 
recorded. In general, simulated failure times were rounded up to the time of the end of 
the interval within which it fell, so that the Cox PH models and the two grouped 
survival data methods were analysing essentially the same data. For observations such 
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as these, the approximate Cox PH model would not perform as well as the exact Cox 
PH model or the grouped survival methods, since it approximates the partial likelihood. 
When the failure time and censoring time were both simulated to have occurred in the 
same interval, if the failure time was less than the censoring time, the grouped survival 
models were using only the fact that a failure occurred within that interval, whereas the 
Cox PH models used the observed censoring time as the first time when the observation 
was known to have failed. 
When there are many short intervals, there would be few of these observations, 
since it would be quite rare for both the failure and censoring times to fall within the 
same interval. When there are few large intervals, such occurrences would be more 
common, and the exact Cox PH model would gain by using observed failure times 
closer to the true failure times than the grouped survival models, which would be forced 
to use only the information that a failure fell within some wide interval. This could also 
explain the better performance of the exact Cox PH model in terms of bias for large 
intervals. 
6.4 Summary 
The two grouped survival analysis methods appear to perform better than the 
other methods over the range of situations representative of most exercise tests, that is a 
maximum of 10 to 20 intervals of observation. The two Cox PH models are nearly as 
good in terms of power, and equally effective in terms of bias and coverage, and would 
be more straightforward to apply in practice, since there is no need to separate the 
observation period of each individual into distinct intervals. The ANOVA methods are 
clearly less adequate in every respect other than coverage, and cannot be recommended 
based on these results. 
The most important decisions about how to analyse such data would most likely 
be based on goodness-of-fit assessments, particularly in terms of the proportional 
hazards assumption (for the PH models). It has not been assessed in these simulations 
how the different methods perform when the data do not satisfy a PH assumption, and 
the robustness of the various methods when this assumption is not met needs to be 
investigated further. 
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CHAPTER 7 Repeated Survival Times 
One of the features of exercise test data is that a test can be repeated on the same 
subject. In a clinical trial, a positive exercise test may be one of the inclusion criteria for 
candidate participants53, and an off-treatment test may be one of the baseline 
measurements. Once a subject has been included in a trial, any number of tests can be 
performed during the follow up of each subject, whether for monitoring of the patient 
and adjustment of treatment, or for use in the final analysis52. However, it will often be 
the case that an off-treatment, baseline exercise test will be compared to an end-of-study 
test to evaluate treatment effects. 
Another setting in which repeated exercise tests occur is in crossover trials of 
angina treatments. Since angina is a chronic condition, without the possibility for cure 
by drug treatment, it is a suitable condition for a crossover stud? °. Such studies include 
repeated exercise tests by design, and may include tests conducted at the start of each 
treatment period, after a suitable washout period, as a baseline for each end-of-treatment 
test. 
When trials are designed to include several exercise tests the resulting data should 
be analysed accordingly. If two or more exercise times have come from the same 
subject, it would be expected that the exercise times produced will be correlated, and 
this should be accounted for in the analysis, if at all possible. By taking account of the 
information from more than one test, it would be hoped that some of the within-subject 
variation in exercise performance can be removed and hence a better understanding of 
between-subject differences can be achieved. This is particularly important in a 
crossover trial, since the purpose of the design is to reduce within-subject variation. 
Repeated survival data can be analysed in a number of ways. Standard (but 
inappropriate) statistical methods such as paired t-tests and repeated measures ANOVA 
can been used, but these ignore the censored nature of the data, and will not be 
considered in detail here. This chapter will consider methods for repeated observations 
where the data are (possibly censored) survival times. 
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Non-parametric methods, similar to the log-rank test96, have been developed for 
the comparison of paired survival times, and some of these will be described. However, 
these methods do not allow for covariate adjustment, which is often desired of an 
analysis. Analogous to the paired t-test, a parametric form may be applied to the 
difference between two survival times, and one such approach will be presented. 
Finally, methods will be considered that seek to extend survival regression techniques to 
multivariate failure time data. These methods can be divided into two strands. Marginal 
models, in which models for the distribution of each survival time are fitted, whilst 
adjusting variance estimates of the resultant parameters to account for the effect of 
correlation between survival times, treat this correlation as a nuisance. Frailty models 
allow the analysis of correlated survival data through a random effects model, in which 
survival times become correlated through the sharing of unobserved covariates, which 
can be thought of as an unknown susceptibility to failure. Some of these models will be 
applied to data from the TIBET Study. 
7.1 Treatment Preference 
One area in which repeated exercise tests arise is in crossover trials of anti-anginal 
therapies104. For a two-treatment, two-period crossover trial, the standard proportional 
hazards model, ? 1; (t)=Xo(t)exp(z; ß), can be applied, where z; includes indicator variables 
to represent treatments and periods. The likelihood, however, reduces to a function of 
the numbers of individuals in each order of treatment allocation that have a preference 
for one treatment or the other. 
These methods are not immediately applicable to a parallel groups study in which 
baseline and on-treatment exercise tests are to be analysed, since each patient receives 
exactly one treatment, and their preference for one treatment over any other cannot be 
determined. To extend the methods would result in comparing the numbers of patients 
that prefer treatment to no treatment between different treatment groups, which would 
result in a between-, rather than a within-subject comparison. Since it is likely that the 
majority would perform better under an exercise test whilst on treatment in all groups, 
this approach would lack power to detect treatment effects in study designs other than a 
crossover. 
93 
7.2 Paired Rank Tests 
Numerous approaches 105,106,107,108,109 have been developed based on rank testing 
procedures that test for differences between correlated survival times. In a simulation 
study' 10, the paired Prentice-Wilcoxon (PPW) tests 
lt and the test devised by Akritas112 
were found to perform consistently better than other tests considered. 
The PPW test derives a score for each observation based on the rank of the 
survival time amongst those from the whole dataset, using both observations from each 
pair. The Akritas test is similar, but uses the Kaplan-Meier survival probability of each 
observation amongst the whole dataset as the basis for the score. In both settings, the 
scores for censored observations are penalised to adjust for the fact that the actual 
survival time is larger than that observed. 
7.2.1 Paired Prentice-Wilcoxon Test 
Calculation of the paired Prentice-Wilcoxon (PPW) test statistic"' requires that 
all observed failure and censoring times, that is both members of each pair, be 
considered as a single set of data. Let D be the number of distinct failure times, and 
define nn to be the number of observation times greater than or equal to the jth ordered 
failure time, for j=1,2, ..., D. 
Then, for i=1,2, ..., D, define 
n. 
Si 
; -, n, +1 
If failure times are tied, those subjects seen to fail at a particular time are assigned 
distinct failure times slightly smaller than the observed time. For example, if there are k 
observed failure times equal to t(j), the it' ordered failure time, then these k times are 
changed to t(i) -6< t(il) < ti2) < .., < t(ik)< t(i), 
for suitably small c. The allocation of these 
new times is arbitrary. The quantities, s;, are then calculated as above, and those values 
corresponding to t(iI), t(j2), ... t(; k) are averaged to produce s; 
for the i`h ordered failure 
time. 
Each subject seen to fail at the ith ordered failure time is assigned a Prentice- 
Wilcoxon score of 1-2s;, whereas each subject who is censored at a time as least as large 
as the ig, but less than the (i+l)th ordered failure time is given a score of 1-s;. Then, for 
each pair of observations, calculate A; as the difference between the Prentice-Wilcoxon 
scores for the i`'' pair. The PPW test statistic is then defined to be 
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nn 
ZPPW Ai2 
12 
ial i=1 
(Eq. 7.1) 
which, under the null hypothesis that there is no difference between the survival 
distributions of each pair member, converges in distribution to a standard normal, to 
which the statistic should be compared to assess the evidence against the null 
hypothesis. 
Alternatively, the statistic Zppw (Eq. 7.1) could be recalculated for all 2° 
permutations of survival times within pairs (or a random sample thereof, if n is large). 
Under the null hypothesis, each value of the statistic obtained in this way is equally 
likely, and if the value corresponding to the observed data should be extreme within the 
permutation sample, this would constitute evidence against the null hypothesis. 
7.2.2 Akritas Test 
An alternative to the PPW test, which gives similar results but is simpler to 
evaluate, is the Akritas test12. Its derivation hinges on the definition of the ranks of 
observed and censored failure times. If S(t) is the Kaplan-Meier estimator of the 
survival function on the set { Ti, S;; i=1,2, ..., n }, then the rank of an individual seen 
to fail at time t is defined to be nS(t). The rank of an individual censored at time t is 
defined to be n[%+%2S(t)]; the true failure time is known to lie between t and +co, so the 
average of the Kaplan-Meier estimator at these two time points, S(t) and 1, is used to 
define the rank. 
The paired test is carried out by computing Kaplan-Meier estimates of the survival 
function for the first and second pair members, S1(t) and S2(t). The average survival 
function is then defined as 
s(t)= 2 {s, (t)+S2(t)}. 
The ranks of all observations are then calculated using the function S(t), and the 
test statistic is that of a paired t-test applied to these ranks. 
Example 7.1 Akritas Test for Time to Anginal Pain 
Table 7.1 shows the mean difference in ranks, as defined for the Akritas test, 
between the third exercise test, taken after six weeks of treatment, and the first, taken 
after a two-week washout period before study treatments were given. All six mean 
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Number of Patients 
Mean (SD) Rank Difference 
Exercise Type 
Treadmill 
Bicycle 
Treatment 
Atenolol Nifedipine Combination 
107 
47.8 (214.1) 
113 
68.4 (226.6) 
104 
95.7 (200.2) 
110 
12.5 (214.9) 
106 
66.2 (212.4) 
104 
104.6 (193.5) 
Table 7.1 Numbers of patients, with mean and standard deviation (SD) of the difference 
in rank between the third and first exercise tests, calculated from the time to anginal 
pain by exercise type and study treatment 
values are positive, indicating that patients tended to exercise for longer on the later test. 
The values for those using a bicycle are larger than for those using a treadmill, 
indicating a greater increase in exercise time. This may be artefactual, since ranks were 
calculated on a pooled dataset, including both treadmill and bicycle exercise times at 
both time points; the greater increase in ranks for the bicycle data may simply reflect the 
shorter timescale of treadmill exercise tests, rather than a greater improvement in 
exercise times per se. 
Table 7.2 shows the results of fitting simple linear regression models to these 
data. Two models are shown, both controlling for the effects of the type of exercise and 
estimating the effects of treatment. Age and weight were found to have no significant 
effects in this model, though gender is seen to have some effect, for those using a 
treadmill, at least, with women showing a greater increase in exercise times. There is 
some evidence that treatment with Atenolol, either alone or in combination with 
Nifedipine, is associated with a greater increase in the ranks of exercise times than 
treatment with Nifedipine alone. 
7.3 Model for the Difference in Survival Times 
The t-test is a powerful tool for analysing paired continuous data; one of its 
advantages is that it performs well so long as the differences between pair members are 
roughly Normally distributed, regardless of the distributions of the actual observations 
in each pair. Pair differences are, in practice, often approximately Normally distributed. 
This view could be extended to look at paired survival data, and assume that the 
difference between two survival times will follow a Normal distribution. 
Let the data be denoted by {(Ti1, S; 1), (T; 2, S; 2); i=1,2, ..., n}; T; j=min(D; j, C1), 
where D; j is the failure time and C; j the censoring time (assumed to be non-informative 
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Estimate Estimate 
(95% CI) p (95% CI) p 
Intercepts 
Treadmill (2961.. 
23 
2) 0.0002 (16 
50.2 
6) 0.0034 
Bicycle 
106.4 
<0.0001 
105.4 
<0.0001 (73.9,138.8) (72.0,138.9) 
Treatment Effects 
Nifedipine - Atenolol (_82 
8'4 
0) 0.031 (_82 6; 3.6) 0.033 
Combination - Atenolol (_47.6,301.6) 0.69 (_46.3,32.8) 0.74 
Gender Effects ( Female - Male ) 
Treadmill 
74.4 0.025 (9.7,139.1) 
0.94 2.6 Bicycle (-62.0,67.3) 
Table 7.2 Effect estimates from linear regression models for changes in ranks of 
exercise times to anginal pain between first and third exercise tests 
for D; j) for the ith individual on the j`h occasion, and 
Sij is the indicator variable, I(D; 1 S 
C; j), equal to one if a failure is observed, or zero 
if the time is censored. Let 0j=Di2-D11, 
and assume that 
Al - N(µ;, a2ý. (Eq. 7.2) 
From this basic model, a natural extension to allow the estimation of treatment and 
covariate effects is to parameterise p as z; ß. In this case, (Eq. 7.2) can be written as 
Ai -z; ß -N(O, 1) 
a 
Regarding the observed data, there are four situations to consider, corresponding 
to whether S; i and 512 are 0 or 1; that is, whether the individual survival times are 
censored or not. If 8i= Si2 = 1, then Tj2 - Ti1 = A;. If 8j = Si2 = 0, then there is no 
information regarding the value of e;, and the ih pair are effectively useless. If Si1 =1 
and Sie = 0, so that T11 is observed exactly whilst T; 2 is censored, then T; 1 - T; 2 is right 
censored, i. e. Al > T12- T11. If 8ij =1 and Si2 = 0, then Ti1 = T12 is censored on the left; A 
<T; 2-T11. 
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Mean Difference (secs) 95% Cl p 
Treatment 
-44.6 -103.1,13.9 0.13 (Nifedipine - Atenolol ) 
Treatment 24.5 -34.4,83.4 0.42 ( Combination - Atenolol ) 
Age 7.9 -23.0,38.9 0.62 (/10 years ) 
Gender 
-15.1 -92.1,61.9 0.70 ( Female - Male ) 
Weight 14.7 -9.7,39.0 0.24 (/10 kg) 
Table 7.3 Treatment and covariate effect estimates, with 95% CIs and p-values from a 
model assuming that differences in exercise times to anginal pain are Normally 
distributed 
If «(z) and i(z) are the probability density and cumulative distribution functions 
of the standard normal distribution, and if u; _ 
ITi2 
- T" 
]- Z'ß then we can write the 
Cr 
likelihood of the data as 
L(ß, oiA1 jj, Sjz)=11f(Ai1- 
F(AF(D1ýh8t (Eq. 7.3) 
14(u1 )sýýs, 2 {1 
- 1(u1)}s'l(i-s")c(u1 
)(ý sýýýý 
_ý ý. 
so that doubly-censored pairs, where 8; 1 = 6i2 = 0, do not contribute to the likelihood. 
Maximum likelihood estimates of the parameters ß and a can be found, along with their 
standard errors from the second derivative of minus the log likelihood evaluated at ß 
and &. The log likelihood, together with first and second derivatives, are given in 
Appendix A. 
Example 7.2 Normal Assumption for Difference in Survival Times, Time to Anginal 
Pain 
Table 7.3 shows the effect estimates, with 95% CIs and p-values from this model 
applied to data from the TIBET Study. There is no evidence that either treatments or 
other covariates influence the improvement of exercise times between visits 3 and 5. 
7.4 Models for Correlated Survival Times 
Whilst modelling the difference between correlated survival times is conceptually 
straightforward, giving a summary of effects in terms of increases in survival time, it 
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relies on assumptions about the distribution of these differences, and any pairs of 
survival times that are doubly censored provide no information to the model and are lost 
from the analysis. Furthermore, this approach is applicable to analysing pairs (in 
particular ordered pairs) of survival times only; larger clusters of survival times could 
only be analysed by multiple pairwise comparisons. However, more general methods 
for the analysis of clusters of arbitrary size, or for clusters of times with no inherent 
order might be preferred. 
To analyse arbitrary clusters of correlated data with a general linear model, there 
are essentially two methods that can be adopted. The generalized estimating equations 
(GEE) approach' 13 models the marginal (population-averaged) effects of independent 
variables on outcomes, whilst simultaneously modelling the correlation between 
members of the same cluster. In general, this results in inflation of the variance of the 
parameter estimates according to the correlation between outcomes within clusters. The 
correlations themselves are treated as nuisance parameters and are not of primary 
interest. An alternative to GEE is mixed effects modelling"4, in which the effects of 
covariates can be modelled as fixed effects and are interpreted in the same way as a 
general linear model, though from the point of view of effects within clusters; 
correlation within clusters is accounted for by assuming that study units within clusters 
share the same value of some unobserved random variable. With some restrictions and 
assumptions about the distribution of these random effects (e. g. zero mean Normal 
distribution), the analysis focuses on estimation of distributional parameters such as the 
variance. This allows the separation of variability in the population as a whole into 
variation between clusters and variation within clusters, i. e. between individuals. 
These two schools of thought have also surfaced in the analysis of clustered 
survival data, motivated by problems in matched case-control studies, litter studies and 
family studies in humans. 
7.4.1 Marginal Models 
In the analysis of clustered survival data, marginal models can be applied by 
assuming a population-averaged model, such as the Cox proportional hazards model83. 
For a sample of independent observations, {T;, S;: i=1,2, ..., n} the 
Cox model would 
normally be expressed in terms of the hazard function, 
X, (t) = X() (t) exp(ziß) (Eq. 7.4) 
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though from this specification, the model survivor function Si(t) is fully determined; 
considered as a random variable, S; (T; ) has a uniform distribintion on the interval (0,1). 
For a clustered sample of observations, {T1,5; 1: i=1,2, ..., n; j=1,2, ..., n; ), the 
same model will apply in the population, such as (Eq. 7.4). Each S; j(T; j) has a uniform 
distribution on (0,1), though there is a degree of dependence between observations 
within clusters. This can be parameterised by a class of distributions known as 
copulas' 15, so that {S; j(T1): i=1,2, ..., n; } 
is an n; variate distribution with uniform 
marginal distributions on (0,1). 
In the bivariate case, such as the analysis of the time to anginal pain during the 
first and third exercise tests in the TIBET Study, a pseudo-likelihood approach' 16 can be 
employed. If the marginal distribution is correctly specified, then an independence 
working model, whereby the marginal model is fitted to the data assuming that pairs of 
survival times are independent, will give parameter estimates, ß that are consistent117 
The variance of ß will not be consistent; however a robust variance estimate for ß can 
be calculated as 
V. ()= v(O) Ui O)Ui (A)' 
}v(O) 
where V(i) is the usual variance estimator from the independence model, derived as the 
inverse of the observed information matrix, and Ui((3) is the contribution of the jth pair 
of observations to the score vector. 
Example 7.3 Marginal Regression Model for Time to Anginal Pain 
Table 7.4 shows the estimated hazard ratios from Cox proportional hazards 
models for the time to anginal pain in the TIBET Study. Each model includes separate 
baseline hazard functions for each exercise type, and includes terms for the effects of 
treatment, gender, age and weight. The first model uses data from the third exercise test 
only, this was the principal exercise test within the study. The two further models also 
incorporate data from the first exercise test, taken prior to the start of study treatment, 
after a washout period without active treatment. The baseline hazard functions with 
these models are stratified by occasion as well as exercise type. An alternative approach 
would be to include test occasion as a binary predictor variable; in this instance the 
models reach similar conclusions in each case. 
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3`d Test Data Only 
Haz. Ratio 
(95% CI) p 
1'` and 3`d Test Data 
Independence model 
Haz. Ratio 
(95% CI) p 
I" and 3`d Test Data 
Marginal model 
Haz. Ratio 
(95% CI) 
Nifedipine- 1.33 0 11 
1.33 0.11 1.33 11 0 
Atenolol (0.94,1.87) . (0.94,1.87) (0.94,1.87) . 
Combination- 1.06 0 76 1.06 0 76 1.06 76 0 Atenolol (0.74,1.52) (0.74,1.52) (0.74,1.53) . 
Gender 1.21 0.43 
1.35 0.032 1.35 0 095 ( Female - Male) (0.76,1.94) (1.03,1.77) (0.95,1.91) . 
Age 
(/10 years) 
1.19 
(0.97,1.45) 0.089 
1.26 
(1.12,1.42) 0.0001 
1.26 
(1.09,1.46) 0.0022 
Weight 0.96 0 60 0.99 0.74 0.99 0 80 ( /10 kg) (0.83,1.12) . (0.90,1.08) (0.88,1.11) . 
Table 7.4 Effect estimates (as hazard ratios, with 95% CIs and p-values) from Cox 
proportional hazards models for the time to anginal pain, stratified by exercise type and 
dependent upon treatment, gender, age and weight 
All effect estimates from the latter two models are identical, since they are 
estimated in exactly the same way. Treatment effect estimates are also the same under 
the model based on data from the third exercise test only, because the first test was 
carried out off treatment, and including these data adds no information to inferences 
about treatment effect differences; this is also apparent from the fact that treatment 
effect confidence intervals are the same when the additional data are included. 
Uncertainty in the covariate effect estimates is reduced by the addition of data 
from the first test, though confidence intervals around the estimates under the marginal 
model are wider than under the independence model, as the correlation between pairs of 
observations is accounted for. The increase in variation around the treatment effect 
estimates is negligible, and since the first exercise test contains no information 
regarding treatment effects, the use of the additional data in this instance would seem 
unnecessary. However, covariate effects are estimated with greater precision under the 
marginal model using data from two occasions, than under the model based on data 
from a single test, demonstrating the potential advantages to using these methods in 
studies where multiple on-treatment tests are administered, such as crossover trials. 
7.4.2 Mixed Effects Models 
Mixed effects analysis of survival data assumes that different individuals have a 
different susceptibility (or frailty) to the event of interest. This heterogeneity is 
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modelled, not as effects of covariates that can be measured, but as the combined effects 
of unmeasured and unmeasurable factors. These methods have been applied in the 
analysis of survival data from animals within litters118, family members' 19 and matched 
case control studies, as well as repeated exercise test data 120. This section will describe 
how to fit these models. 
7.4.2.1 Frailty Distributions 
Frailties can be thought of as unmeasurable information, such as the genetic 
susceptibility to disease shared by members of the same family, or the motivation of an 
individual to exercise. They can also be thought of as unmeasured information, such as 
shared environmental exposures experienced by siblings during childhood, or variables 
that might influence exercise capacity but are not recorded, such as percentage body fat 
or normal daily exercise levels. 
In general, after allowing for the effects of those factors that are measured, the 
remaining heterogeneity between individuals could be due to factors of both kinds. Over 
the population as a whole, there will be a distribution of frailties. The methods 
considered here will assume that the unobserved frailties come from a continuous 
distribution. There are situations where a discrete distribution would suffice; for 
example we might assume that the population consists of those with or without coronary 
artery disease. Alternatively, a mixed distribution might be appropriate, for example in a 
population made up of some immune and some susceptible subjects, with those 
susceptible having a continuous distribution of frailties. 
7.4.2.2 Incorporating Frailty Effects 
Fitting regression models to survival data involves making a number of 
assumptions. For example, we may assume a proportional hazards model, or choose a 
particular distribution for the true failure times. Fitting frailty models involves making 
further assumptions about how the frailty factors influence survival times, and what the 
distribution of the factors is in the population under study. In practice, these decisions 
are often based on convenience, to make the process of fitting the model simpler. 
The most common regression model for survival data assumes proportional 
hazards. A parsimonious extension would be to include frailty factors as acting 
multiplicatively on the hazard function. That is, an individual with frailty factor co and 
covariates z has a hazard function of 
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x(tl(O, z)=w2, o(tý xp(zß), (Eq. 7.5) 
where co >0 has some distribution over the population under investigation. To make the 
parameters identifiable, the distribution of co has some fixed mean, usually 1. Thus the 
"average" hazard is set by the baseline hazard function, ? o(t), and the spread in the 
distribution of co describes the degree of heterogeneity in the population. If the variance 
of co is large, then multiple survival times will show a large degree of correlation within 
individuals or clusters. If the variance of co is small, there will be little correlation within 
groups, meaning that multiple survival times are essentially independent, after allowing 
for the effects of measured covariates. 
The effects of measured covariates are modelled through ß, viewed as log hazard 
ratios between members of the same cluster. At the population level, hazard ratios 
associated with covariate differences are not necessarily constant over time 
121. For 
example, consider a population made up of families, within which individuals share the 
same susceptibility for some disease, even though these susceptibilities have some 
distribution across different families. Now assume that men have a greater hazard for 
the disease than women, and that within any single family, the hazard for men is a 
constant multiple of that for women. Over time, more men will contract the disease, 
with those that do being more likely to come from families with high susceptibility. As 
a result, the average susceptibility amongst the total population of men that remains 
disease free will progressively decrease, more so than amongst women, and the hazard 
ratio between the sexes over the surviving population will fall. 
7.4.2.3 EM Algorithm 
One method of fitting a frailty model is to consider the problem to be one of 
incomplete data, and to use the EM algorithm122. The frailties common to each 
individual (in the context of repeated exercise tests) are viewed as unobserved variables. 
These variables are assumed to come from some specified distribution with a known 
mean of 1 and an unknown variance, 0. 
This method can be applied to a proportional hazards model where the baseline 
hazard function is defined parametrically or semi-parametrically. The notation Xo(t) and 
Ao(t) shall be used to denote the baseline hazard and cumulative hazard functions at 
time t, which will depend upon a vector of parameters. In the case of a semi-parametric 
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model, these parameters will be the set of baseline cumulative hazard increments at the 
distinct failure times. 
Assuming that the density of the frailty factors can be written as g(io O), then the 
likelihood of the data {t; 3,5; j: i=1,2, ..., n; 
j=1,2, 
..., n; 
}, where i indexes individuals 
or clusters, and j indexes the multiple survival times or individuals within clusters, 
could be written as 
n n; 
L(O, P. XoItl>>sg wý)=ftfts(t;; Iw;, ß)x(t>>Ico>>a)S° g(w; 10) i=1 j=l 
fl rl eXP[ A(ti; Ico>>ß)]X(t,; lw>>ß)8'9(coile) 
1=1 ; _1 
=flflexp[ co1Ao(til)exp(ztip)]lwi%0(tri/exp(z p)}B°g((, 
Jo) 
1=1 j=1 
if the frailty factors w; were observed. Thus the log likelihood can be written as 
1(8, ß, a , oltu, 8jj, (0j) 
°jE{4 
(iog(xo(tJ; ))+log(w1)+zj)-Ao(tü)exp(iog(c1)+z p)) 
i=l j =l 
+ Inilog(g((JO))} 
= lb, 2,01t495ij9CVi, +12(eltij3'8i l'CUi) 
so that the full log likelihood, given the true values of the frailty factors, consists of two 
parts, the first dependent upon ß and 7 o, the second upon 0. 
Since the distributions of the co; are assumed to have a mean of 1, the initial values 
of the co; can be taken as 1 (i. e. the initial value of 0 is 0). Initial values for ß and Xo can 
be taken from the fit of the standard model, assuming that there are no frailty effects. 
The E-step of the EM algorithm will entail calculating the expected values of cog, 
given t j, 5; j, and the current values for 
0, ß and 4. The M-step will require the 
maximisation of the log likelihood, that is, maximisation of l, 
(ß, xoltÜ, Sü, w; 
) 
and 
12(Oltb, ÖU, cu; 
). 
At this point, note that 1, 
(0, X0 lt j, S; j, co; 
) is exactly the log likelihood of a standard 
proportional hazards model which includes an offset term of log(w; ) in the linear 
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predictor, and the maximum likelihood estimates for ß and ko can be found using 
standard statistical software. Maximisation of 12 
(oIt1, S; j , w; 
) 
may be achieved 
algebraically, or by numerical methods, depending on the form of log(g(w; 
IA)). It will 
often be possible to automate this step by using the previous value of 0 as the starting 
point for the subsequent numerical maximisation. 
The only remaining problem is to determine the expectation of w; given the 
observed data and the current values of the parameters, 0, ß and Xo. That is, to find the 
expectation of 
f(w; ltps,, Z;;, e, ß, Xo) 
f(tri, ööico;, z;;, e, R, 2, o)x 
f(w, 1Z;;, e, ß, Xo) 
f tii, 8ijIzii, 0,13,2, o 
n 
a g(co; le)xjjs(t;; lw;, Z;;, 0, R, 2. o)2(t;; lw;, Z;;, 0, ßlxoyu ; _l 
=g(o1 o)x1Jexp( w, A, 
(t1; )exp(zbß))(w, 2o(ts; ýxP(z, ß))su 
n" 
ag(o1I0)o; D; exp -cri Ao(tii)exp(zijo) 
; _l 
n; 
where D. =ZS, is the total number of observed failures for subject or cluster i. 
-1 
A convenient form for g(o O) is therefore the gamma distribution, with variance 0, 
so that 
(0 1/0-1 exp(- w/6) 
g(0)i0) = r(i/e) aue ' 
(Eq. 7.6) 
Thus 
(CoiIt; 
i, S; izue> 
(3>%o)a (Di exp wi D+V81 e+Jno(tü)eXp(Züß) I i=ý 
so that, conditional upon the observed data and the current values of the parameters, the 
individual frailty factors have gamma distributions with shape parameters equal to 
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ni 
A; = Di + 
YO and scale parameters C; =e+Z AO 
(t1 
j)exp(z; i ß) . 
Consequently, the 
expected values of co can be written as A; C;. 
Convergence of the EM algorithm provides maximum likelihood estimates of the 
parameters, but not the standard errors of these parameter estimates. Profile likelihood 
methods could be used to determine the statistical significance of parameter values and 
their confidence intervals. Alternatively, standard errors could be estimated from the 
observed information matrix, i. e. the second derivative of the negative log likelihood. 
Klein123 applied the EM algorithm to a model with a semi-parametric baseline 
hazard and calculated the information matrix by substituting the maximum likelihood 
estimates of the cumulative hazard function, 
Ä0(t), into the observable log likelihood, 
and differentiating with respect to 0 and P. It was subsequently noted124 that this would 
produce standard errors for the parameters that were too small, since the estimator 
ÄO(t(k) ) is a random variable and is not independent of 
6 and 0. To derive unbiased 
estimates of the variance of 
6 and 0, it is necessary to calculate the derivatives of the 
log likelihood with respect to 0, ß and Xok, the increments of the cumulative hazard at 
the unique death times. 
This parameterisation introduces an increasing number of unknowns into the 
likelihood, as the sample size and hence the number of unique event times increases, so 
that normal likelihood theory may not apply and variance estimates may not be 
consistent. As noted by Andersen et a1124, it is possible to use the non-parametric 
information matrix to gain consistent and asymptotically normal estimates in a frailty 
model. Once the correct information matrix is used, standard errors of the parameter 
estimates can be obtained, allowing the construction of confidence intervals and 
performance of hypothesis tests for these quantities. 
More complex models than the Gamma frailty model can also be fitted using the 
EM algorithm. The Cox model has been extended to incorporate random genetic and 
environmental effects on the age of onset of disease 
125, written as 
J(t; ýl(o;, z; j, gij)=wi%'o(tjexp(z, 
P+µgö )' 
where coi are Gamma distributed frailty terms representing random environmental 
effects and µga =0 if the (iJ)`h individual is not susceptible to the disease (i. e. gjj = aa, 
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according to the single Mendelian diallelic locus model) or µg, =µ if the (i, j)t' 
individual is susceptible to disease (gij = Aa or AA). The E-step of the EM algorithm 
cannot be carried out directly, but a Monte Carlo method based on the Gibbs sampler126 
can be used. 
7.4.2.4 Maximum Likelihood 
The EM algorithm approach can be used for either parametric or semi-parametric 
baseline hazard models. However, the algorithm may be slow when nearing the 
maximum likelihood estimates of the parameters. Also, if the likelihood must be 
differentiated twice to obtain the observed information matrix, it may be preferable to 
use numerical techniques to maximise the likelihood directly. If the frailty factors of 
each individual or cluster are themselves of interest, these can be calculated once the 
maximum likelihood estimators have been reached. 
As before, a proportional hazards model is assumed, with frailty factors acting 
multiplicatively on the hazard function. Frailty factors are assumed to have a gamma 
distribution, with mean 1 and variance 0, so that the density of co is given by (Eq. 7.6). 
Conditional upon the frailty term for subject i, co, ; that subject's survivor function can be 
written as 
S(t1lw; )=P(T1 ? t; lw=cot) 
= exp{- e Ao 
(t; ) exp(z; ß)} 
JA 
where Ao (t; ) =o 
(t) dt is the baseline cumulative hazard function. Since a is 
0 
unobserved, the population (rather than the individual) survivor function, 
S(t; )=P(T; >_t; 
=EJ[P(T; _t; 
lco=(O; )] 
= E. 
[exp {- o; A0 (t 1) exp 
(z J)}] 
(Eq. 7.7) 
which is the Laplace transform of w; evaluated at A0 
(t1)exp(z; ß), is used. Since w; is 
gamma distributed, (Eq. 7.7) can be evaluated explicitly as 
+ OAo (t; ) exp(z; ß)}"y 
and 
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S'(t; ) 
s(ti ) 
. o(t1)exp(z; 
ß) 
1+ 8A o 
ýt; ) exp(z; ß) 
Thus, given the data of survival times t;, j and censoring indicators S; j observed on n 
subjects, with n; (>_1) observations made of each subject, the likelihood function can be 
written as 
L(O, ß, xo(t)) = rl Fl S`tri)x(tii) 
i=> j=i 
n nj 
_ UU 
{1+ 0A0(t1 )exp(z jp)} e'Su 
{xo(t1)exp(z; 
jp)}si. 
The gamma distribution is a special case of a broader class of distributions, the 
positive stable class 127, for which similar algebra can be used to derive a closed form for 
the likelihood of the data. 
This approach is particularly advantageous when using a parametric baseline 
hazard function, since there are few parameters associated with the hazard. With a semi- 
parametric hazard, however, a large number of parameters may be associated with the 
baseline hazard, since one parameter must be included for every unique event time. 
Even for moderately large sample sizes, this could mean a few hundred parameters, and 
the second derivative of the likelihood can become extremely unwieldy, slowing down 
the maximisation routine. 
Example 7.4 Gamma Frailty Model with Weibull Baseline Hazard Function for Time to 
Anginal Pain 
A convenient and flexible parametric baseline hazard function is the Weibull 
distribution (so that fi(t) = at°C'1 and Ao(t) = ta), so that the log likelihood can be written 
as 
y, B+öv log(l+6t; jaexp(zvß))+ö 
(log(a)+(a-1)log(t+zvß) 
. 
ß, 
i1 , 
This is equivalent to the usual two-parameter form of the Weibull distribution (Table 
4.1) if the covariate matrix z includes a column of ones, as with the intercept term of a 
standard linear regression model. 
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Hazard Ratio 95% CI P 
Test Occasion 0.13 0.08,0.20 <0.0001 
(Test 3: Test 1) 
Treatment 1.43 0.83,2.48 0.19 
(Nifedipine : Atenolol ) 
Treatment 0.98 0.56,1.70 0.93 
( Combination : Atenolol ) 
Gender 2.15 1.30,3.54 0.0028 
(Female : Male) 
Age 1.55 1.27,1.90 <0.0001 
(/10 years) 
Weight (Treadmill) 1.33 1.05,1.68 0.019 
(/10 kg) 
Weight (Bicycle) 0.77 0.64,0.92 0.0054 
(/10 kg) 
Estimate 95% Cl 
Gamma Frailty Variance 2.35 2.04,2.66 
Baseline Weibull Shape 4.02 3.67,4.37 
Baseline Weibull Scale (Treadmill) 0.0033 0.0031,0.0036 
Baseline Weibull Scale (Bicycle) 0.0019 0.0017,0.0020 
Table 7.5 Period, treatment and covariate effect estimates, with 95% CIs and p-values 
from Gamma frailty model with Weibull baseline hazard function for repeated exercise 
times to anginal pain, plus estimates and 95% CIs for frailt y variance, common baseline 
shape parameter and exercise-type-s pecific baseline scale p arameters 
This can be maximised with respect to 0, ß and a, subject to 0, a>0, to obtain 
the maximum likelihood estimators of these parameters, 6, 
ß and C X, and the variance- 
covariance matrix of these estimates can be estimated from the observed information 
matrix. The first and second derivatives of this likelihood function are given in 
Appendix B. 
Table 7.5 shows the estimates from fitting this model to data from the TIBET 
Study. The exercise times used were the times to anginal pain during both the first (off- 
treatment) and the third (on-treatment) exercise tests. The hazard for suffering anginal 
pain during exercise was much reduced at the third exercise test, with a 
hazard ratio of 
0.13 (95% CI 0.08-0.20). Women and older patients were seen to be more likely to 
suffer an event, and the effect of weight was dependent upon the type of exercise, with 
heavier patients being more likely to experience anginal pain when using a treadmill, 
but on a bicycle, increased weight was associated with lower hazard. There was no 
evidence of any treatment effects based on this model. 
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There was a considerable frailty effect, with a frailty variance estimate of 2.35. 
This can be interpreted by considering the hazard ratio between two individuals with 
identical covariates, one of whom lies at the 90th percentile of the population frailty 
distribution and the other who lies at the 10th percentile. Since the frailty terms are 
Gamma distributed with mean 1 and variance 0, the shape and scale of this Gamma 
distribution will both be 8-'. The hazard ratio between these extreme individuals would 
be 16.2, demonstrating the degree of variability within the population being studied. 
7.4.2.5 Penalized Likelihood 
Penalized likelihood can be incorporated into survival regression models to allow 
the application of shrinkage methods and fitting of smoothing splines for the estimation 
of non-linear covariate effects 128. To illustrate, consider a statistical model that is 
parameterised by ß and y, so that the log likelihood can be written as 
log lik = log lik 
(J3, yldata). 
The method of penalized likelihood defines the parameters y to be "constrained", and 
reflects this in the log likelihood function through a penalty function that assigns large 
values to unwanted values of y, 
pen log lik = log lik 
(ß, yldata) -f 
(y, 0), (Eq. 7.8) 
where the penalty function f() depends upon 0, a vector of "tuning" parameters. 
If the Cox model partial likelihood is used, along with the penalty function 
f (r, 8) _-e [r; - exP(Y; )] -loge - iogr(i/e), 
then the penalized log likelihood can be shown93 to be equivalent to the gamma frailty 
model, with the gamma frailties w; exp(y; ). 
An alternative penalty function, 
n 
f(f, 0)=2: yj2 , 20 ; _, 
results in a Cox model with frailties from a Normal distribution87 with variance 0; these 
techniques can be extended further to allow frailty terms to have any viable covariance 
matrix, such as an autoregressive correlation 
129. However, for the analysis of exercise 
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Standard Cox Model 
Haz. Ratio 
(95% CI) p 
Cox Model with 
Gamma Frailty 
Haz. Ratio 
(95% Cl) p 
Cox Model with 
Gaussian Frailty 
Haz. Ratio 
(95% CI) p 
Nifedipine- 1.33 0 11 
1.55 0.050 1.47 0.083 
Atenolol (0.94,1.87) . (1.00,2.40) (0.95,2.26) 
Combination- 1.06 0 76 
0.85 0.49 0.89 0 61 
Atenolol (0.74,1.52) . (0.54,1.34) (0.57,1.39) . 
Gender 1.35 032 0 
1.87 0.035 1.86 0.020 
( Female - Male) (1.03,1.77) . 
(1.04,3.36) (1.10,3.14) 
Age 1.26 0001 0 
1.58 0.0002 1.53 0.0002 
(/10 years) (1.12,1.42) . (1.24,2.00) (1.23,1.92) 
Weight 0.99 74 0 
0.91 0.32 0.94 0.47 
(/10 kg) (0.90,1.08) . (0.76,1.09) (0.79,1.11) 
Frailty Variance - 2.48 2.52 
Table 7.6 Effect estimates (as hazard ratios, with 95% CIs and p-values) from Cox 
proportional hazards models for the time to anginal pain, stratified by exercise type and 
dependent upon treatment, gender, age and weight, fitted with and without frailty 
test data, such generality would seem unnecessary, and a simple shared frailty model 
should suffice. 
Example 7.5 Cox Regression Model with Gamma Frailties Fitted by Penalized 
Likelihood to Time to Anginal Pain 
Table 7.6 shows treatment and covariate effect estimates from Cox proportional 
hazards models for the time to anginal pain during the first or the third exercise test of 
the TIBET Study. All models are fitted with separate baseline hazard functions 
according to the type of exercise performed and the occasion (off-treatment or on- 
treatment) of the test. The first model is a standard Cox model, as shown in Table 7.4, 
also shown are the results obtained by fitting the Cox model with frailty terms included, 
in these examples using frailty terms from Gamma and Gaussian (Normal) distributions. 
The Gamma and Gaussian frailty models give very similar estimates of model 
effects as well as the frailty variance. Both give greater variance to these estimates than 
the standard Cox model, though the effect estimates tend to be larger, particularly for 
gender and age. 
In the penalized likelihood formulation of the model (Eq. 7.8), the frailty terms 
are incorporated into the hazard through the linear predictor 
III 
X(t) =%o (t) exp(zß + xy), (Eq. 7.9) 
where the x matrix consists of indicator variables for membership of each cluster of 
observations and the frailty terms, y, relate to the multiplicative definition (Eq. 7.5) as 
co = exp(y), so that whilst co follows a Gamma distribution with mean 1, y follows a log 
Gamma distribution, subject to the constraint that E[exp(y)] = 1, though the variance 
reported in the model fit is that of y. The Gaussian frailty model, however, is fitted 
according to (Eq. 7.9) with y following a Normal distribution with zero mean, and the 
variance of this distribution is reported with the model fit. 
The interpretation of these variances in terms of statistical significance is unclear. 
On the one hand, from the point of view of the classical frailty model, there is one 
additional parameter being fitted to each frailty model, and so the change in log 
likelihood from the non-frailty model should be compared to a x2 distribution with one 
degree of freedom. However, in the penalized likelihood framework128'87, the degrees of 
freedom attached to the estimation of the frailty variances are much larger; 396.6 in the 
Gamma model and 351.4 in the Gaussian. There is as yet no consensus as to the best 
method of testing the goodness-of-fit of frailty models fitted in this way, in terms of 
likelihood comparisons with standard survival regression models. 
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CHAPTER 8 Simulation Study II: Analysis of 
Paired Survival Data 
In this chapter the results of a second simulation study will be presented. The aim 
of this study was to compare different methods of analysing paired survival data, 
designed to mimic pairs of exercise tests carried out in a clinical trial, in order to gain 
some insight into the situations that contribute to the performance of these methods. 
With this in mind, pairs of correlated survival times were simulated, the first 
corresponding to an "off treatment" exercise test, and the second "on treatment". Two 
groups of pairs were generated, corresponding to two treatment groups, so that the 
distribution of exercise times in the two groups was the same for the "off treatment" 
test, but different in the "on treatment" test. 
8.1 Generation of simulated data 
Data were simulated for two parallel groups of individuals, as if each performed 
two exercise tests, with the first test being carried out off treatment and the second test 
being carried out on treatment, with different treatments being used in the two groups of 
individuals. Three sample sizes were considered; 100,200 and 400 individuals per 
treatment group. 
Varying levels of dependence within pairs of exercise times on the same 
simulated individual was imposed by assuming a Normal frailty model. Each individual 
in a simulated trial was assigned a frailty, taken to be an observation from a standard 
Normal distribution. Taking a to be the shape parameter and y to be the baseline scale 
parameter in the simulated off treatment exercise times, then if w; is the simulated 
frailty of the ith individual, their off treatment survival time was an observation from a 
Weibull distribution with shape a and scale 
j 111 =y0exp 'a 
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where 0 is the desired standard deviation of the frailty distribution. In these simulations, 
a was taken as 2, and yo as 
t 1+1 
a 
400 
so that an individual with mean (zero) frailty would have a mean failure time of 400. 
Five values of ý were considered; 0,0.1,0.3,0.9 and 2. 
On treatment survival times were also generated from a Weibull distribution with 
a shape parameter of 2, with scale parameters related to the baseline scale parameter 
through constant hazard ratios. The on treatment scale parameter of the ih individual 
was taken to be 
'Y i2 =YoexP - ä-1 
[4ci +ß1 +ßzxi] 
where ßl was given the value 0.1, to represent a period effect. x; took values 0 or 1 
depending on the treatment group so that (32 represents the simulated treatment effect. 
Four values of ßi were considered; 0, -0.1, -0.3 and -1. 
For each simulated failure time, a corresponding censoring time was generated 
independently as an observation from an exponential distribution with a mean of 800. A 
fixed maximum observed time of 1000 was also imposed, to mimic this aspect of an 
exercise test. The lesser of the failure and censoring times for each individual was taken 
as their observed exercise time, and failure indicators were calculated accordingly. 
Under each of the 60 combinations of sample size, frailty variance and treatment 
effect, 1000 simulated studies were generated and analysed by each of the methods 
being compared. 
8.2 Models 
Four different methods were applied to analyse each set of simulated data. Of the 
rank tests available for correlated survival data, the Akritas test was used, since a 
previous simulation study"° has suggested this to be as good as, if not better than other 
similar methods. Three Cox proportional hazards models were considered. The first was 
a standard model, ignoring baseline exercise times and estimating the hazard ratio 
between the two groups of on treatment times. The other two models were a marginal 
model, and 'a frailty model with Gamma-distributed frailties. For these, all observations 
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were analysed, with a single categorical variable included in the model with three levels 
corresponding to whether the test was off treatment, on treatment (group A) and on 
treatment (group B). The treatment effect was determined by the contrast between the 
two on-treatment levels of this variable. 
Three methods based on the t-test were applied. The first simply performed a test 
on the difference between on-treatment and off-treatment survival times, comparing the 
two treatment groups. The second was to perform the same test using only those pairs of 
observations where both survival times corresponded to failures. Finally, the method 
outlined in Section 7.3 was applied, in which the differences between pair members are 
assumed to come from a Normal distribution, and maximum likelihood is used to 
estimate the difference between treatment groups taking account of the left- and right- 
censoring. 
8.3 Results 
8.3.1 Bias 
Table 8.1 shows the mean estimated treatment effects from the proportional 
hazards models under each combination of simulated treatment effect, frailty standard 
deviation (SD) and sample size. As expected, all models show no bias when there is no 
treatment effect. All models are unbiased when there is no frailty variability, since all 
models are correctly specified under these circumstances. Otherwise, the frailty model 
performs best, with no discernible bias from these results except when the treatment 
effect is at its largest in this set of simulations and the frailty SD is 0.9 or 2.0. In these 
extreme conditions, the use of a Gamma frailty model to estimate parameters when the 
data were generated from a Normal frailty model leads to underestimation of treatment 
effects by approximately 5%. However, with the same simulation parameters, the other 
models used underestimate treatment effects by more than 50%. The degree of bias is 
related to the extent of frailty variability, with estimates from the marginal and standard 
Cox models being approximately half of the true value when the frailty SD is 2, and 
about 70% of the true value when the frailty SD is 0.9. The degree of bias seems to 
reflect the degree of model mis-specification, since with smaller levels of frailty SD, 
there is no detectable bias with any of the models. 
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Model 
Frailty Marginal Cox (2°d period) 
Sample Size 100 200 400 100 200 400 100 200 400 
02 4) 
0 0 -0.01 0.01 0.01 -0.01 0.01 0.01 -0.01 0.01 0.01 
0 0.1 0.01 -0.01 0.01 0.01 -0.01 0.01 0.01 -0.01 0.01 
0 0.3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0 0.9 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 
0 2 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 
-0.1 0 -0.11 -0.09 -0.10 -0.10 -0.09 -0.10 -0.10 -0.09 -0.10 
-0.1 0.1 -0.10 -0.11 -0.10 -0.09 -0.10 -0.10 -0.09 -0.10 -0.10 
-0.1 0.3 -0.11 -0.09 -0.10 -0.10 -0.08 -0.09 -0.10 -0.08 -0.09 
-0.1 0.9 -0.09 -0.10 -0.09 -0.07 -0.08 -0.07 -0.07 -0.08 -0.07 
-0.1 2 -0.10 -0.09 -0.09 -0.05 -0.04 -0.04 -0.05 -0.04 -0.04 
-0.3 0 -0.32 -0.31 -0.30 -0.31 -0.31 -0.30 -0.31 -0.31 -0.30 
-0.3 0.1 -0.31 -0.32 -0.30 -0.30 -0.31 -0.30 -0.31 -0.31 -0.30 
-0.3 0.3 -0.31 -0.29 -0.29 -0.30 -0.28 -0.28 -0.30 -0.28 -0.28 
-0.3 0.9 -0.28 -0.30 -0.30 -0.21 -0.22 -0.22 -0.21 -0.22 -0.22 
-0.3 2 -0.29 -0.28 -0.28 -0.14 -0.13 -0.14 -0.15 -0.13 -0.14 
-1 0 -1.03 -1.01 -1.01 -1.01 -1.00 -1.00 -1.00 -1.00 -1.00 
-1 0.1 -1.04 -1.03 -1.01 -1.02 -1.02 -1.00 -1.02 -1.02 -1.00 
-1 0.3 -1.02 -0.99 -0.98 -0.96 -0.95 -0.95 -0.97 -0.95 -0.95 
-1 0.9 -0.97 -0.97 -0.98 -0.74 -0.73 -0.73 -0.75 -0.74 -0.74 
-1 2 -0.94 -0.93 -0.94 -0.48 -0.47 -0.47 -0.48 -0.47 -0.47 
Table 8.1 Mean treatment effect estimates from three Cox proportional hazards models 
(Gamma frailty model, marginal model for clustered data and standard Cox model using 
2nd period data only) for each combination of simulated treatment effect (02), frailty 
standard deviation (0) and sample size 
The methods that assume a Normal distribution for the difference between 
survival times are not estimating a quantity that can be directly specified from the 
parameters of the model. The off-treatment baseline mean failure time was designed to 
be 400, though the expected failure time for the it' individual, given their frailty, would 
be 
ýwi 
µi, = 400exp -a 
and their expected on-treatment failure time would be 
µ12 =400exP - 
[4)i +PI +ßzxi1 
The population expected difference between treatment groups in their change in 
survival time (which is the same as the population expected difference between 
treatment groups in on-treatment survival times) can be written as 
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Figure 8.1 Distribution of deviations of treatment effect estimates from target values 
under t-test using all data, t-test using fully observed pairs and maximum likelihood 
method assuming differences in survival times to be Normally distributed, where 
sample size is 100 and 13Z= -0.3, for increasing levels of frailty SD 
400exp -I Oco; exp -äß, ex -äp2 -1 E[0; 
J= E. 
I(a )f ý 
= 400 E. 
I(a )l ()( 
exp - 
14(o; 
exp -1ß, exp -äß2 -1 
for which the expectation can be evaluated numerically, since the distribution of the co; 
is known to be a standard Normal. 
By these means, the expected difference between treatment groups in the change 
in survival time can be evaluated for each simulated treatment effect and frailty SD, so 
that the deviation of each simulation estimate from its expected value can be derived, 
and over the set of simulations, give an estimate of mean bias of each method. There 
was no evidence of bias under the simulations with no treatment effect. When treatment 
effects were non-zero, the estimates differed from their target values as shown in Figure 
8.1, for simulations where ß2= -0.3 and the sample size was 100. 
When the frailty SD was 0.9 or less, there was a slight positive bias for each 
method over a set of 1000 simulations, though when the frailty SD was large, all three 
methods drastically underestimated the true difference in survival time between 
treatment groups. This picture became more extreme as simulated treatment effects (and 
sample sizes) were increased, as shown in Figure 8.2. For moderate simulated frailty 
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Figure 8.2 Distribution of deviations of treatment effect estimates from target values 
under models assuming the difference in survival times to be Normally distributed, 
where sample size is 400 and P2= -1, for increasing levels of frailty SD 
SDs, the three methods are biased, producing estimates of the difference between 
treatment groups that are too large. When the frailty SD is 2, there will be larger 
numbers of simulated pairs for whom the hazard will be small, and the expected failure 
times will be relatively large, so that the difference in mean failure times will also be 
large. However, these pairs will be censored at the maximum censoring time of 1000, 
and so would provide a zero estimate of the difference in survival time under the t-test 
using all data, and would be excluded from the t-test that used only fully observed pairs, 
and would not contribute to the likelihood of the third method, since both observations 
were censored. 
In fact, the likelihood based method, assuming differences in survival times 
within pairs were Normally distributed, showed very poor convergence when the frailty 
SD was at its largest value, with between 15% and 45% of simulations in any set of 
1000 failing to converge. A number of different algorithms were tried to find starting 
values for which the minimisation routine would converge, but none proved successful. 
However, it is most likely a consequence of the way the data were generated, with a 
common fixed maximum survival time that causes this poor performance, rather than a 
failing of the method itself. 
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Method 
Proportional Hazards Normally Distributed Differences 
u v0 N 'd Ü 
" 10 "0 91 
CIS 
0 6.11 9 
Cd oo Ce 00 w 
(I) 0 4. 
ý vý d C7 
0 5.4% 5.7% 5.5% 6.4% 5.6% 5.7% 6.8% 
0.1 5.3% 5.0% 5.1% 5.2% 5.3% 5.5% 5.1% 
100 0.3 5.6% 5.2% 4.6% 4.8% 4.0% 4.7% 4.4% 
0.9 6.6% 6.6% 6.1% 6.4% 4.8% 3.7% 5.8% 
2 4.7% 4.3% 4.0% 4.2% 5.6% 5.0% 6.5% 
0 5.8% 6.5% 5.9% 5.0% 6.3% 5.1% 4.9% 
0.1 4.4% 4.7% 4.4% 5.0% 4.7% 4.7% 5.0% 
200 0.3 5.3% 4.8% 4.5% 4.6% 6.0% 5.5% 5.4% 
0.9 5.1% 4.2% 4.0% 4.1% 4.5% 5.5% 6.4% 
2 5.1% 4.6% 4.7% 5.4% 5.3% 4.3% 6.2% 
0 5.2% 4.8% 4.7% 5.1% 5.1% 5.3% 4.3% 
0.1 5.1% 4.8% 4.8% 4.7% 5.2% 4.2% 4.4% 
400 0.3 4.6% 4.9% 4.2% 5.5% 5.3% 5.1% 4.5% 
0.9 6.7% 5.9% 5.6% 5.3% 5.3% 4.5% 4.9% 
2 5.0% 6.4% 6.3% 6.0% 5.6% 5.7% 4.4% 
Table 8.2 Type I error rates (% ) of each method under di fferent simulated sample sizes 
and frailty standard deviations (SDs), based on a 5% sign 
ificance test 
8.3.2 Error Rates and Power 
Table 8.2 shows the Type I error rates of each method based on statistical tests at 
the 5% significance level under each simulated scenario (Type I error rates are the 
proportion of trials in which a significant result 
is found when there is no treatment 
effect, i. e. ß2=0). Based on these simulations, all the methods considered appear to 
perform adequately in this respect. 
The power of the different methods are shown 
in Table 8.3, for those simulations 
in which the treatment effect was simulated to 
be a log hazard ratio of -0.1 between 
groups for the on-treatment exercise test. 
None of the sample sizes is adequate to detect 
this small an effect using any method. The marginal model 
in achieving only 12.5% 
power with a sample size of 400 per group when 
the frailty SD is a modest 0.1 gives the 
best performance of any of these methods. 
When the simulated treatment effect is increased to -0.3, the power of all of these 
methods increases, as shown in Table 
8.4. Again none of the methods is powerful 
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Method 
Proportional Hazards Normally Distributed Differences 
0Üäö 0 
vý w C7w vý Q C7w vý 
0 6.6% 6.8% 6.2% 5.6% 5.8% 5.7% 4.9% 
0.1 7.8% 8.0% 7.3% 6.6% 5.8% 5.6% 5.7% 
100 0.3 7.1% 7.1% 6.3% 6.2% 4.4% 6.2% 6.6% 
0.9 7.7% 7.0% 6.2% 8.1% 4.4% 5.7% 5.7% 
2 4.4% 6.0% 6.0% 5.4% 5.0% 5.8% 7.8% 
0 7.9% 8.1% 8.3% 7.2% 5.6% 5.8% 6.3% 
0.1 9.3% 9.9% 8.8% 7.9% 5.5% 4.8% 6.8% 
200 0.3 7.7% 7.7% 6.6% 6.9% 6.7% 5.6% 5.8% 
0.9 7.7% 7.9% 7.5% 8.9% 4.2% 4.8% 6.7% 
2 5.8% 4.6% 4.6% 6.6% 5.3% 3.9% 5.0% 
0 12.0% 12.2% 12.0% 8.8% 7.5% 6.8% 8.7% 
0.1 12.4% 12.5% 11.8% 10.8% 7.1% 7.8% 9.1% 
400 0.3 10.7% 10.2% 10.0% 9.4% 8.2% 7.3% 8.6% 
0.9 8.4% 8.0% 7.5% 8.4% 5.6% 5.9% 7.2% 
2 6.2% 6.7% 6.5% 6.8% 6.1% 5.2% 6.3% 
Table 8.3 Power (%) of each method based on a 5% significance test, under different 
simulated sample sizes and frailty standard deviations (SDs) for treatment effect 
simulated as a log hazard ratio of -0.1 
enough for practical use; the best performance in this set of simulations was 64%, 
observed using the marginal model for a sample size of 400 with no frailty effect. 
However, a pattern is seen whereby the three proportional hazards models have 
approximately the same power when there is no or moderate frailty, but when the frailty 
SD is large (0.9 or 2) the Gamma frailty model out performs the other two models. It is 
of note that the marginal model fails to demonstrate clearly better power than the 
standard Cox model using only the on-treatment 
data. The Akritas test has levels of 
power close to those of the marginal and standard 
Cox models. 
When the simulated frailty SD is 2, the method that has greatest power, after the 
(almost) correctly specified Gamma frailty model, is the maximum likelihood method 
that assumes the differences in survival times to 
be Normally distributed. This method 
has consistently greater power than either t-test, though 
itself has low power compared 
to the proportional hazards models and the Akritas test when there 
is little or no 
simulated within-pair correlation. 
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Method 
Proportional Hazards Normally Distributed Differences 
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0 21.5% 22.3% 20.5% 19.1% 7.8% 7.1% 12.6% 
0.1 20.4% 21.6% 20.3% 18.9% 8.2% 8.4% 12.6% 
100 0.3 19.4% 19.6% 18.5% 16.7% 8.9% 6.5% 9.9% 
0.9 13.8% 13.1% 12.0% 13.0% 6.6% 8.3% 12.9% 
2 10.5% 8.7% 8.6% 7.9% 7.0% 7.0% 9.1% 
0 36.7% 38.1% 36.6% 31.1% 13.3% 12.4% 19.2% 
0.1 38.5% 38.9% 37.6% 33.2% 13.3% 12.2% 19.3% 
200 0.3 32.5% 32.7% 31.8% 28.9% 10.7% 8.3% 17.5% 
0.9 25.0% 21.9% 21.4% 22.9% 11.9% 12.2% 16.7% 
2 16.5% 12.3% 12.3% 11.5% 6.4% 7.2% 13.2% 
0 63.1% 64.0% 62.8% 52.7% 22.6% 16.7% 32.2% 
0.1 62.0% 61.1% 60.4% 53.2% 22.2% 16.4% 29.8% 
400 0.3 57.7% 57.8% 56.9% 52.0% 20.4% 18.0% 32.5% 
0.9 43.5% 38.5% 38.2% 36.7% 16.7% 19.4% 27.2% 
2 27.7% 17.8% 17.3% 17.8% 11.8% 14.6% 23.5% 
Table 8.4 Power (%) of each method based on a 5% significance test, under different 
simulated sample sizes and frailty standard deviations (SDs) 
for treatment effect 
simulated as a log hazard ratio of -0.3 
When the simulated treatment effect is at is largest, as shown in Table 8.5, the 
Gamma frailty model achieves in excess of 80% power in every combination of sample 
size and frailty effect, except in the extreme frailty case with a sample of 100 per group. 
Otherwise, the patterns are similar to those observed previously. 
8.4 Summary 
In these simulations, when the data were generated according to a Weibull 
baseline hazard with proportional hazards effects and Normally distributed individual 
frailty terms, the Gamma frailty model performs best, with the least bias and greatest 
power in most circumstances, particularly when the extent of correlation 
due to the 
frailty distribution is large. This is as would be expected since this model matches most 
closely the way in which the data were generated. 
The marginal model does not out-perform the standard Cox proportional 
hazards 
model using data from the 2nd period only, and 
both are similar to the frailty model 
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Method 
Proportional Hazards Normally Distributed Differences 
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0 93.6% 93.6% 92.4% 87.7% 43.7% 34.6% 70.4% 
0.1 94.1% 94.6% 93.9% 89.9% 44.1% 35.0% 69.5% 
100 0.3 91.8% 92.1% 91.2% 87.0% 44.2% 35.7% 67.5% 
0.9 80.3% 74.2% 73.2% 73.2% 37.2% 33.4% 64.3% 
2 59.3% 38.1% 35.9% 41.6% 19.9% 27.0% 52.9% 
0 100.0% 100.0% 100.0% 99.7% 71.8% 59.8% 93.4% 
0.1 99.9% 99.8% 99.8% 99.4% 76.6% 64.7% 94.5% 
200 0.3 99.7% 99.7% 99.7% 99.7% 71.9% 65.1% 94.2% 
0.9 97.5% 96.4% 96.2% 95.5% 63.2% 56.9% 89.0% 
2 86.7% 65.4% 64.6% 68.5% 38.4% 48.4% 78.1% 
0 100.0% 100.0% 100.0% 100.0% 96.9% 92.0% 99.8% 
0.1 100.0% 100.0% 100.0% 100.0% 95.6% 91.7% 100.0% 
400 0.3 100.0% 100.0% 100.0% 100.0% 94.7% 91.1% 99.9% 
0.9 100.0% 100.0% 100.0% 99.9% 90.2% 88.1% 99.8% 
2 99.5% 92.5% 92.7% 93.5% 63.0% 77.0% 97.4% 
Table 8.5 Power (%) of each method based on a 5% significance test, under different 
simulated sample sizes and frailty standard deviations (SDs) for treatment effect 
simulated as a log hazard ratio of -1 
when within-pair correlation in survival times are small. Their bias and reduced power 
when the frailty SD becomes larger might reflect the breakdown of the proportional 
hazards assumption at the population level, since the frailty model assumes proportional 
hazards within pairs of observations, but this assumption will be incorrect over the 
population as a whole. 
The Akritas test offers a good alternative to proportional hazards models when the 
assumptions underlying these models might be in doubt, since it has good power over 
the range of frailty SDs considered here. The maximum likelihood technique, assuming 
differences in survival times to be Normally distributed, appears to perform well when 
heterogeneity due to frailty is large, but the convergence problems experienced in this 
situation and the extreme levels of bias found make it difficult to conclude that the 
method is of practical use. However, these features were observed only in the most 
extreme frailty case, and may be an artefact of the way that the data were generated, 
whereby the imposition of an upper limit to observed survival times will result in 
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double censoring of the least frail individuals, in whom the largest differences in 
exercise times would be expected. In practice, where initial exercise tests might be used 
as a final exclusion test, so that all (or most) first period tests are uncensored and 
therefore no (or few) pairs will be doubly censored, this may not be an issue. 
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CHAPTER 9 Further Work 
In this penultimate Chapter some avenues for further work will be explored. 
Firstly, the application of competing risks methods to exercise test data will be 
considered. These methods can be used to model survival times when there is more than 
one type of failure. There are several reasons for which an exercise test can be stopped 
besides anginal pain, including fatigue, dyspnoea and muscular pain. Secondly, methods 
for analysing multivariate repeated measures data will be reviewed. 
The driving principle behind the exploration of these methods is the desire to 
analyse the total response of test subjects to exercise. This mirrors the way that exercise 
tests are assessed by the experienced physician, who considers the haemodynamic and 
electrocardiographic response of each individual, before, during and after exercise, as 
well as the occurrence of various endpoints, both ischaemic and non-ischaemic. 
Wherever possible, methods will be illustrated through examples using data from 
the TIBET Study. 
9.1 Competing Risks 
The theory of competing risks has its origins in the work of Daniel Bernoulli in 
1760, when he presented his solution to the problem of describing the effect on 
population mortality of preventing deaths due to smallpox. The solution he provided 
rested on the assumption that the individuals who would otherwise have died from 
smallpox would have survival distributions for other causes of death that were the same 
as those of the rest of the population. Then, and in similar analyses since, the 
assumption of independence among types of failure in competing risks was made for 
reasons of computational feasibility. 
Much work in the field of competing risks has been conducted in industrial 
statistics, in the analysis of failure times of systems made up of separate components, 
where the whole system is observed to fail at the first time that any single component 
fails. Applications in the medical arena have included demographic studies of 
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populations subject to several competing causes of death, or in cancer studies where the 
analysis models the times to either remission or death, where times to both types of 
failure could be censored due to withdrawal or loss to follow up. 
In the analysis of exercise test data, competing risks could be applied to total 
exercise times, with the different possible reasons for stopping the test representing the 
different types of failure. The possible reasons for stopping an exercise test might 
include anginal pain, muscle pain (e. g. in the legs), fatigue, breathlessness, severe ST- 
segment depression or a sudden fall in systolic blood pressure. Within any particular 
study, the numbers of occurrences of some of these endpoints might be small, and the 
analysis may need to be restricted to the most common forms of stopping, with other 
failure types being regarded as censoring, or being combined into a catchall "other" 
category. 
9.1.1 Model Specification 
9.1.1.1 Independent Failure Types 
As with other methods of survival analysis, models can be specified in terms of 
the hazard function, ? (t). In the competing risks setting, each individual is at risk of a 
number of events, so there are several hazard functions, and 
I X0 (t): i =1,2,..., n; j =1,2,..., J} 
are the J hazard functions for the n individuals under study. One of these J types of 
failure could be censoring in the sense of withdrawal of consent or loss to follow up in a 
cohort study, so that the hazard function for being censored in the study is modelled 
specifically. In the case of exercise test data, it would be unlikely that a participant 
would withdraw consent during an exercise test, and so the failure types observed 
should fall into one of a small number of recognised categories. 
Each hazard function defines a corresponding survivor function 
t; 
P(T, > t; +cp; = j) = S; j 
(t; ) = exp - 
fl 
;; 
(t) dt 
0 
where cp; indexes the failure type of the ith individual. Since the observed failure time, 
Ti, is in fact the time of the first type of failure to occur amongst a mostly unobserved 
set of failure times, 
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Ti =min{T;,, T; 2,..., T;, 
}, 
and if these failure times are assumed to be independent, the marginal survivor function 
can be written as 
S; (t; )=P(T; >t; ) 
= P(T; > t; Icp; =1)P(T; > t; I(p; =2) ... P(T; > t; 
I(p; =J) 
=rjsri(t1) 
= flexp - 
j? (t) dt 
io 
= exp - 
fZt, %U(t)Idt , 
01 
so that the marginal hazard function for the ith individual is 
9.1.1.2 Markov Process 
An alternative specification of the competing risks problem is to consider it as a 
Markov process 13o That is, if there are J types of failure, then at any time t, an 
individual can be in one of J+1 states, where state 0 indicates being "alive", and states 
j=1,2, ..., J indicate 
failure of type j. The general Markov process can be modelled in 
terms of a (J+1)x(J+1) matrix of transition intensities, X(t), where Xjk(t) is the hazard (or 
transition intensity) for an individual in state j moving into state k at time t. In the 
competing risks setting, all individuals begin in state 0, and from there can move into 
any other state, but when failure has occurred, the individual cannot move out of that 
state. 
To express this algebraically, let P(s, t) be the (J+1)x(J+1) transition probability 
matrix for the process, so that PPk(s, t) is the probability that an individual in state j at 
time s will be in state k at time t. By definition, Poo(0,0)=1. The transition intensity 
matrix can be written as 
0 
x01 (t) 
... 
x» (t) 
1 """ 0 
0 """ 1 
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since the rows of X(t) must sum to 1. The overall survivor function under this 
framework is simply the transition probability from state 0 to state 0 between times 0 
and t, 
S(t)=P, (0, t)=exp - 
j{1-2,.. (u)}du =exp - 2, j(u)du 
00 
which can be estimated by the Kaplan-Meier curve for any cause of failure. 
It is not sensible, however, to consider the survivor functions for specific types of 
failure. By constructing the competing risks problem in this way, there has been no need 
to construct an imaginary set of survival times, all but one of which will be unobserved, 
and to assume that these survival times are independent, an assumption that is highly 
tenuous in the context of medical data. Rather than view the competing risks problem in 
terms of multiple survivor functions, it is more sensible to estimate the probabilities 
over time that individuals will suffer each of the failure types, or the cumulative 
incidence of each failure type. 
The cumulative incidence of the jt' failure type can then be defined as 
P0; (0, t)= jP00(0, t)A, o; 
(u)du, 
0 
which can be estimated from the cause-specific baseline hazard estimate, and the all- 
cause survivor function estimate. 
9.1.1.3 Model Fitting 
A set of competing risks data can be written as 
fiT;, S : i=1,2,..., n; j=1,2,..., J}, 
where 8; j=1 if the jth type of failure is observed to occur for the ith individual and 5; j=0 if 
it is not. Notice that exactly one of the 3ij will be equal to 1, and all others will be zero. 
The log likelihood of the data is then 
ES-Au(ti)+11a;; io9Xi; (t; ). 
;; ý; 
(Eq. 9.1) 
The first term of (Eq. 9.1) reflects the fact that the ith individual survives all J types of 
failure until time t;, whilst the second term reflects the fact that a type j failure occurs at 
time t;, and no other type of failure occurs. 
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The traditional approach to fitting models for independent competing risks is by 
separating the model into its J component parts, and fitting each submodel individually, 
with models for the jt' failure type being fitted by treating other types of failure as 
censored data. This is valid, and is a convenient technique given the wide availability of 
software for fitting survival models to censored data. Covariate information can be 
incorporated into the model in exactly the same way as with univariate survival data, for 
example through application of the Cox proportional hazards regression model. 
However, it is not straightforward to compare the effects of a covariate across different 
types of failure or to test for differences between the J baseline hazard functions. 
To allow these features, the model can be fitted in its entirety by the method of 
data duplication 131. The survival times and covariate data are replicated J times, so that 
each individual contributes J sets of `observations', which are indexed by a variable 
representing the J types of failure. The event indicators for the observations are all zero, 
except for the one type of failure that was observed to have occurred, if any. Thus if an 
individual experiences none of the events considered in the study, than all of their 
observations are censored at the survival time. However, if an individual does suffer an 
event, then (s)he contributes the information that a particular type of event occurred at 
their survival time, and at that time all other types of event were censored. 
The standard Cox model can then be fitted to these data. Separate baseline hazard 
functions can be fitted for each failure type, or hazard functions could be related 
between some or all types of failure through a constant of proportionality. Similarly, the 
effects of covariates can be modelled as being equal for all or some types of failures, or 
they could be different for each failure type. In fact, the covariates could be included in 
the model in such a way that different subsets of the predictor variables apply to each 
failure type. 
Given the baseline hazard function estimates from any model, it is relatively 
straightforward to estimate the overall survivor function and the cause-specific 
cumulative incidence functions. Though standard statistical software packages are not 
usually designed to accommodate competing risks data, the survival analysis elements 
of these packages will provide the user with cause-specific estimates of survival, from 
which the baseline hazard function estimates can be derived. 
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Figure 9.1 Estimated cumulative incidence functions for times to end of exercise 
subject to competing risks of fatigue, chest pain, dyspnoea and clinical signs (severe 
ST-segment depression, cardiac dysrhythmia or sudden fall in SBP). 
Example 9.1 Independent Competing Risks in the TIBET Study 
Six possible reasons for stopping the exercise test were recorded, and of the 611 
subjects included in this analysis, 350 stopped due to fatigue, 114 to chest pain, 100 to 
dyspnoea, 38 to severe ST-segment depression, 2 to cardiac dysrhythmia and 7 to a 
sudden fall in systolic blood pressure (SBP). As there were so few tests stopped due to 
dysrhythmia or a fall in SBP, these were included with severe ST-segment depression 
since these three reasons for stopping the test were based on clinical decisions rather 
than the decision of the patient. The analysis modelled the total exercise time in the face 
of these four competing risks. The chest pain component of this model is not the same 
as previous analyses looking at the times to anginal pain, since many subjects that 
experienced anginal pain during the test continued to exercise, and did not necessarily 
stop exercising due to their chest pain 
For this analysis, to increase the sample size, the 119 individuals for whom weight 
was not recorded had the predicted value based on a linear model of weight on age and 
sex substituted for their weight. 
After duplicating the dataset as described in Section 9.1.1.2, a null model was 
fitted in order to determine the four cumulative incidence functions, and Figure 9.1 
shows the corresponding estimates. Individuals are clearly most 
likely to withdraw from 
exercise due to fatigue, with more than 50% of tests ending 
in this way. There are 
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Figure 9.2 Estimated cumulative incidence functions for times to end of exercise 
subject to competing risks of fatigue, chest pain, dyspnoea and clinical signs adjusted 
for mode of exercise, age, gender and weight. 
visible "jumps" in the incidence of fatigue at one-minute intervals, particularly over the 
range from 7 to 15 minutes. 
Covariate effects were then added for exercise type, age, sex and weight. Exercise 
type was included as a proportional hazards effect, rather than as a stratifying variable, 
to reduce the number of strata in the model and allow a simpler presentation of the 
results. Assuming these covariates to have equal effects on the four hazard functions, all 
these variables were found to have significant effects, with shorter exercise times being 
experienced by those exercising on a treadmill, by older patients and by women. Weight 
was found to have differential effects dependent upon the type of exercise being 
performed; with treadmill exercise greater weight was associated with shorter exercise 
times, whilst on a bicycle heavier patients exercised for longer. 
Figure 9.2 shows the estimated cumulative incidence functions from this model. 
The curves are derived from the baseline hazard function increments as estimated in a 
stratified Cox proportional hazards model. These 
functions are the estimated curves for 
imaginary individuals whose covariate values are equal to the population mean values. 
Compared to Figure 9.1, the curves have very similar limiting values. Just visible in the 
curve for fatigue, the predominant reason 
for stopping, is an increased curvature in the 
cumulative incidence curve, with lower incidence early on, 
but an increased probability 
of withdrawal over the second part of the timescale. 
This is a result of the model 
identifying those most likely to suffer an event and "explaining" early withdrawals and 
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5 10 Is 20 
Hazard Ratio 95% Cl p-value 
Heterogeneity Test 
p-value 
Exercise Type 0.24 (0.20,0.29) <0.0001 0.0086 
( Bicycle : Treadmill ) 
Age 1.49 (1.33,1.67) <0.0001 0.69 
/10 years) 
Gender 2.93 (2.25,3.82) <0.0001 0.0015 
(Female : Male) 
Weight (Treadmill) 1.19 (1.03,1.37) 0.016 0.69 
(/10kg) 
Weight (Bicycle) 0.72 (0.63,0.81) <0.0001 0.61 
(/10kg) 
Table 9.1 Covariate effect estimates, with 95% CIs and p-values, from competing risks 
model of total exercise time assuming effects are equal across the four reasons for 
stopping exercise. Also shown is p-value for test of heterogeneity of effects upon 
different failure types. 
long survivals. The figure is constrained to have the same limiting incidence levels, 
since the curves correspond to the average participant. The effect estimates from this 
model are listed in Table 9.1. Also shown are the p-values from likelihood ratio tests 
comparing this model to the extensions allowing each covariate to have differential 
effects on the four endpoints. There is good evidence that exercise type and gender have 
different effects on the incidence of stopping the test for different reasons. 
A more complex model was then fitted, allowing exercise type and gender to 
show heterogeneity between the four competing risks. The resulting estimates of the 
cumulative incidence functions are shown in Figure 9.3, and the effect estimates from 
this model are shown in Table 9.2. It was not possible to estimate an effect of gender on 
the time to withdrawal from exercise due to clinical indications, since all 47 of these 
withdrawals including 38 due to severe ST-segment depression, were experienced by 
men. 
Gender had other drastic influences on the reasons for stopping the tests, with 
hazard ratios between women and men of 4 and 4.5 for stopping due to fatigue or 
dyspnoea. The hazard ratio for stopping due to chest pain was not seen to be associated 
with gender, so that whilst men and women will stop testing 
due to angina at roughly 
equal rates, women will withdraw due to non-anginal reasons at much 
higher rates, so 
there will be more withdrawals due to angina amongst men; 
in the data as a whole, 20% 
of men and 12% of women stopped exercising 
for this reason. 
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Figure 9.3 Estimated cumulative incidence functions for times to end of exercise 
subject to competing risks of fatigue, chest pain, dyspnoea and clinical signs adjusted 
for cause-specific effects of mode of exercise, age, gender and weight. 
Exercise using a bicycle was associated with much lower hazard for all endpoints, 
as expected, though whilst the hazard ratio for ending exercise due to fatigue was 0.32 
between bicycle and treadmill exercise, it was only 0.24 for ending exercise due to chest 
pain and as low as 0.1 that exercise should end due to dyspnoea or be interrupted due to 
clinical indications. Thus, though the hazard for all endpoints is lower under bicycle 
exercise, fatigue will be a relatively more common reason for stopping the test. This is 
borne out in the raw figures, since 70% of bicycle tests end in fatigue, compared to 45% 
of treadmill tests. Likewise, 33% of treadmill tests were stopped due to anginal pain or 
adverse clinical signs, compared to only 19% of bicycle tests. 
There was no evidence of heterogeneity of the effects of age or weight between 
different endpoints. A 10-year difference in age was associated with 50% greater hazard 
for all endpoints. Under treadmill exercise, a 10 kg increase in weight was associateed 
with nearly 20% greater hazard for ending a test, though during bicycle exercise the 
same weight difference offered a 28% reduction in hazard. 
Finally, treatment effects were considered. Overall, there was no evidence that 
treatment had any influence on times to first events (likelihood ratio test statistic, 2.5 on 
2 df, pß. 29). When the effects of treatment on each endpoint were considered 
individually, there was some evidence that treatment group was associated with time 
until stopping exercise due to fatigue (likelihood ratio test statistic, 6.3 on 2 df, 
p=0.044), with the suggestion that those using Combination therapy were most likely to 
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Reason for Stopping Exercise Test 
Fatigue Chest Pain Dyspnoea Clinical 
Haz. Ratio Haz. Ratio Haz. Ratio Haz. Ratio 
(95% CI) (95% Cl) (95% Cl) (95% CI) 
p p p p 
0.32 0.24 0.11 0.10 
Exercise Type (0.25,0.41) (0.16,0.36) (0.07,0.18) (0.05,0.22) 
(Bicycle: Treadmill) <0.0001 <0.0001 <0.0001 <0.0001 
1.50 
Age (1.34,1.67) 
(/10 years) <0.0001 
Gender 
3.99 1.42 4.46 
( Female : Male) 
(2.90,5.51) (0.74,2.71) (2.61,7.64) 
<0.0001 0.29 <0.0001 
1.19 
Weight (Treadmill) (1.03,1.36) 
(/10kg) 0.017 
0.72 
Weight (Bicycle) (0.64,0.82) 
(/10 kg) <0.0001 
Table 9.2 Covariate effect estimates, with 95% CIs and p-values, from competing 
risks model of total exercise time adjusted for cause-specific effects of mode of 
exercise, age, gender and weight. 
withdraw from the test for this reason; Atenolol : Combination hazard ratio estimate, 
0.76 (95% CI 0.58,0.98), pß. 034; Nifedipine : Combination estimate 0.62 (0.47,0.81), 
p=0.0005. However, since this is an effect of borderline significance found amongst 
four possible effects, without evidence of a global treatment effect, it must be viewed 
with some scepticism. 
9.1.2 Dependent Failure Types 
The competing risks model was derived in two ways, firstly by assuming the 
existence of a set of independent survival times, only one of which is observed, and then 
by constructing the model within the framework of a Markov model, which does not 
depend upon these assumptions. 
Within the first conceptual framework, it would be natural to assume that times to 
failure from different causes within the same individual would be correlated. There are 
also clear parallels between the multivariate survival models explored 
in Section 7.4 and 
the way that the data are replicated to facilitate the 
fitting of competing risks models, 
producing multiple "observations" of survival 
data in the same individual. An obvious 
approach to modelling dependent competing risks 
data would therefore be to employ 
the methods for marginal and frailty models of correlated multivariate survival 
data. 
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There are, however, crucial differences between competing risks data and 
multivariate survival data. With competing risks data all survival times will be equal, 
and there will be precisely one event observed for each individual, with all other 
"observations" on that individual censored at the same time. With multivariate survival 
data, survival times will in general be different, and within any cluster of observations, 
any number of events could occur. 
The fact that the same specification for a competing risks model is reached from 
two different perspectives, one of which assumes independent survival times whilst the 
other does not, indicates the fundamental problem with modelling dependent survival 
times in a competing risks setting. For any distribution of dependent survival times, it is 
possible to construct an independent distribution of survival times with the same 
marginal distribution for the time to the first event132. Thus the competing risks problem 
when constructed in terms of a set of dependent survival times is inherently 
unidentifiable. 
9.2 Haemodynamic and Electrocardiographic Response 
In a clinical setting, when exercise tests are used to evaluate cardiac patients, the 
physician will evaluate the total response of the patient to the test. This will involve 
monitoring the patient for signs of discomfort or fatigue, as well as their heart rate, 
blood pressure and electrocardiographic response. Whilst some of these will be 
subjective observations, interpreted based on experience and knowledge of the patient, 
some of these are objective measurements that are recorded as part of a standard 
exercise protocol. 
Standard analyses of these measures often involve drastic reduction of the data, so 
that ECG response is summarised as the time until the first recorded occurrence of 
>_lmm ST-segment depression, or heart rate response as the time until the patient 
reaches their age-, sex- and weight-predicted maximal 
heart rate, or a percentage 
thereof. A more detailed analysis of these responses to exercise could be achieved by 
considering a complete set of observations as repeated measures 
data. Random effects 
models could be applied to study changes 
in outcomes throughout the exercise test, 
either one outcome at a time, or as a group of correlated responses. 
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9.2.1 Repeated Measures 
Repeated measures data can arise in medical studies for a number of reasons. It 
may be a planned part of a clinical trial to measure participant outcomes at a number of 
time points in order to demonstrate treatment efficacy over a specified length of time. In 
studies of pharmacokinetics the concentrations of drug metabolites will be measured on 
several occasions after taking a preparation in order to model the dispersion of the agent 
in the body. In retrospective studies involving case note review, the outcomes of a 
number of contacts with the health service might be recorded. 
In clinical trials that involve exercise tests, levels of ST-segment depression, heart 
rate and blood pressure will be recorded on several occasions. This is partly to 
determine pre-specified endpoints such as the time until >_lmm ST-segment depression 
or the heart rate at maximal exercise. There is also an element of safety monitoring, 
since a subject will be withdrawn from the test upon signs of severe ST-segment 
depression, dysrhythmia or a sudden fall in systolic blood pressure. Thus the fact that a 
number of data series are recorded is incidental to the study, since a per-protocol 
analysis might only investigate specific parts of the data. However, the fact that 
repeated measurements of the cardiac response have been recorded under increasing 
levels of exercise allows an opportunity for further analysis. 
The distinguishing feature of repeated measures data is that the same 
measurement is made on several occasions on the same individual. In general, this will 
allow more precise estimation of within- and between-subject variability, and therefore 
more precise estimation of associations between patient outcomes and exposures of 
interest. If the measurements are made under changing conditions, such as increasing 
levels of exercise during an exercise test protocol, this allows more precise estimation of 
individual responses to these conditions. 
9.2.2 Within-Subject Correlation 
The main analytical problem with repeated measures data is that multiple 
measures of the same quantity made on several occasions in the same individual will be 
correlated. In order to gain the full benefit of repeated measures data and to obtain 
improved precision of estimates of between-subject differences will require the best 
possible estimation of between- and within-subject variability. This will entail the 
modelling of the within-subject correlation structure. 
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It would be expected that responses measured on the same subject would be more 
closely related than those measured on different subjects, so that there would be a 
positive correlation between repeated measurements. Furthermore, when measurements 
are made at short intervals such as during an exercise test, it would seem likely that 
measurements made at consecutive time points would be more closely related than 
those made several minutes apart. These two aspects of the correlation structure should 
be incorporated into the analysis. 
Example 9.2 Repeated Measurements of ST-Segment Depression and Heart Rate during 
Exercise in the TIBET Study 
To illustrate the application of repeated measures analysis to exercise test data, the 
following example models ST-segment depression and heart rate (HR) increases during 
exercise. The response variables used in this analysis were the changes from baseline 
ST-segment and HR levels (prior to the start of exercise), with the sign of ST-segment 
changes reversed, so that depression relative to baseline was expressed as positive 
values. For simplicity, the analysis was restricted to those subjects that performed 
exercise using a treadmill. The analysis models both responses simultaneously, allowing 
for the likely correlation between the two responses, the correlation between repeated 
measurements of responses in the same individual, and the autocorrelation between 
responses over time. 
The time course of both response variables was modelled as linear for the purpose 
of this analysis, though in principle non-linear associations could be fitted. The time 
trend in both responses was also be considered as a random effect, allowing for the 
possibility that the response to exercise of one or both outcomes may differ between 
individuals. The effects of age, gender, weight and treatment were estimated as fixed 
effects. In other words, 
Yil Eil T 
OST;, ,..., OST;, «"2 
(X; 
, X; (ý + Nit Eiz 
where AST; and DHR; 1 are the response variables and Xi is the design matrix for subject 
i, including a column of is to model the intercept and a column taking values (1,2,..., J1) 
to model the dependence of each response on the time spent exercising. Notice that the 
intercept term in this model corresponds to the change from baseline ST-segment 
depression or HR when time is 0, which when viewed as the immediate response to 
starting exercise, need not necessarily be zero. The residual vectors c; l and Ci2 are i. i. d. 
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N(0, ß12) and N(O, a22) respectively. The regression coefficients were also, in general, 
considered to be random variables 
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The model was fitted as a multilevel model, using the statistical package 
MLwiN133. The model was fitted over three levels, with individual being the highest 
level, time point the middle level and type of response (ST-segment depression or 
increase in HR) the lowest level. The lowest level in the hierarchy is included to allow 
the model to estimate correlations between the two types of response, even though none 
of the effects included in the models were considered as random at this level. 
The data are arranged as a single vector of response variables. By including 
indicator variables for the two types of response variable and separate variables for the 
time trends of each response as random effects at the individual level, the model fits 
separate intercepts and slopes for each individual for the associations between response 
variables and the time spent exercising. These intercepts and slopes are random in the 
population and may be correlated amongst themselves. The variation in the intercept 
coefficients between time points can be interpreted as residual variation. Residuals for 
the AST and OHR response variables may be correlated. Thus the multilevel structure of 
the model implies a general correlation between repeated measures on the same 
individual, without directly specifying a given correlation structure. 
To allow for serial correlation between responses, fixed effects were included of 
the previous pair of measurements, so that the last recording of ST-segment depression 
was seen to influence the current level of ST-segment depression, and similarly for the 
previous measurement of HR. The coefficients for these terms can be interpreted as 
estimates of a first-order autocorrelation, so that the correlation between pairs of 
measurements decays as the distance between them (in time) becomes larger. 
Table 9.3 shows the effect estimates obtained from fitting a model with these 
effects as the only terms in the model. Significant variation was found between 
individuals in terms of their ST-segment depression and HR intercepts, and in their 
gradients over time in these variables. 
For example, changes from baseline ST-segment depression levels were seen to 
have a mean intercept of -0.12 mm, so that immediately upon starting exercise, ST- 
segment levels become elevated by an average of 
0.12 mm. These intercepts were not 
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Estimate 
(95% Cl) 
Mean 
Standard deviations 
ST-segment depression (mm) Heart rate (b/min) 
Intercept Slope Intercept 
-0.12 0.14 15.3 
(-0.17, -0.07) (0.12,0.16) (13.8,16.8) 
Between-subject 0.19 
(population variation) (0.13,0.24) 
Within-subject 0.36 
(residual variation) (0.34,0.37) 
0.10 10.4 
(0.08,0.11) (9.3,11.5) 
_ 
4.4 
(4.3,4.6) 
Slope 
3.9 
(3.6,4.1) 
1.3 
(1.2,1.5) 
Repeated measures correlations 
ST-segment depression 
0.23 
- 
0.35 
(0.13,0.32) (0.27,0.44) 
Heart rate 
0.35 
- 
0.85 -0.25 (0.27,0.44) (0.82,0.88) (-0.37, -0.13) 
Autocorrelations 
0.41 
_ 
0.13 
(0.36,0.46) (0.09,0.16) 
Table 9.3 Random effects estimates from initial model of repeated measurements of 
ST-segment depression and heart rate during treadmill exercise, allowing for subject- 
specific average levels and reactions to exercise, as well as first-order serial correlation 
between responses 
the same for every individual, with a standard deviation of 0.19 mm (95% CI 0.13 - 
0.24 mm) over the population, so that a 95% range in this population for the initial 
response to exercise of the ST-segment could be estimated as between 0.5 mm of 
elevation and 0.26 mm of depression. After an initial response, ST-segment depression 
was seen to increase by on average 0.14 mm/min, but this slope varied between 
individuals with a standard deviation of 0.10 mm/min (0.08 - 0.11 mm/min). 
Based on the estimated between- and within-subject variance-covariance matrices, 
estimates of the correlations between repeated measures of each response can be derived 
(i. e. correlations between responses without taking account of autocorrelation). The 
variance-covariance matrix for these correlations can be estimated by the delta method, 
based on the variance-covariance matrix of the variance components. The 
autocorrelation between successive responses is estimated from the estimate of the 
regression coefficient for the previous response. 
Correlation between repeated measures of ST-segment depression has a strong 
serial component, though correlation between measurements more than 2 minutes apart 
would seem to be influenced mainly by individual effects. Correlation between repeated 
HR measurements was mainly a result of variation between individuals, though there 
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Estimate 
ST-segment depression Heart rate 
(95% CI) Intercept Slope Intercept Slope 
(mm) (mm/min) (b/min) (b/min/min) 
Mean -0.32 
0.15 8.5 3.8 
(-0.45, -0.19) (0.13,0.16) (4.6,12.4) (3.6,4.1) 
Standard deviations 
Between-subject 0.17 
0.10 10.2 1.3 
(0.11,0.22) (0.09,0.12) (9.1,11.2) (1.2,1.5) 
Within-subject 0.35 - 
4.4 
- (0.34,0.36) (4.3,4.6) 
Repeated measures correlations 
ST-segment depression 
0.20 
- 
0.28 
- (0.10,0.30) (0.19,0.37) 
Heart rate 
0.28 0.15 0.84 -0.30 (0.19,0.37) (0.01,0.28) (0.81,0.87) (-0.42, -0.18) 
Autocorrelations 
0.38 
_ 
0.13 
(0.33,0.42) (0.10,0.16) 
Table 9.4 Random effects estimates from final model of repeated measurements of ST- 
segment depression and heart rate during treadmill exercise, allowing for subject- 
specific average levels and reactions to exercise, first-order serial correlation and fixed 
effects of age, gender, weight and treatment 
was a correlation of -0.25 between underlying HR and the HR reaction to exercise, such 
that individuals with less of an initial increase in HR upon starting exercise would tend 
to show greater increases in HR during exercise. 
This model was then extended to include fixed effects for the age, gender and 
weight of each individual, as well as for differences between the three treatment groups. 
Table 9.4 shows the random effects estimates from this model. The random effects are 
similar to those obtained from the initial model, though there is some evidence of a 
positive correlation between the initial HR response to exercise and the gradient of ST- 
segment depression with time (estimated correlation 0.15; 95% CI, 0.01 - 0.28). The 
positive correlation might indicate that less physically fit patients (with greater initial 
reactions of HR to exercise) tend to have reduced cardiac fitness (greater increase in ST- 
segment depression with continuing exercise). 
Table 9.5 lists the fixed effects estimates from this model. Age was not seen to be 
associated with either ST-segment depression or HR. Female gender was associated 
with initial reactions to exercise that were 0.18 mm greater for ST-segment depression 
(95% CI 0.04,0.32 mm) and 5.9 b/min higher for HR (1.8,10.1 b/min). Weight was 
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Estimate ST-segment depression (mm) Heart Rate (b/min) 
(95% CI) 
Covariate effects 
Age 0.01 0.3 
(/10 years) (-0.05,0.07) (-1.5,2.0) 
Gender 0.18 5.9 
( Female - Male) (0.04,0.32) (1.8,10.1) 
Weight 0.03 1.9 
(/10 kg) (-0.02,0.07) (0.6,3.4) 
Treatment effects 
Atenolol - Combination 
0.11 1.2 
(0.00,0.21) (-2.0,4.5) 
0.21 5.5 
Nifedipine - Combination (0.11,0.32) (2.3,8.8) 
Table 9.5 Estimated fixed effects of age, gender, weight and treatment from the final 
model of repeated measurements of ST-segment depression and heart rate during 
treadmill exercise, allowing for subject-specific average levels and reactions to exercise, 
and first-order serial correlation 
seen to affect HR but not ST-segment depression, with a 10 kg greater body weight 
being associated with an increased initial reaction to exercise of 1.9 b/min (0.6,3.4 
b/min). 
Relative to those on combination therapy, there was some evidence that the initial 
response of ST-segment depression is 0.11 mm (0.00,0.21 mm) greater for those treated 
with atenolol, but there was no evidence that the initial change from resting HR was 
affected. Those treated with nifedipine, however, showed clearly higher changes from 
rest relative to the combination therapy group, with the 
initial changes in ST-segment 
depression and HR increased by 0.21 mm (0.11,0.32 mm) and 5.5 b/min (2.3,8.8 
b/min) respectively. 
9.3 Summary 
The methods outlined in this section have gone beyond what is often done in 
practice, where the data are reduced to the time until a pre-specified event occurs. 
Attempts have been made to consider a broader picture, and to model the effects of 
covariate and treatment information within more complex 
frameworks. 
The competing risks model investigated the effects of variables on total exercise 
time, where exercise could be stopped due to a number of reasons. 
In a standard 
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survival analysis model, the assumption of non-informative censoring might be 
violated, and observed relationships between treatment groups and the time to an 
ischaemic event could arise due to an imbalance in the likelihood of stopping exercise 
for some other reason. The competing risks method attempts to disentangle the many 
causes of an exercise test stopping, in order to determine the true nature of covariate 
effects. 
The application of methods for the analysis of repeated measures is a broad and 
complex subject, and the example shown in Section 9.2 was undoubtedly over- 
simplified. The correlation structure employed was basic, and determined to a large 
degree by the limitations of the software used. However, by differentiating between 
effects that act on the initial and continuing responses to exercise, it provided important 
insights into the mechanism of treatment and covariate effects. 
Repeated measures data are naturally prone to missing values, particularly in this 
case where the previous observation was used as an independent variable, in order to 
model the autocorrelation in the data. For this model, observations with missing data 
were excluded, so that a single missing response would result in two missing 
observations. The use of imputation techniques might well give improved performance 
with this model. 
Further improvements could be made by the use of more appropriate covariance 
structures, by the inclusion of information regarding systolic blood pressure, or by 
incorporating non-linear associations between response variables and time. For instance, 
the time course of ST-segment depression could well be non-linear, with the gradient 
increasing when ischaemia begins. Also, with continuing improvements in computing 
performance and statistical software, it would seem 
likely that models for analysing 
continuously recorded ECG output and other responses 
during exercise could be 
developed. 
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CHAPTER 10 Concluding Remarks 
This thesis has addressed the statistical analysis of exercise test data, with 
particular attention paid to the analysis of times spent exercising until the occurrence of 
ischaemic events such as anginal pain or the first observation of zlmm ST-segment 
depression. Various techniques have been applied to data from the Total Ischaemic 
Burden European Trial (TIBET) and their results compared. Simulation studies have 
been used to evaluate the performance of some of these methods with respect to 
particular features of exercise test data, namely interval censoring and repeated survival 
times. Some novel approaches to analysing exercise times and other data that are 
accrued during exercise tests have also been explored. 
To conclude, this Chapter will briefly discuss the findings of this work, and make 
recommendations for which methods should be used to analyse exercise test data in 
practice. 
10.1 Survival Analysis 
In clinical trials of anti-anginal therapies, it is a regulatory requirement that 
exercise testing be employed to evaluate patients48. The main outcome variables from 
exercise tests used in this setting are the times spent exercising until the occurrence of 
anginal chest pain or significant ischaemia as determined by depression of the ST- 
segment of the ECG trace. These variables can be censored, though in practice, analyses 
are carried out that ignore this fact, despite the observation that the failure to use 
appropriate statistical methods could be inefficient or misleading52. 
The fact that inappropriate methods continue to be used may reflect a lack of 
awareness of the censored nature of these data or an intransigence amongst those 
conducting or publishing the results of these studies to accept novel analytical 
approaches. This is not a criticism; since methods for uncensored data have traditionally 
been used, it is natural for researchers to adopt similar methods for analysis, as it is 
natural that reviewers of journal articles would question the use of alternative methods. 
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In most cases, the use of survival analysis as opposed to an alternative method that 
treats the data as uncensored will not affect the conclusions of a study, and those who 
attempt to use more appropriate statistics may find that the gain from being more correct 
in their analysis is outweighed by the difficulty in presenting the results to clinical 
colleagues and those who would publish their findings. 
From the standpoint of a statistician, it is preferable to use survival techniques to 
analyse exercise times, despite the difficulties in presenting this to non-statistical 
collaborators. Many analyses involve a trade-off between statistical correctness and ease 
of comprehension by the target audience. However, part of the responsibility of the 
statistician is to push the boundary of this compromise, by finding better ways of 
presenting data and of explaining the methods used. For example, in addition to 
reporting hazard ratios associated with particular treatments, estimated differences in 
median exercise time could be reported from a Cox proportional hazards model. In 
Section 4.1, it was found that the time to anginal pain could be well represented by a 
Weibull distribution, and it would be relatively straightforward to report differences in 
mean exercise time based on such a parametric model. In this way a more appropriate 
method is used to analyse the data, whilst the results are presented in a format familiar 
to others. 
10.2 Interval Censoring 
The time until the occurrence of significant ST-segment depression will often be 
restricted to take one of a set of distinct values, since the ECG trace is recorded at 
intervals only. For an observed occurrence, the actual time of the first occurrence is 
known only to lie in the interval since the previous recording. 
Methods exist for the analysis of such interval censored data, though the results of 
simulations presented in Section 6.3 would suggest that it is the use of survival methods 
that is most important for the validity of the analysis. Standard methods for survival 
analysis, rather than methods designed for this type of data perform sufficiently well, 
and would be recommended for use in practice. 
10.3 Repeated Exercise Times 
The fact that exercise tests may be repeated is often made advantage of in clinical 
studies. Baseline exercise tests are performed, and study results reported in terms of the 
mean change in exercise times. This would be expected to improve the power of a study 
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to detect treatment effect differences. Also, in studies where it may be unethical to 
include a placebo arm, since the treatments being compared have previously been 
shown to be of benefit, the use of baseline data allows improvements in exercise 
tolerance to be reported for each intervention, if only to quantify the scale of treatment 
effects. 
The use of survival analysis methods with repeated data is a relatively new field, 
and until recently not supported by standard statistical software packages. The results of 
the simulation study presented in Section 8.3 indicate that when exercise times follow a 
frailty model, there can be significant advantages to using this model for the analysis. It 
is not clear, however, whether the frailty model performs as well when this model is a 
misspecification of the underlying process. Nonetheless, for the analysis of repeated 
exercise times in practice, such models would appear to offer the best initial option, 
though the use of a fully parametric baseline hazard function, such as a Weibull 
distribution, might allow greater flexibility in terms of reporting the results. 
10.4 Other Methods 
Competing risks analysis of exercise times can be used to assess the effects of 
treatments and other covariates on the multiple potential reasons for stopping an 
exercise test, and can be used to gain additional insight into the process of maximal 
exercising. However, the primary endpoints of an exercise test would be the first 
occurrences of chest pain or significant ST-segment depression, so such an analysis 
would most likely form part of a secondary analysis. 
The use of mixed effects models to analyse the wealth of ECG and 
haemodynamic data that are collected could be used as part of a main analysis of 
exercise test data. The levels of these variables at specific points, such as at maximal 
exercise or at the occurrence of an ischaemic event, are often reported alongside 
exercise times. The analysis shown in Section 9.2 is somewhat basic, but this type of 
analysis offers much potential for extracting 
important information from studies using 
exercise tests. To use such methods in practice would require 
both development of the 
models and their interpretation. In the same way as the use of survival methods 
for the 
analysis of exercise times, there would need to be a considerable effort to persuade the 
clinical audience for the results the method added value to an analysis. 
However, there 
would perhaps be less resistance to accepting these mixed effects models 
for data that 
have in general not been analysed in detail before, than to the use of survival models for 
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data that have traditionally been analysed by other methods. Also, since the results can 
be viewed in terms of mean changes in outcomes over time, it might be easier for the 
target audience to interpret the results of such an analysis. 
10.5 Conclusion 
In the analysis of exercise test data, is has been recognised that times spent 
exercising before the occurrence of ischaemic events should be analysed using methods 
appropriate for survival data, though these methods do not appear to have been widely 
adopted in clinical trials of anti-anginal therapies. Given the wealth of 
electrocardiographic and haemodynamic data collected during exercise tests, there is 
scope for the development of more complex mixed effects models that would provide 
additional insight into factors influencing exercise tolerance. 
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Appendix A Parametric Form for Difference in 
Survival Times 
Section 7.3 derived the likelihood function (Eq. 7.3) for a model in which the 
differences between pairs of survival times were assumed to follow a Normal 
distribution. If the data are written as 
{T;, 
9T; 2,8i1,8; 2, z; :i =1,2,..., n) 
where the Ts are observed survival times, the Ss are failure indicators and z; is a vector 
of covariates for the it' individual. By defining the difference in observed exercise times 
to be 0; T; 2-T; 1, and 
ui = 
Ai -zip , a 
the contribution to the log likelihood for the ith individual is 
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where 0 and (D are the p. d. f and c. d. f of a Standard Normal distribution, respectively 
and the negative log likelihood function can be written as 
-1(i, aIO; ,8;, , S; 2) _ -21 
ij = -ý 
{ A; - S;, S; 2loges} . 
Maximisation of the likelihood function, in order to find estimates for the model 
parameters, can be achieved using the statistical software package S-Plus134 using the 
minimisation function nlminb. For optimal performance, the nlminb function requires 
code to calculate both the first and second derivatives of the negative log likelihood 
with respect to the model parameters. The matrix inverse of the second derivative of the 
negative log likelihood evaluated at the minimum then provides an estimate of the 
variance-covariance matrix of the parameter estimates. 
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Some useful identities when evaluating the derivatives of the negative log 
likelihood are 
ij i 
'' and -u; 
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the first and second derivatives of the negative log likelihood can be written as 
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Appendix B Gamma Frailty Model with Weibull 
Baseline Hazard 
Example 7.4 derives the log likelihood for a Gamma frailty survival regression 
model with a Weibull baseline hazard function as a sum over all observations of the 
form (in terms of the negative log likelihood, ignoring subscripts and summation signs) 
- 1(0, p, a) =0 +8 log(l + Ot"exp(zp))- S(1og a+ 
(a 
-1) log t+ zp), 
so that the first derivatives can be written as 
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The second derivatives are 
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The maximum likelihood estimates for the fit can be found by minimising the 
negative log likelihood, for example using the nlminb routine in the statistical package 
S-Plus 13a The resultant matrix of 2nd derivatives can be inverted to estimate the 
variance-covariance matrix of the parameter estimates. Since the first column of z is 1, 
the parameter ßl is related to the scale parameter of the baseline hazard function by 
y= exp( a) ' 
and the variance of the estimate of y can be derived by the delta method from the 
original variance-covariance matrix. 
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